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        SUMMARY 
	  
Oncolytic viral therapies have shown great promise pre-clinically and in human 
clinical trials for the treatment of various cancers. Oncolytic viruses selectively infect 
and replicate in cancer cells, destroying tumor tissue via cell lysis, while leaving 
noncancerous tissues unharmed. Vaccinia virus (VACV) is arguably one of the 
safest viruses, which has been intensively studied in molecular biology and 
pathogenesis as a vaccine for the eradication of smallpox in more than 200 million 
people. It has fast and efficient replication, and cytoplasmic replication of the virus 
lessens the chance of recombination or integration of viral DNA into the genome of 
host cells. Anti-tumor therapeutic efficacy of VACV has been demonstrated for 
human cancers in xenograft models with a variety of tumor types. In addition 
recombinant oncolytic VACVs carrying imaging genes represent an advance in 
treatment strategy that combines tumor-specific therapeutics as well as diagnostics.  
As for other targeted therapies, a number of challenges remain for the clinical 
translation of oncolytic virotherapy. These challenges include the potential safety risk 
of replication of oncolytic virus in non-tumor tissue, the relatively poor virus spread 
throughout solid tumor tissue and the disadvantageous ratio between anti-viral and 
anti-tumoral immunity. However, manipulation of components of the tumor 
microenvironment may help oncolytic virus infection in killing the tumor tissue and 
thereby increasing the anti-tumor efficacy. Furthermore, dogs with natural cancer are 
considered as one of the best animal models to develop new drugs for cancer 
therapy. Traditionally, rodent cancer models have been used for development of 
cancer therapeutics. However, they do not adequately represent several features 
that define cancer in humans, including biology of initiation of tumor, the complexity 
of cancer recurrence and metastasis and outcomes to novel therapies. However, the 
tumor microenvironment, histopathology, molecular and genomics data from dog 
tumors has significant similarities with corresponding human tumors. These 
advantages of pet dog cancers provide a unique opportunity to integrate canine 
cancer patients in the studies designed for the development of new cancer drugs 
targeted against both human and canine cancers. This dissertation centers on the 
use of VACV strains in canine cancer xenografts with the aim of understanding the 
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effects of modulation of tumor microenvironment on VACV-mediated tumor therapy.  
In the first studies, wild-type VACV strain LIVP6.1.1 was tested for its oncolytic 
efficiency in canine soft tissue sarcoma (STSA-1) and canine prostate carcinoma 
(DT08/40) cells in culture and xenografts models. LIVP6.1.1 infected, replicated 
within, and killed both STSA-1 and DT08/40 cells in cell culture. The replication of 
virus was more efficient in STSA-1 cells compared to DT08/40 cells. In xenograft 
mouse models, LIVP6.1.1 was safe and effective in regressing both STSA-1 and 
DT08/40 xenografts. However, tumor regression was faster in STSA-1 xenografts 
compared to DT08/40 xenografts presumably due to more efficient replication of 
virus in STSA-1 cells. Biodistribution profiles revealed persistence of virus in tumors 
5 and 7 weeks post virus injection in STSA-1 and DT08/40 xenografts, respectively, 
with the virus mainly cleared from all other major organs. Immunofluorescence 
staining detected successful colonization of VACV in the tumor. Consequently, 
LIVP6.1.1 colonization in the tumor showed infiltration of innate immune cells mainly 
granulocytes and macrophages in STSA-1 tumor xenografts. These findings suggest 
that virotherapy-mediated anti-tumor mechanism in xenografts could be a 
combination of direct viral oncolysis of tumor cells and virus-dependent infiltration of 
tumor-associated host immune cells. 
In further studies, the effects of modulation of tumor angiogenesis of VACV therapy 
were analyzed in canine cancer xenografts. GLV-1h109 VACV strain (derived from 
prototype virus GLV-1h68) encoding the anti-VEGF single chain antibody GLAF-1 
was characterized for its oncolytic efficacy in STSA-1 and DT08/40 cancer cells in 
culture and tumor xenografts. Concomitantly, the effects of locally expressed GLAF-
1 in tumors on virus replication, host immune infiltration, tumor vascularization and 
tumor growth were also evaluated.  
GLV-1h109 was shown to be similar to the parental virus GLV-1h68 in expression of 
the two marker genes that both virus strains have in common (Ruc-GFP and gusA) 
in cell cultures. Additionally, the anti-VEGF single-chain antibody GLAF-1 was 
expressed by GLV-1h109 in both cell cultures and tumor xenografts. The insertion of 
GLAF-1 did not significantly affect the replication and cytotoxicity of GLV-1h109 in 
the STSA-1 and DT08/40 cell lines, although at early time points (24-48 hpi), the 
replication of GLV-1h109 was higher in STSA-1 cells compared to DT08/40 cells. In 
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addition, STSA-1 cells were more susceptible to lysis with GLV-1h109 than DT08/40 
cells. GLV-1h109 achieved a significant inhibition of tumor growth in both STSA-1 
and DT08/40 canine xenografts models. Consequently, the significant regression of 
tumor growth was initiated earlier in STSA-1 tumor xenografts compared to 
regression in DT08/40 xenografts. The reason for the higher efficacy of GLV-1h109 
in STSA-1 xenografts than DT08/40 xenografts was attributed to more efficient 
replication of virus in STSA-1 cells. In addition, tumor-specific virus infection led to a 
continued presence of GLAF-1 in peripheral blood, which could be useful as a 
pharmacokinetic marker to monitor virus colonization and persistence in GLV-1h109-
injected xenograft mice. GLAF-1 is a single-chain antibody targeting human and 
murine VEGF. It was demonstrated that GLAF-1 was functional and recognized both 
canine and human VEGF with equal efficiency. 
Histological analysis of tumor sections 7 days after GLV-1h109 injection confirmed 
that colonization of VACV and intratumoral expression of GLAF-1 translated into a 
significant decrease in blood vessel number compared to GLV-1h68 or PBS-treated 
control tumors. Subsequently, reduction in blood vessel density significantly 
improved the spread and replication of VACV as observed by FACS analysis and 
standard plaque assay, respectively. Inhibition of tumor angiogenesis and increased 
replication of virus further improved the infiltration of innate immune cells mainly 
granulocytes and macrophages in STSA-1 tumor xenografts.  Both the results, i.e. 
improved virus spread and increased infiltration of innate immune cells in tumor, 
were explained by a phenomenon called “vascular normalization”, where anti-VEGF 
therapy normalizes the heterogeneous tumor vasculature thereby improving delivery 
and spread of VACV. In summary, the effects of inhibition of tumor angiogenesis on 
virus spread and replication were demonstrated using a vaccinia virus caring an anti-
angiogenic payload targeting vascular endothelial growth factor (VEGF) in canine 
cancer xenografts. 
In the final studies, the effects of VACV therapy on modulation of the immune system 
were analyzed in canine cancer patients enrolled in a phase I clinical trial. V-VET1 
(clinical grade LIVP6.1.1 VACV) injection significantly increased the percentages of 
CD3+CD8+ T lymphocytes at 21 days after initiation of treatment. CD3+CD8+ T 
lymphocytes are mainly cytotoxic T lymphocytes that have potential to lyse cancer 
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cells. Subsequently, the frequency of immune suppressor cells, mainly MDSCs and 
Treg was also analyzed in peripheral blood of canine cancer patients. Increase in the 
MDSC population and decreased CD8/Treg ratio is known to have inhibitory effects 
on the functions of cytotoxic T cells. We demonstrated that injection of V-VET1 in 
canine cancer patients significantly reduced the percentages of MDSCs at 21 days 
post initiation of treatment. Additionally, CD8/Treg ratio was increased 21 days after 
initiation of V-VET1 treatment. We also showed that changes in the frequency of 
immune cells neither depends on dose of virus nor depends on tumor type according 
to the data observed from this clinical trial with eleven analyzed patients.  
This preclinical and clinical data have important clinical implications of how VACV 
therapy can be used for the treatment of canine cancers. Moreover, dogs with 
natural cancers can be used as an ideal animal model to improve the oncolytic 
virotherapy for human cancers. Furthermore, modulation of tumor microenvironment 
mainly tumor angiogenesis and tumor immunity has significant impact on the 
success of oncolytic virotherapy.  
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          ZUSAMMENFASSUNG 
	  
Therapien für verschiedenste Krebsarten mittels onkolytischer Viren zeigten sowohl 
in präklinischen- als auch in humanen klinischen Studien ein erfolgversprechendes 
Potenzial. Onkolytische Viren infizieren selektiv Krebszellen und replizieren 
ausschließlich in diesen. In der Folge zerstören sie Tumorgewebe durch Zelllyse, 
während gesundes Gewebe unbeeinträchtigt bleibt. Das Vaccinia-Virus besitzt ein 
äußerst geringes Risikopotential,  und wurde intensiv auf molekularbiologischer 
Ebene und in Bezug auf seine Pathogenese untersucht. All das qualifizierte es als 
Vakzin zur Ausrottung der Pocken und seit Markteinführung mehr als 200 Millionen 
Menschen injiziert. Das Vaccinia-Virus zeigt eine schnelle und effiziente Replikation, 
welche im Zytoplasma der Zelle stattfindet. Dies verringert die Möglichkeit der 
Rekombination oder Integration der viralen DNA in das Wirtsgenom. Die 
therapeutische Wirksamkeit onkolytischer Vaccinia-Viren (VACVs) wurde in 
humanen Xenograft-Mausmodellen mit unterschiedlichen Tumorarten gezeigt. 
Rekombinante onkolytische VACVs, welche mit fluoreszierenden Genen 
ausgestattet sind, kombinieren die Vorteile tumorspezifischer Therapeutika und 
dienen gleichzeitig als Diagnostika.  
Wie auch andere spezifische Therapien, steht auch die onkolytische Virustherapie 
vor einer Reihe von Herausforderungen. Dazu gehören die Replikation onkolytischer 
Viren in nicht-kanzerogenem Gewebe, relativ schlechte Virusverbreitung durch 
solides Tumorgewebe und ein unvorteilhaftes Verhältnis zwischen antiviraler und 
antitumoraler Immunität. Die gezielte Manipulation einzelner Komponenten des 
Tumormikromilieus kann jedoch zu einer verbesserten Virusinfektion und Lyse des 
Tumorgewebes führen und somit die Effizienz der antitumoralen Therapie 
verstärken.  
Hunde, welche auf natürlichem Weg eine Krebserkrankung entwickeln, gelten als 
eines der besten Tiermodelle für die Entwicklung von Medikamenten gegen Krebs. 
Traditionell wurden Mausmodelle für die Therapieentwicklung von 
Krebserkrankungen eingesetzt. In Mausmodellen fehlen jedoch verschiedene 
Eigenschaften, welche eine Krebserkrankung in Menschen definieren. Dazu gehören 
die Tumorentstehung, die Komplexität des Widerauftretens des Tumors, die 
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Metastasierung und Therapievorhersagen für neuartige Medikamente. Daten auf 
molekularer und genomischer Ebene, das Tumormikromilieu und die Histopathologie 
von Hundetumoren zeigen jedoch signifikante Ähnlichkeit zu entsprechenden 
humanen Tumoren.  
Die genannten Vorteile von Hundetumoren bieten eine einmalige Chance, Hunde-
Krebspatienten in Studien einzubeziehen, die auf die Entwicklung neuer 
Krebsmedikamente zur Behandlung von Human- und Hundetumoren abzielen. Im 
Rahmen dieser Arbeit wurde die Verwendung von VACV-Stämmen zur Therapie von 
Hundetumoren im Mausmodell und die Auswirkungen der Modulation des 
Tumormikromilieus auf die VACV-vermittelte Tumortherapie untersucht.  
Im ersten Teil der Studie wurde der wildtypische VACV-Stamm LIVP6.1.1 auf seine 
onkolytische Effizienz in caninen Weichteilsarkom- (STSA-1) und 
Prostatakarzinomzellen (DT08/40) sowohl in Zellkultur wie auch im 
Xenotransplantatmodell getestet. Es konnte gezeigt werden, dass LIVP6.1.1 in 
Zellkultur erfolgreich in STSA-1- und DT08/40-Zellen replizieren und diese lysieren 
kann, wobei eine verbesserte Replikation in STSA-1-Zellen verglichen mit DT08/40-
Zellen festgestellt werden konnte. Im Mausmodell konnte nachgewiesen werden, 
dass LIVP6.1.1 sicher ist und sowohl in STSA-1- als auch DT08/40-
Xenotransplantaten zur Regression führte. Aufgrund der höheren 
Replikationsgeschwindigkeit des Virus in STSA-1-Zellen wurde eine schnellere 
Rückbildung der STSA-1-Xenotransplantate im Vergleich zu DT08/40-Tumoren 
beobachtet. Weiterhin wurde in Bioverteilungssstudien in beiden 
Xenotransplantatmodellen jeweils die höchste Virusmenge in den Tumoren 
nachgewiesen, wohingegen in den Organen nur vereinzelt Virus gefunden wurde. 
Mittels Immunfluoreszenzfärbung konnte ebenfalls die erfolgreiche Kolonisierung der 
Tumore durch das Virus veranschaulicht, sowie auch die Einwanderung von Zellen 
des angeborenen Immunsystems, hauptsächlich Granulozyten und Makrophagen, in 
STSA-1-Xenotransplantate dargestellt werden. Diese Ergebnisse legen nahe, dass 
der antitumorale Mechanismus in diesen Xenotransplantaten eine Kombination aus 
direkter Onkolyse der Tumorzellen und Virus-abhängiger Einwanderung von Tumor-
assoziierten Wirtsimmunzellen sein könnte. 
In weiteren Studien wurden die Auswirkungen der Veränderung der 
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Tumorangiogenese im Rahmen der VACV-Therapie im Xenotransplantatmodell von 
Hundetumoren untersucht. Hierfür wurde die onkolytische Effizienz des VACV-
Stammes GLV-1h109 in STSA-1- und DT08/40-Zellen in Zellkultur und im 
Mausmodell untersucht. GLV-1h109 wurde durch Insertion des Gens für den anti-
VEGF-Einzelketten-Antikörper GLAF-1 in das Parentalvirus GLV-1h68 hergestellt. 
Außerdem wurden die Effekte des in Tumoren lokal exprimierten GLAF-1 auf die 
Virusreplikation, Einwanderung von Wirtsimmunzellen, Tumorvaskularisierung und 
Tumorwachstum untersucht.  
Unter Zellkultur-Bedingungen zeigte GLV-1h109 eine  ähnliche Expression der 
beiden Marker-Gene (ruc-gfp und gusA) wie sein isogener Stamm GLV-1h68. Die 
zusätzliche Expression des GLAF-1-Proteins hatte keinen signifikanten Effekt auf die 
Replikation und Zytotoxizität von GLV-1h109 in den STSA-1- und DT08/40 Zelllinien. 
Interessenterweise waren STSA -1-Zellen anfälliger für GLV-1h109-Infektion als 
DT08/40 Zellen. GLV-1h109 wies eine signifikante Hemmung des Tumorwachstums 
in beiden getesteten STSA-1- und DT08/40-Xenograft-Modellen auf. Die schnellere 
Regression des Tumorwachstums im STSA-1-Tumor im Vergleich zur Regression 
von DT08/40-Tumoren, konnte auf die effizientere Kolonisierung und Replikation des 
Virus in diesen Tumorzellen zurückgeführt werden.  
Darüber hinaus führte Tumor-spezifische Virus-Infektion zur dauerhaften Präsenz 
der GLAF-1 Antikörper im peripheren Blut. Dadurch könnte das Protein als 
pharmakokinetischer Marker für die Virus Kolonisierung und Persistenz in Mäusen 
dienen. GLAF-1 ist ein Einzelketten-Antikörper gegen Human-und Maus-VEGF. Wir 
konnten zeigen, dass das virusproduzierte GLAF-1 Protein funktional ist und sowohl 
canines wie auch humanes VEGF mit gleicher Effizienz erkennt. 
Die histologische Analyse von eingebetteten GLV-1h109-injizierten Tumorschnitten 
haben bestätigt, dass, die intratumorale Expression von GLAF-1 zu einer 
signifikanten Abnahme der Blutgefäß-Zahl im Vergleich zu der Zahl der in GLV-1h68 
oder PBS-injizierten Kontrolltumoren führte. Interessanterweise führte die Senkung 
der Blutgefäßdichte zu einer deutlich verbesserten Ausbreitung und Replikation von 
GLV-1h109, wie durch FACS-Analyse und Standard-Plaque-Test beobachtet wurde. 
Hemmung der Tumorangiogenese und erhöhte Replikation des Virus bewirkte eine 
bessere Infiltration von Zellen des angeborenen Immunsystems, hauptsächlich 
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Granulozyten und Makrophagen in STSA-1-Tumore. Alle diese Vorgänge 
(verbesserte Virusausbreitung und verstärkte Infiltration der angeborenen 
Immunzellen im Tumor) könnten durch eine „Gefäß-Normalisierung" nach der 
GLAF1–Behandlung erklärt werden.  
Zusammenfassend wurde gezeigt, dass im Hunde-Xenograftmodell mittels Virus-
vermittelter GLAF-1-Expression die Angiogenese gehemmt wird und dies sich auf 
die Verteilung und Replikation des Virus auswirkt. 
Zuletzt wurde die Wirkung der VACV-Therapie auf die Regulierung des 
Immunsystems in krebserkrankten Hunden in einer klinischen Studie Phase 1 
untersucht. Die Injektion von V-VET1 (klinische Bezeichnung des LIVP6.1.1-Virus) 
führte 21 Tage nach der Behandlung zu einem signifikanten Anstieg an CD3+ CD8+-
Lymphozyten. CD3+CD8+-T-Lymphozyten gehören zu den zytotoxischen T-
Lymphozyten, welche Krebszellen lysieren. Anschließend wurde die Anzahl an 
Immunsuppressor-Zellen, überwiegend Myeloid-derived Suppressor (MDS)-Zellen 
und Treg-Zellen im peripheren Blut krebserkrankter Hunde untersucht. Eine 
funktionale Hemmung der zytotoxischen T-Zellen wird durch eine Zunahme an MDS-
Zellen mit gleichzeitiger Abnahme der CD8/T-Zellen charakterisiert. Die Daten 
zeigen, dass der Anteil an MDS-Zellen in krebserkrankten Hunden 21 Tage nach 
Start der Behandlung mit V-VET1 signifikant gesunken ist. Zusätzlich stieg das 
Verhältnis von CD8/Treg-Zellen 21 Tage nach Injektionsstart. Des Weiteren wurde an 
Hand der erhaltenen Daten von 11 Patienten im klinischen Versuch gezeigt, dass die 
veränderte Anzahl an Immunzellen weder von der Dosis der Virusinfektion noch von 
der Art des Tumors abhängig ist.  
Unsere präklinischen- und klinischen Studien geben wichtige Informationen für eine 
klinische Behandlung von krebserkrankten Hunden mittels Virustherapie. Des 
Weiteren wurde veranschaulicht, dass Hunde sich aufgrund der natürlichen 
Krebserkrankung als optimales Modell zur Optimierung der onkolytischen 
Virustherapie in der Humanmedizin eignen. Zusätzlich wurde gezeigt, dass 
besonders die Regulierung des tumoralen Milieus in Bezug auf Angiogenese und 
Immunität entscheidend für den Behandlungserfolg sind. 
 
	   9 
	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   	  	  	  	  	  	  	  	  CHAPTER 1: INTRODUCTION 
1.1 Overview of human and canine cancer 
Cancer is the leading cause of death worldwide, accounting for 7.6 million deaths 
annually [1]. By 2030, it is projected that there will be ∼26 million new cancer cases 
and 17 million cancer deaths per year [2]. In addition to loss of life, cancer attributes 
considerable economic loss and drastically reduces quality of life. Furthermore, not 
only does cancer devastate the lives of humans, it also afflicts animals. Cancer is the 
most common cause of natural death in dogs. The incidence of cancer is 1 to 2% in 
the canine population and accounts for about half of the deaths in dogs older than 10 
years [3, 4]. Canine cancer has become more prevalent in recent years because of 
increased life expectancy and greater attention to the health of pets. The range of 
cancers seen in dogs is as diverse as that in human patients. Because domestic 
pets share our environment, greater cross-application and study of the 
protumorigenic and antitumorigenic factors in our shared environment will benefit all 
species, leading to the development of new families of less toxic antitumorigenic 
therapies based on novel and established molecular targets [5]. As the standard 
therapy is usually palliative in canine cancer, there is an excellent opportunity to 
evaluate alternative approaches.  
1.2 Oncolytic virotherapy 
While substantial progress has been made in combating cancer, including improved 
techniques in early diagnosis, advances in surgery, improved chemotherapy, 
hormonal therapy, immunotherapy, gene therapy, and radiation therapy, treating 
cancer still remains a considerable challenge. For many cancer types, for which 
current standard therapies do not provide a cure, new research has lead to the 
development of alternative treatment approaches. One alternate therapeutic 
approach is oncolytic virotherapy. Oncolytic virotherapy uses viruses that specifically 
kill cancer cells, while leaving healthy cells unharmed. Conventional chemotherapy is 
mostly non-targeted, causing general toxicity and severe side effects. Because of the 
specificity of oncolytic viruses (OVs) for cancer cells, anti-cancer effects may occur 
in the absence of off-target toxicity.  
Cancer virotherapy has progressed into the clinic, with several oncolytic virus 
platforms currently in or entering phase III human clinical trials. In addition, the 
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oncolytic adenovirus H101 was approved in China in 2005 for the treatment of head 
and neck cancer [6]. Additionally, virotherapy has been tested in veterinary 
medicine. Phase I clinical trials are currently underway in dogs to assess the safety 
of oncolytic vaccinia virus [7]. 	  
1.2.1 What are oncolytic viruses? 
Oncolytic viruses are the viruses that selectively infect, replicate in and kill cancer 
cells, while leaving healthy cells intact. These are multi-mechanistic antitumor 
agents. OVs not only kill cancer cells by direct infection and oncolysis, but also affect 
uninfected cells of the tumor by altering the tumor vasculature and by activating 
antitumor immunity. 
Over the last 15 years, antitumor activity of OV’s has been demonstrated in different 
animal models as well as in human and dog cancer patients. Examples include 
vaccinia virus [8], Newcastle disease virus (NDV) [9], reovirus [10], lentivirus [11], 
Herpes simplex virus (HSV) [12], enterovirus [13], sindbis virus [14], seneca valley 
virus [15], adenovirus [16] and raccoonpox virus [17]. 
1.2.2 History of oncolytic virotherpay 
The use of viruses in the treatment of cancer started from the observation that 
cancer patients who contracted an infectious disease showed brief periods of cancer 
remission. These patients suffered primarily from hematological malignancies such 
as leukemia or lymphoma. In 1896, Dock described a 42-year-old woman with 
“myelogenous leukemia” that went into remission after presumed influenza infection 
[18]. In another case, chickenpox led to the regression of lymphatic leukemia in a 4-
year-old boy [19]. Unfortunately, remission in both these cases lasted only for one 
month, subsequently progressing rapidly until death. Nonetheless, these 
observations gave the impression that under the right circumstances certain viruses 
can destroy tumors. 
During the same time, A. Moore, who pioneered the testing of OVs in animal cancer 
models, teamed up with a clinical oncologist C. Southam. Moore and Southam 
contributed much to the advancement of OVs in both preclinical trials in animal 
models and clinical trials in human subjects. They used the Egypt 101 isolate of 
West Nile virus in more than 150 virus therapy trials against a wide range of cancers 
[20]. Viremia and intra-tumoral virus replication were confirmed in most patients, but 
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tumor responses were rare and side effects such as neurotoxicity associated with 
the viral pathology were observed [20, 21]. Subsequently, other less toxic viruses 
such as adenovirus and virus strains of poxvirus family entered these investigations. 
Adenovirus was found to have relatively moderate side effects and consequently, 
entered clinical trials for the treatment of cervical cancer [22]. 
Despite their tremendous anti-cancer potential, it became clear that viruses needed 
to be more specific to the cancer and less toxic to healthy tissues. Thus began the 
era of adaptation and genetic engineering of viruses. It was recognized early that 
viruses were capable of increasing their replication in specific tissues by adaptation 
on specific cell types. Thus, viruses when continuously passaged in particular cell 
types were able to replicate only in that cells. Vaccinia virus used as a vaccine 
against small pox disease is one of such example. Small pox vaccine was 
continuously passaged from one individual to another, which limited its replication to 
epithelial cells. In 1922, Levaditi et al. showed that a small pox vaccine was able to 
inhibit the growth of various tumors in rats and mice [23]. 
The dire need for effective cancer therapy in 1950 drove attempts to reduce virus 
pathogenicity and increase anti-cancer effects, albeit with limited success. Major 
advances in virus manipulation were not possible until methods were developed for 
direct modification of the viral genomes. After it arrived, recombinant DNA 
technology was applied predominantly to the engineering of adenovirus [24], 
paramyxovirus [25], Herpes virus [26], and poxviruses [27]. Most viruses can now 
be adapted or engineered to eliminate their pathogenicity without destroying their 
oncolytic potency. Yet, even with the newfound ability to engineer viral genomes to 
produce a new generation of safer, more specific oncolytics, a true therapeutic 
frontrunner has not emerged.  
1.2.3 How do oncolytic viruses kill cancer cells? 
Oncolytic viruses destroy malignant cells and display anti-tumor effects through 
several different mechanisms. Certain viruses like reovirus, vesicular stomatitis virus, 
measles virus have natural tumor tropism, that is, they infect tumor cells more than 
they infect healthy cells [28]. Infected tumor cells die either through the direct action 
of the replicating virus, for example, the overconsumption of cell metabolites, or by 
secondary effects, such as excessive budding of virus from the cell surface (cell 
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lysis). The replication cycle repeats, as progeny viruses infect adjacent tumor cells 
and subsequently kill them. Some OVs synthesize specific proteins during replication 
that are cytotoxic to cancer cells. For example, adenoviruses led to expression of the 
death protein E3 and the E4ORF4 protein late in the cell cycle, both of which are 
toxic to cells [29]. Alternatively, virus replication in endothelial cells of blood vessels 
may directly or indirectly induce apoptosis in tumor blood vessel endothelium, which 
further lead to cancer cell death [30]. The third mechanism by which OVs act is by 
initiating specific and nonspecific anti-tumor immune responses. This may be derived 
from either the innate immune system, for example, natural killer cells, or the 
adaptive immune system, via the action of dendritic cells. Induction of specific anti-
tumor immunity is thought to provide long-term defense against cancer recurrence 
[31]. An illustration of the various mechanism of action of oncolytic viruses is 
provided in Figure 1 
 
Fig. 1 Mechanism of action of oncolytic Virus [31] 
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OVs, which are not naturally oncotropic, can also be engineered to replicate in tumor 
tissue. Better understanding in recent years of molecular events of virus-cell 
interactions has allowed for the design of genetically engineered viruses that target 
selected molecules or signaling pathways such as p16, p21, p53, IFN pathway, 
PTEN, EGFR, VEGFR, STAT3, HSP70, anti-apoptosis or hypoxia [32]. Several OVs 
including adenoviruses and vaccinia viruses are targeted to human cancer cells by 
taking advantage of these defective pathways. 
1.2.4 Current status of clinical trials with oncolytic viruses 
In this modern era, clinical trials of oncolytic virotherapy began using OVs belonging 
to at least ten different oncolytic virus families. Clinical tolerability of OVs has been 
excellent, even at the current highest feasible doses. Additionally, recent clinical 
evidence supporting the efficacy of oncolytic virotherapy comes from several clinical 
trial reports. The adenovirus ONYX-015 was tested in over 200 patients through 
Phase I to Phase III clinical trials. Single agent treatment showed limited tumor 
regression (maximum14%) with no objective response, however, in combination with 
chemotherapy 54%-63% patient showed tumor regression. [33]. Meanwhile, 
randomized, double blind Phase III study of REOLYSIN (Reovirus Type 3 Dearing) in 
combination with paclitaxel and carboplatin in patients with head and neck 
carcinoma is currently going on [34]. Reolysin treatment was well tolerated in 
metastatic melanoma patients in a Phase II study and viral replication was 
demonstrated in biopsy samples [35]. Likewise, a modified form of the Herpes 
simplex virus type 1, talimogene laherparepvec (T-Vec), was tested in a Phase III 
clinical trial in patients with metastatic melanoma. Virus treatment showed 16% 
durable response rate (DRR) compared to 2% in GM-CSF treated control patients 
[33]. Similarly, a VACV encoding GM-CSF, JX594, administered by intratumoral 
injection led to 16% complete response and 10% partial response in metastatic 
melanoma patients in Phase II trials [36]. In addition to these oncolytic virus strains, 
various other viruses including measles virus, coxsackie virus and vaccinia virus 
have completed multiple Phase I trials with promising results. The detailed overview 
of clinical trials with oncolytic viruses is listed in Table1. 
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Table 1: Clinically tested oncolytic viruses in human cancer patient 
Virus Construct Phase  Cancer type Response 
Adenovirus 
CG0070 
(Encoding GM-
CSF) 
Phase II 
Phase III 
Bladder Cancer 
Papillary Tumors Recruiting 
ICOVIR-5 Phase I Melanoma Recruiting 
CGTG-102 Phase I Solid tumors Recruiting 
ColoAd-1 Phase I Colon cancer Recruiting 
Vaccinia Virus 
JX-594 Phase II Hepatocellular 
carcinoma 
15 % Objective 
response rate 
[36] 
GL-ONC1 Phase I Advanced solid 
Cancers Recruiting 
Herpes 
simplex virus 
(HSV) 
type 1 
HSV1716 Phase I/IIa Malignant pleural 
mesothelioma Recruiting 
G207 Phase Ib/II Glioma, 
Glioblastoma 
Safe and virus 
replicated in 
tumor [37]  
OncoVEX GM-
CSF Phase III 
Metastatic 
melanoma 
16 % Durable 
response rate 
[38] 
Reo virus REOLYSIN Phase I/II Malignant Glioma 
Soft tissue sarcoma 
Safe with 
Stable 
Disease[35]  
Vesicular 
stomatitis 
virus (VSV) 
VSV encoding 
INF-β Phase I 
Hepatocellular 
carcinoma Recruiting 
Measles virus Measles 
encoding CEA Phase I 
Ovarian and 
Peritoneal cancer Active 
Parvo virus H-1 PV Phase I/IIa Glioblastoma Recruiting 
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1.3 Oncolytic virotherapy for canine cancer patients 
Despite recent progress in the diagnosis and treatment of advanced canine cancer, 
overall patient treatment outcome has not been substantially improved. Virotherapy 
using oncolytic viruses is one promising new strategy for cancer therapy. Oncolytic 
virotherapy has been tested for the treatment of canine cancer as proof of concept 
investigations. However, the use of oncolytic virotherapy in veterinary medicine is 
still far from becoming commercially available as promising laboratory results have 
yet to be translated into clinical outcomes. So far, canine cancers, such as 
osteosarcoma, malignant melanoma, lymphoma, soft tissue sarcoma, mammary 
adenoma and carcinoma, have been tested with only a few oncolytic viruses, mainly 
the human and canine adenoviruses, canine distemper virus and vaccinia virus 
strains [32].  
Several Ad5-based adenoviral vectors encoding different genetic or molecular 
factors associated with cancer have been tested with success for treatment of 
different canine tumors. Adenoviral vector-mediated p53 gene transfer had an anti-
tumor effect in canine osteosarcoma xenografts [39]. Moreover, a genetically 
engineered adenovirus vector targeted to CD40 ligand induced strong cellular and 
humoral immune response to tumor antigen CEA in dogs [40]. The conditionally 
replicating canine adenovirus 2 (CAV-2) with the osteocalcin promoter showed 
significant therapeutic effect in canine osteosarcoma xenograft. In addition, 
administration of this modified canine adenovirus to normal dogs showed only 
moderate virus-associated toxicity [32]. A very recent study demonstrated that 
canine mast cell tumors (MCT) were highly susceptible to reovirus infection in vitro 
and a single intratumoral reovirus injection significantly regressed canine mast cell 
tumor xenografts. However, reovirus also infected normal canine mast cells raising 
safety concerns [41]. 
Like adenovirus and reovirus, VACV has demonstrated promising oncolytic potential 
against canine cancer xenografts in mouse model. GLV-1h68 (Genelux Corporation, 
USA), a VACV strain that has shown promising preclinical data and is now 
undergoing clinical trials in humans, was tested for the treatment of canine cancers. 
GLV-1h68 (named GL-ONC1 as produced for clinical investigation) was developed 
from the Lister strain by inserting three expression cassettes encoding Renilla 
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luciferase–Aequorea green fluorescent protein fusion (Ruc-GFP), lacZ, and β-
glucuronidase into the F14.5L, J2R (thymidine kinase) and A56R (hemagglutinin) loci 
of the viral genome, respectively [8]. The effect of the virus was studied in xenograft 
models with the canine mammary carcinoma cell line MTH52c, the canine soft tissue 
sarcoma and the canine mammary adenoma cell line ZMTH3 in nude mice. GLV-
1h68 efficiently infected, replicated in and destroyed all three types of cells in culture 
[42]. In all three models, significant inhibition of tumor growth was observed after a 
single systemic administration of GLV-1h68. Additionally, GLV-1h68 enabled the 
detection of metastases via optical imaging. Another oncolytic vaccinia virus strain 
LIVP1.1.1, a new variant isolated from the wild-type LIVP strain, efficiently killed the 
canine soft tissue sarcoma cells. Systemic administration of LIVP1.1.1 led to 
significant growth inhibition of canine soft tissue sarcoma xenografts in nude mice. 
The LIVP1.1.1 mediated therapy significantly improved survival of sarcoma bearing 
mice and resulted in almost complete tumor regression [42]. Considering the 
promising results in several canine cancer xenografts, the VACV derived from LIVP 
strain called V-VET1 is being analyzed in phase I study for safety and dose 
escalation in dogs with different cancers [7]. 
1.3.1 Translation of oncolytic virotherapy from dogs to humans and reverse 
The preclinical development of anticancer drugs has been based primarily on the 
implantation of murine or human cancer cells into mice. Naturally occurring cancers 
in pet dogs that share many features with human cancers are prominent and 
alternative models for development of anticancer drugs [43]. Studying dogs with 
cancer is likely to provide valuable information that is distinct from that generated in 
studies of rodent cancers alone. Canine cancers show significant similarity with 
human cancers including histological appearance, tumor genetics, molecular targets, 
biological behavior and response to conventional therapy [44, 45]. In both species, 
tumor initiation and progression is influenced by similar factors like age, nutrition, sex 
and environmental exposure. Dogs show as diverse cancers as seen in humans. 
Many of the treatment options used in veterinary medicine resemble protocols used 
to treat human cancer patients. In addition, public release of nearly 99% canine 
genome sequences provided a window of opportunity to expand the scope of 
comparative oncology [46]. Comparison of canine genome sequences with the 
human genome suggests that around 19,000 genes identified in the dog match to 
	   17 
similar or orthologous genes in the human genome. The genetic and biological 
similarities between two species have been utilized for the development of various 
anticancer drugs for canine as well as human cancers patients and oncolytic 
virotherapy is not an exception [47].  
It is well known that despite evidence of oncolytic virus efficacy in mouse cancer 
models, many viruses fail in human trials due to unacceptable toxicity or lack of 
efficacy [48]. Some strains of oncolytic viruses such as the human adenovirus and 
the vaccinia virus in general do not productively replicate in mouse cells [49]. Thus, 
certain permissive cancer cells are grown in immunecompetent animals to study 
virus replication. Although these cancer models provide certain degree of 
understanding of oncolytic activity of virus, artificial establishment of these tumors as 
subcutaneous xenografts raises concern as to how well this model mimics their 
natural human counterparts. Hence, pet dogs with tumors are necessary models to 
demonstrate efficacy of OVs for both canine and human cancers. In addition, an 
alternative approach may be the use of species-specific viruses in their natural 
hosts. For example, application of canine adenovirus 2 in osteosarcoma of dog has 
shown to address the issue of tumor setting, efficient virus replication and oncolysis 
[50]. Canine osteosarcoma resembles human osteosarcoma at several levels 
including histopathology and metastatic behavior. In addition, canine adenovirus 2 
shares similarities with human adenoviruses that are used as oncolytic agents for 
human osteosarcoma. Thus, considering vast similarities between osteosarcoma 
and adenovirus strains from both the species, the data from these studies are more 
reliable and helpful in designing human clinical trials.  
Development of oncolytic virotherapy for treatment of canine cancer patients is of 
prime importance. Taking into consideration the value of comparative oncology, data 
obtained from human clinical trials can be effectively transferred to canines and vice 
versa.  
1.4 Oncolytic vaccinia virus 
Vaccinia virus (VACV) is arguably the most successful live biotherapeutic agent in 
medical history. It was the active agent of the smallpox vaccine that successfully 
eradicated smallpox, one of the most deadly diseases in human history [51]. VACV 
has also been exploited as a therapeutic agent against cancer since 1922. This virus 
selectively infects and destroys tumor cells, while sparing normal cells, both in cell 
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culture and in animal models. Anti-tumor therapeutic efficacy also has been 
demonstrated in human patients and in canine patients with a variety of tumor types 
[8, 42]. In addition recombinant oncolytic VACVs carrying imaging genes represent 
an advance in treatment strategy that combines tumor specific therapeutics as well 
as diagnostics (theranostics) [52]. This chapter briefly describes previous and 
current vaccinia viruses as oncolytic agents in cancer therapy. 
1.4.1 History of oncolytic vaccinia virus 
The true origin of VACV is not known. In the 18th century, Edward Jenner used as a 
vaccine for smallpox a virus that he isolated from a milkmaid, presumably a cowpox 
virus [53]. The virus was passaged from one individual to another over the next 130 
years. In the 1930s, when small pox vaccination commenced with this virus, it 
became clear that the strain was distinct from the cowpox virus. This new strain, 
subsequently named “vaccinia virus”, is speculated to have either derived from the 
cowpox virus through serial passages under laboratory conditions or represented a 
laboratory survivor of a virus that is extinct in nature [54].  
Even before VACV gained popularity in the medical community as the choice for 
smallpox vaccination, it was used as a therapeutic agent for the treatment of cancer. 
In 1922, Salmon and Baix observed that VACV successfully infected and produced 
characteristic lesions in a large breast carcinoma of a female patient after 
intratumoral inoculation [23]. In 1960, Burdick reported that malignant melanoma of 
a female patient went into remission after VACV treatment [55]. In 1987, Arakawa 
reported for the first time, that intravenous injection of VACV was effective in treating 
patients with lung, renal adenocarcinomas or multiple myeloma [56]. Subsequently, 
with the advances in recombinant DNA technology, VACV strains have been 
engineered to encode foreign genes in cancer cells that can kill the cancer cells or 
help the activation of the immune system [57].  
1.4.2 An overview of vaccinia virus biology  
VACV is a double-stranded DNA virus that replicates entirely in the cytoplasm of 
host cells. It produces three forms of infectious particles: intracellular mature virus 
(IMV), cell-associated enveloped virus (CEV) and extracellular enveloped virus 
(EEV). Vaccinia IMV particles are brick-shaped, approximately 300 X 240 X 120 nm 
in size, with a lipoprotein shell surrounding a complex core structure. The core 
structure contains a linear, double-stranded DNA genome of approximately 192 kb. 
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The VACV genome encodes around 200 genes that are largely non-overlapping. 
The process of cell entry by VACV is not well understood. For instance, it is 
presumed that VACV gains entry into cells via a cellular receptor, yet that receptor 
has not been unequivocally identified.  Moreover, VACV can enter many different cell 
lines, suggesting that either it uses many different receptors or it uses a single 
receptor ubiquitous to all cells. IMVs enter cells by fusion with the plasma membrane 
[58]. In contrast, EEVs enter cells by endocytosis followed by low pH disruption of 
the EEV outer membrane and fusion of the released IMV with endosomal 
membranes [59]. 
Unlike other DNA viruses, vaccinia virus remains in the cell cytoplasm for the entire 
duration of the infectious cycle [60]. Vaccinia encodes its own proteins required for 
replication, especially those essential for DNA replication and mRNA synthesis. 
Because of its lack of dependency on host proteins, VACV replicates well in many 
different cell types. 
After entry into the cytoplasm while the viral cores are only partially uncoated, the 
virus transcribes early class genes encoding viral proteins required for synthesis and 
maturation of viral RNA. The encoded early proteins include RNA polymerase, 
transcription factors, mRNA capping and methylating enzymes, and poly (A) 
polymerase. Subsequently, the viral cores undergo a second uncoating in 
preparation for viral DNA replication. Replication of the viral DNA occurs very 
efficiently within the infected cell. The time of onset of DNA synthesis varies to some 
extent with multiplicity of infection (m.o.i.) and cell type. It typically begins 1–2 h after 
infection and within several hours results in the generation of about 10,000 genome 
copies per cell, of which half are ultimately packaged into infectious virions [27]. 
DNA replication occurs at sites in the cytoplasm termed “viral factories”.  DNA 
synthesis begins with the introduction of a nick in one DNA strand near one or both 
ends of the viral genome [57]. Viral DNA replication is followed by expression of 
intermediate class genes, which encode late class viral proteins. Late viral proteins 
encode enzymes and structural proteins that are assembled into the final viral 
particles. Promoters for early, intermediate, and late viral genes contain distinctive 
sequence elements that regulate the timing and the extent of viral gene transcription 
and translation [61]. Upon synthesis of the late structural proteins, infectious virus 
particles are assembled, a process that eventually leads to lysis of the infected cell. 
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Assembly of viral particles takes place in the so-called “virus factories”. The newly 
synthesized viral genomes are wrapped in a complex scaffold of proteins and lipids 
to form the first infectious viral particles called IMVs [62]. The majority of the IMVs 
remain within the cell until lysis. However, a small subset of IMVs leaves the factory 
in a microtubule-dependent manner and these particles become wrapped by a 
double-layer of membrane derived either from the early endosomes or from the 
trans-Golgi network to form intracellular enveloped viruses (IEVs), an intermediate 
between the IMVs and the CEVs/EEVs [63]. IEVs then move along microtubules to 
the cell surface [64], where the outer envelopes of the IEVs fuse with the plasma 
membrane, exposing enveloped virions on the cell surface. Some of them are 
retained on the cell surface to become CEVs, while others dissociate from the cell as 
EEVs. The different forms of virus particles produced by VACV replication have 
different properties relating to the promotion of cell-to-cell virus spread and evasion 
of circulating antibodies and complement in the blood stream. The replication cycle 
of VACV is represented diagrammatically in Fig. 2. 
 
Fig 2. The cytoplasmic replication of vaccinia virus  
Abbrevations: IMV, intracellular mature virus; IEV, intracellular enveloped virus; CEV, 
cell-associated enveloped virus; EEV, extracellular enveloped virus. [65] 
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1.4.3 Preclinical research with vaccinia virus as an oncolytic agent 
VACV exhibits a broad host range, allowing its use in many experimental animal 
models. This broad host range makes it possible that a VACV strain characterized in 
preclinical studies may also be used in human and canine cancer patients. VACV is 
used for cancer therapy mainly via three approaches:  
i) As a replication competent (oncolytic) virus to directly lyse tumor cells,  
ii) As a gene delivery vector to express therapeutic and diagnostic genes 
with added therapeutic benefit and  
iii) Combination of VACV with other anti-cancer therapies.  
1.4.3.1 Replication-competent oncolytic vaccinia virus in preclinical research 
VACV has a natural tropism for tumors. Studies have shown that after intravenous 
administration of VACV into tumor-bearing animals, the highest amounts of virus 
were recovered from tumors with little virus detected in other organs [8]. The 
oncolytic potential of VACV varies depending on the strain of the virus. Lister, 
Copenhagen, Wyeth and Western Reserve strains have demonstrated oncolytic 
potency [66]. In contrast, strains such as MVA and NYVAC do not replicate in 
mammalian cells and, therefore, have no oncolytic potential. The antitumor efficacy 
of each strain is predominantly based on its infectivity to cancer cells, its replication 
potential, its cell-to-cell spreading and its cell lysis potential. LIVP1.1.1 virus derived 
from the lister strain; exhibit significant oncolytic potency in various human and 
canine cancer xenograft models[42, 67]. Interestingly, the virus thymidine kinase (tk) 
gene, important for VACV replication, was found to be naturally inactivated in both 
these Lister-derived strains, making them dependent on host-derived thymidine 
kinase activity, found mostly in cancer cells [42].  
Replication competent viruses also kill cancer cells by modulating host immunity. 
VACV infection results in cell destruction and release of cellular danger signals 
(danger-associated molecular pattern molecules) and viral danger signals 
(pathogen-associated molecular pattern molecules) as well as tumor associated 
antigens. These antigens activate immune responses against the tumor tissues. 
LIVP6.1.1 infection in mouse tumor xenografts enhances Infiltration of innate 
immune cells into mouse xenograft tumors by infection with LIVP6.1.1 and, resulting 
in an overall improvement in oncolytic efficacy [42]. Additionally, oncolytic VACV 
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infection of tumors induces blood vessel collapse within the infected tumors 
contributing to tumor regression [68].  
1.4.3.2 Development of vaccinia virus as a delivery vehicle for therapeutic 
and diagnostic genes 
Oncolytic VACV, with its ability to replicate exclusively in tumor tissue, may be an 
ideal gene transfer agent for therapeutic proteins to cancer cells. VACV infection 
enables the localized expression of transgene-encoded proteins at high 
concentration in a large proportion of the tumor cells.  Because of its large genome, 
VACV can easily contain and simultaneously lead to expression of multiple 
transgenes. Different promoters can regulate the timing and extent of expression of 
these transgenes. Transgene products can either be produced intracellularly or can 
be efficiently secreted from the infected cells. Indeed, many recombinant VACV 
constructs containing transgenes have been made and tested preclinically for 
expression and activity of the heterologous products and their benefit in antitumor 
efficacy and/or in imaging.  
VACV has been engineered to express tumor-associated antigens to elicit antigen-
specific immune responses. Recombinant VACV vectors carrying carcinoembryonic 
antigen (CEA) were constructed and examined in numerous preclinical studies [69]. 
Clinical trials have been conducted with these vectors to examine their toxicity, 
immune activities, and tumor responses in patients with advanced or metastatic 
CEA-expressing adenocarcinomas [70]. The vaccines were well tolerated and 
effective at inducing CEA-specific cytotoxic T cell responses [71]. In another 
example, use of VACV as a vehicle for delivery of anti-angiogenic factors to tumor 
sites has been well established. Destruction of tumoral vasculature using anti-
angiogenic agents is emerging as a promising therapeutic modality for treatment of 
solid tumors. VACV encoding single-chain antibody against VEGF (GLV-1h109) 
improved the therapeutic response in mice with human tumor xenografts [72]. The 
VACV platform has been used also to express other immunomodulatory molecules 
like interleukins (IL-4, IL-24, hyper IL-6), interferons (IFN-γ) and several immune 
activating antibodies (CTLA-4, PD-1 and PDL-1), each of which regulate the immune 
response and exert potent antitumor immunity to various extents [27, 73]. In 
addition, VACVs express prodrug-converting enzymes that kill tumor cells by 
	   23 
localized conversion of a prodrug to a cytotoxic agent. Two prodrug-converting 
enzymes/prodrug systems (i.e. cytosine deaminase/5-flurocytocine (CD/5-FC) 
system and purine nucleoside phosphorylase/6-methylpurine deoxyriboside (PNP/6-
MPDR) system) have been analyzed using replication selective VACV platforms. In 
both cases, the prodrug-converting enzymes were expressed by the recombinant 
VACV. Virus-mediated oncolysis and concomitant expression of cytosine deaminase 
enzymes significantly improved tumor cell death after addition of 5-FC. Furthermore, 
oncolytic VACVs containing imaging genes represent a new treatment strategy that 
combines tumor site-specific therapeutics and diagnostics, also called 
“therognostics” [51]. The genes encoding green fluorescent protein (GFP), luciferase 
and luciferase-GFP fusion protein have been incorporated in many oncolytic VACV 
constructs to detect and monitor therapy and virus distribution in live animal. The 
oncolytic VACV GLV-1h68 containing the gene encoding the fusion protein, Renilla 
luciferase- Aequorea GFP, enabled accurate, non-invasive detection and optical 
imaging of tumor regression in real time in a xenograft mouse model, as well as 
microscopic imaging of tumor biopsies at the tissue and cellular levels. In addition, 
the VACV platform has been used for gene-directed production of melanin 
specifically in tumor tissue [52]. Intratumoral production of melanin has the potential 
for use in several clinical diagnostic (e.g. marker during surgery, for endoscopy, in 
optoacoustic and MR imaging) and therapeutic procedures (near IR light induced 
thermotherapy). 
1.4.3.3 Combination of VACV and other therapeutic modalities 
Since the modes of tumor destruction of oncolytic virotherapy and other therapeutic 
modalities (e.g. chemotherapy, radiotherapy and immunotherapy) are different, the 
potential exists for synergy in combination treatments. In preclinical studies, oncolytic 
VACV GLV-1h68 was used in combination with cisplatin or gemcitabine, and the 
combination therapy resulted in a significantly faster decrease in tumor size [74]. In 
combination with radiation therapy, VACV showed improved virus replication and 
therapeutic response in several tumor models. Preferential replication of systemically 
delivered oncolytic VACVs GLV-1h68 and LIPV1.1.1 was seen in glioma xenografts 
that had been focally irradiated. The increased virus replication correlated with 
increased tumor regression and improved overall mouse survival [75]. Thus, tumor 
targeted ionizing radiation can be combined with systemically delivered oncolytic 
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VACV with synergistic results [76]. Other complementary therapeutic combinations 
of VACV with immunotherapy, surgery, hyperthermia and therapeutic monoclonal 
antibodies have also been evaluated with evidence of compatibility and/or improved 
efficacy.  
1.4.4 Clinical trials with oncolytic vaccinia virus 
Following a century of preclinical and clinical work, oncolytic viruses are now proving 
themselves in advanced phases of clinical trials. Oncolytic VACV strains (attenuated 
and genetically modified) are in various phases of clinical trials for treatment of a 
wide variety of cancers in both human and canine. VV-IL-2 a recombinant VACV 
leading to expression of the human IL-2 gene was the first cytokine-encoding VACV 
studied clinically in human patients with solid tumors [77]. Neither toxicity nor virus 
shedding was detected with VV-IL-2 in these patients. However, no significant tumor 
regression was observed. Another recombinant VACV strain, JX-594 that leads to 
expression of human GM-CSF, was evaluated  in Phase I and Phase II clinical trials 
for treatment of human patients with malignant mesothelioma and liver carcinoma. 
The virus was administered either intravenously or intratumorally and it was well 
tolerated with only infrequent, mild adverse effects. The virally encoded GM-CSF 
was detected at the injection sites in the tumors explaining capacity of virus to 
successfully expressing the transgene in tumor tissue. In addition, injection lesions 
were heavily infiltrated with CD4+ and CD8+ T lymphocytes, B lymphocytes, 
macrophages and eosinophils in patients with malignant mesothelioma. A second 
randomized Phase II trial with JX-594 virus in hepatocellular carcinoma patients 
showed anti-tumor efficacy, effects on tumor vasculature, and a dose dependent 
improved overall survival [78].  
Oncolytic VACV GLV-1h68 (GL-ONC1) has also been tested for its safety in Phase I 
clinical trials in human patients with solid tumors. This recombinant VACV is 
systemically delivered either as a single agent for treatment of advanced solid 
tumors or in combination with cisplatin and radiotherapy in head and neck cancer 
patients. GL-ONC1 is also in a Phase I/II clinical study in human patients with 
peritoneal carcinomatosis in which virus is delivered intraperitoneally [34]. The 
clinical trials with GL-ONC1 are currently ongoing and results are pending. Several 
additional VACV platforms are currently under trial for treatment of various human 
malignancies. The detailed overview of clinical trials with VACV is listed in table 2.  
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Table 2: Clinically tested oncolytic viruses in human and canine cancer patient 
Virus Phase/ (Route) Modification 
Cancer type 
 Response 
GL-ONC1 I/II (i/p) TK deletion +GFP, B-gal, B-gluc 
Peritoneal Car
cinoma Active trial 
GL-ONC 1 I (i/v) TK deletion +GFP, B-gal, B-gluc Solid tumors Active trial [79] 
GL-ONC1  + 
cisplatin and 
radiation therapy 
I (i/v) TK deletion +GFP, B-gal, B-gluc 
Head and 
neck cancer Active trial 
GL-ONC1 I (i/pl) TK deletion +GFP, B-gal, B-gluc 
Lung cancer, 
mesothelioma Active trial 
JX-594 I (t/d) TK deletion + GM-CSF 
Hepatic 
carcinoma 
30% PR, 60% 
SD, 10% PD 
[78] 
JX-594 II (i/t) TK deletion + GM-CSF 
Hepato- 
Cellular 
carcinoma 
16% CR [36] 
JX-594 I (i/v) TK deletion + GM-CSF Solid tumors Active trial 
JX-594 + 
Irinotecan 
I/IIb 
(i/v) 
TK deletion + GM-
CSF 
Colorectal 
carcinoma Active trial 
JX-594 I/II (i/t) TK deletion + GM-CSF 
Malignant 
Melanoma Safe and SD 
V-VET1 I (i/v) TK deleted lister strain 
Canine solid 
tumors Active trial [7] 
VV-IL-2 I (i/t) TK deleted + P7.5-hIL-2 
Malignant 
mesothelioma 
No significant 
tumor 
regression 
Wild type Vaccinia 
Virus I (i/ves) Not applicable 
Advanced 
bladder 
cancer 
75 % patients 
showed 4-year 
survival. 
rV-B7.1 I (i/t) Human B7.1 Malignant melanoma 
10% patient 
showed PR 
i/p: Intra-peritoneal, i/v: Intravenous, t/d: Transdermal, i/t: Intra-tumoral, i/ves: Intra-vescicle, 
i/pl: Intra-plural, TK: thymidine kinase, GM-CSF: Granulocyte-macrophage-colony 
stimulating factor, GFP: Green fluorescent, β-Gluc: β-glucoronidase, 
 
In contrast to the clinical progress of human oncolytic virotherapy, there are very few 
clinical trials using OVs for canine cancer patients. Currently, a Phase I clinical study 
is underway to evaluate the safety of intravenous administration of VACV strain 
LIVP6.1.1 (V-VET1) in canine cancer patients at Angel Care Cancer Center, 
	   26 
Carlsbad, California, USA. Results from this dose escalation study in dogs are 
positive and LIVP virus was found in biopsies weeks after treatment [7]. 
Despite the continuing results of VACV clinical studies showing acceptable safety 
and promising efficacy, the mechanisms of action of VACV in cancer therapy are still 
ill defined. The relative contributions of “pure” oncolysis, modulation of tumor 
microenvironment post-oncolysis, and the benefit of adding a transgene are not 
clearly understood. For example, while much is known about how OVs initially infect 
tumors, very little attention is placed on the multiple barriers that inhibit optimal virus 
spread throughout the tumor. Understanding the complex nature of the tumor 
microenvironment and its effects on oncolytic virotherapy could be of significant 
importance for improving the overall therapeutic activity and clinical utility of OVs.    
1.5 Tumor microenvironment and oncolytic virotherapy 
Systemic infection of oncolytic VACV specifically infects tumor cells and 
subsequently virus spreads throughout the tumor. While only a very small fraction of 
the intravenously administered virus reaches the tumor site and the virus that does 
infect the tumor rapidly amplifies within the tumor cells. For efficient intratumoral 
amplification, virus must overcome several obstacles within the tumor 
microenvironment. For example, VACV must travel through heterogeneous and 
perfused tumor vasculature, avoid entrapment in the extracellular matrix (ECM) and 
evade various immune cells. However, the poorly arranged and chaotic nature of the 
tumor microenvironment may constitute weaknesses in the anti-virus defenses that 
improve effectiveness of oncolytic VACV-mediated tumor therapy. Numerous 
strategies are employed to manipulate the components of tumor microenvironment 
to improve virus infection and spread within the tumor tissue as well as the killing of 
tumor cells by the immune system.  
1.5.1 Strategies to manipulate ECM 
The extracellular matrix in solid tumors is composed of complex secretions of 
proteins and proteoglycans produced by both neoplastic and normal stromal cells. 
Slight changes in the tumor ECM organization can have tremendous impact on 
cancer cell biology and its response to therapy. ECM of most tumors includes 
mesenchymal proteins that are absent in normal tissue and render the matrix of 
these tumors very distinct from normal tissue. Increased ECM secretion in tumors 
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also results in increased water retention that increases interstitial fluid pressure. 
Apart from increased pressure, the interlocked meshwork of secreted proteins 
presents a physical barrier that interferes with efficient dispersal of therapeutics 
within the solid tumor [80]. Inefficient dispersal of OV through the solid tumor has 
been previously noted and is considered to be one of the major limitations of 
Oncolytic virotherapy. This has been evidenced by discrete focal viral localization in 
tumor xenografts treated with VACV in mice [81]. Viral presence has also been 
shown to localize only in small discrete areas in clinical tissues harvested from 
human patients treated with HSV [82]. These observations indicate that approaches 
used to modulate the complex extracellular matrix should enhance oncolytic VACV 
efficacy. Several innovative strategies to enhance VACV spread within the tumor 
microenvironment have been investigated in recent years. A naturally occurring form 
of poxvirus, an extracellular enveloped virus (EEV) that possesses host cell derived 
lipid bilayer has been evolved for rapid spread within the tumors. Kirn et al. 
compared the oncolytic potential of low versus high-EEV producing VACV strains. 
VACV strains that produced high amount of EEV particles displayed improved 
spread within the tumor after systemic delivery, resulting in significantly improved 
therapeutic response [83]. Another approach to manipulate ECM is to arm oncolytic 
viruses with the enzymes that degrade the ECM. Oncolytic vaccinia virus GLV-1h255 
containing the matrix metalloproteinase-9 gene was constructed and used to treat 
PC-3 tumor-bearing mice. VACV-mediated intra-tumoral over-expression of matrix 
metalloproteinase-9 lead to a degradation of collagen IV, facilitating intra-tumoral 
viral dissemination and resulting in accelerated tumor regression [84]. 
1.5.2 Strategies to target tumor angiogenesis 
Angiogenesis is the process of formation of new blood vessels that involves the 
migration, growth, and differentiation of vascular endothelial cells. Folkman in 1971 
proposed that primary solid tumors could attain a size of around 1-2 mm diameter 
even in an avascular state. When tumors attains a size of 1-2 mm diameter, 
surrounding mature host blood vessels begin formation of new blood capillaries, 
which grow towards and infiltrate the tumor mass [85]. A variety of growth factors 
families and their related receptor; collectively called as tumor angiogenic factors 
(TAFs), trigger the angiogenic switch in tumors. TAFs mainly include fibroblast 
growth factor (FGF), vascular endothelial growth factor (VEGF), VEGF tyrosine 
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kinase receptors, platelet derived growth factors (PDGFs), angiopoeitin and 
angiopoeitin tyrosine kinase receptors. Tumor cells and surrounding normal cells 
release TAFs, which regulate the formation of new blood vessels. The newly formed 
blood vessels provide oxygen and nutrients to the growing tumor and allow the tumor 
to invade nearby tissue and to proliferate. However, the newly formed blood vessels 
are highly permeable because of immature endothelial cells and fewer intracellular 
junction complexes than in the normal vasculature. These abnormal blood vessels 
allow escape of tumor cells from the primary tumor to distant organs leading to 
metastasis. Therefore targeting tumor vasculature remains a very significant area of 
preclinical and clinical cancer research. 
Obstructions of blood flow to the tumor by treatments that target tumor vasculature 
induces ischemia or cytostasis thereby preventing oxygen and nutrient supply to 
cancer cells in the center of solid tumors. Further lack of oxygen and nutrients leads 
to death of the cancer cells. Moreover, Jain et al. showed that use of anti-angiogenic 
agents that were originally targeted to inhibit formation of new blood vessels, could 
transiently “normalize” the tumor vasculature. Normalization of tumor vasculature 
alleviates hypoxia, increases delivery of drugs and anti-tumor immune cells, and 
improves the outcome of various therapies [86].  
Inhibiting tumor angiogenesis by blocking TAFs can potentially affect tumor growth. 
Most of the anti-angiogenic agents that entered the drug development pipeline 
targeted VEGF ligands or receptors. VEGF has a key role in the signaling pathways 
that mediate angiogenesis, tumor growth, and metastasis. Monoclonal antibodies 
against VEGF are now in widespread clinical use in oncology. Bevacizumab 
(Avastin, Genentech, USA), a humanized anti-VEGF-A monoclonal antibody was the 
first anti-angiogenic drug approved by FDA of USA. However, efforts to develop 
other anti-angiogenic targets such as angiopoeitin and PDGFs are ongoing [87]. 
Various anti-angiogenic molecules e.g. Aflibercept (Zeltrap, Sanofi Aventis, USA), 
Sorafenib (Nexawar, Bayer Healthcare, USA), Sunitinib (Sutent, Pfizer inc, USA) are 
approved for the treatment of one or more tumor types. In addition, clinical trials are 
ongoing with new anti-angiogenic agents that mainly target TAFs [34]. Despite these 
efforts, the clinical outcomes in cancer patients treated with anti-angiogenic 
therapies have been less than anticipated. However, anti-angiogenic therapy alone 
was not expected to be curative but can only prevent any new expansion and tumor 
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when reach the size of 1-2 mm diameter can regrow without vasculature. Therefore, 
combining anti-angiogenic approaches with additional anti-cancer approaches, like 
oncolytic virotherapy would provide combined benefits. Viral oncolysis would kill the 
tumor cells and anti-angiogenic therapy would inhibit the tumor spread and 
metastasis.  
Oncolytic VACVs are the leading viral vectors that are targeted against tumor 
angiogenesis. VACV engineered to target cells with activated of Ras/MAPK signaling 
pathway (JX-549) specifically infected tumor-associated vascular endothelial cells in 
hepatocellular carcinoma patients hence, and caused disruption of tumor perfusion. 
This virus has shown natural ability to infect vascular endothelial cells [68]. In 
addition, VACVs have been able to deliver angiogenesis inhibitors to the tumor site, 
providing local expression of these proteins on a continual basis consequently 
maximizing efficacy and limiting side effects. Since VEGF is highly expressed in 
many cancers, this pathway has been targeted by many VACV encoding anti-
angiogenic inhibitors. More recently, Guse et al. showed that VACV armed with 
soluble VEGF receptor 1 protein enhanced antitumor efficacy in a renal cell cancer 
model [88]. VACV has also been used to deliver a single chain antibody directed at 
VEGF. The VACV strain GLV-1h109 that expresses anti-VEGF single-chain antibody 
has significantly improved therapeutic efficacy in human tumor xenografts compared 
to parental virus GLV-1h68 [72]. In addition, VACV armed with other endogenous 
inhibitors of, for example, angiostatin and FGF was shown to be more efficient than 
its unarmed counterpart [89]. 
1.5.3 Strategies to modulate the immune response 
Apart from tumor vasculature and ECM, infiltrating host immune cells are another 
significant component of the tumor microenvironment. While host immune cells have 
the potential to initiate and activate a potent anti-tumor immune response, they are 
often utilized by the tumor to produce pro-angiogenic, pro-invasive and pro-
tumorigenic signaling. Classically, the immune system is thought to limit efficacy of 
oncolytic virotherapy, leading to viral clearance. However, preclinical and clinical 
data suggest that in some cases virotherapy may in fact act as a cancer 
immunotherapy. Oncolytic viruses induce tumor cell death by inducing apoptotic or 
necrotic pathways. During the cell death process, dying cells release tumor-
associated antigens (TAAs). These TAAs coupled with danger signal associated with 
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virus infection could create a favorable environment that would elicit a specific 
immune response. Considering the dual role of immune system in tumor biology, it is 
important to understand the immune response to viruses and virus-colonized tumors 
in order to develop successful strategies to combat cancer with OVs. 
1.5.3.1 Innate immune response and oncolytic virotherapy 
The ability of the innate immune response to limit viral replication has been 
demonstrated in several experimental models [90] and in clinical studies [91]. The 
manipulation of the innate immune response in favor of antitumor activity represents 
a critical target for achieving successful tumor immunotherapy. Innate immune 
response may be directly cytotoxic to tumors, while it can also help to induce an 
adaptive immune response [92]. Among innate immune cells, the strongest 
anticancer response exists for Natural Killer (NK) cells [93]. In addition, dendritic 
cells (DCs) play a role in priming the adaptive T cells as well as recruit and interact 
with NK cells [94]. Macrophages constitute a dominant fraction of the innate immune 
cells that infiltrate developing tumors. Although macrophages are key orchestrators 
of the microenvironment that supports tumor progression, certain phenotype 
macrophages can mediate antitumor functions [95]. The impact of macrophages on 
tumor biology is largely influenced by cytokine signals within the tumor 
microenvironment. These signals produce a heterogeneous population of 
macrophages, which are commonly described based on their similarity to an M1 
(classically activated) or M2 (alternatively activated) phenotype. M1 macrophages, 
following exposure to interferon-γ (IFN-γ), have tumoricidal activity and elicit 
destruction of tumor tissue [96]. However, another type of innate immune cells 
categorized as myeloid derived suppressor cells (MDSCs) are potent 
immunosuppressive cells. In malignant states, MDSCs are induced by growth factors 
secreted by tumor cells. MDSCs play an important part in suppression of host innate 
and adaptive immune responses through several mechanisms such as production of 
arginase 1, release of reactive oxygen species and nitric oxide and secretion of 
immune-suppressive cytokines. This leads to a permissive immune environment 
enabling the growth of malignant cells. MDSCs may also contribute to angiogenesis 
and tumor invasion [97]. These findings highlight two extreme views of the immune 
system in relation to the efficacy of oncolytic virotherapy. On one hand, innate 
immune system promotes tumor progression; on other hand, experimental data 
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indicate that it has significant anti-tumor activity. Attempts have been made to 
modulate the innate immune response, aiming either to limit the innate response in 
order to enhance viral replication, or to enhance innate antitumor activity. The 
outcomes of these conflicting strategies provide insight into the role of the innate 
response to oncolytic virotherapy.  
Expression of IFN-β has been hypothesized to limit viral replication in normal tissue 
while allowing replication in tumor tissue, as tumor cells are commonly resistant to 
antiviral effects of type I IFNs. A VACV encoding INF-β (JX-594) significantly 
improved tumor selectivity and efficacy, in association with generation of anti-tumor 
immunity compared to a control VACV without IFN-β [98]. In addition, genetically 
engineered VACV (Vvdd) when combined with an agonist antibody specific for co-
stimulatory molecule CD137 induced an antitumor response. In an immune 
competent mouse model this combination treatment significantly reduced tumor 
growth relative to either treatment alone. Tumor growth inhibition was associated 
with greater infiltration of CD8+ T cells and NK cells, and more sustained presence 
of neutrophils at the tumor site. Depletion of T or NK cells or neutrophils reduced 
efficacy, confirming their contribution to an effective therapeutic response [99]. 
Furthermore, inhibition of MDSCs has improved the efficacy of oncolytic virotherapy. 
Oncolytic herpes simplex virus 1 (HSV-1) viruses armed with 15-prostaglandin 
dehydrogenase effectively reduced primary tumor growth and inhibited secondary 
metastasis in BALB/c mice with 4T1 breast cancer xenografts. Mice treated with 
HSV-1 encoding 15-prostaglandin dehydrogenase showed statistically significant 
decrease in splenic MDSCs compared to parental virus [100].  
1.5.3.2 Adaptive immune response and oncolytic virotherapy 
Cytotoxic T cells (CTL) and helper T cells are major contributors of the adaptive 
immune system that have significant antitumor effects. Oncolytic virus mediated 
tumor cell lysis release TAAs in tumor microenvironment and interacts with DCs via 
Pattern recognition receptors (PRRs) or Toll like receptors (TLRs). DCs and 
macrophages are classical antigen presenting cells (APCs) that present TAAs and 
induce adaptive immune response. A tumor-directed immune response involving 
cytotoxic CD8+ T-cells, T helper 1 (Th1) cells, and natural killer (NK) cells appear to 
protect against tumor development and progression. On the contrary, the immune 
response that involves B-cells, the activation of chronic humoral immunity and/or a T 
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helper 2 (Th2) polarized response can promote tumor development and progression 
[101]. CD8+ cytotoxic T cells recognize TAAs presented by MHC class I molecules 
on tumor cells and kill cancer cells using the perforin / granzyme system. Another 
type of T cells i.e. CD4+ T-cells are an important factor of the tumor 
microenvironment, which modulate the anti-tumor immune response. CD4+ T cells 
are activated in response to cytokines that are classified into two categories, Th1 
and Th2. After stimulation, the Th1 cells secrete interferon gamma (IFN-γ), 
transforming growth factor-beta (TGF-β), tumor necrosis factor alpha (TNF-α), and 
interleukin 2 (IL-2). These cytokines cooperate with the functions of cytotoxic CD8+ 
T-cells, producing a tumoricidal activity. In contrast, Th2 cells express interleukin (IL) 
4, 5, 6, 10, and 13 induce anergy of T-cells and loss of cytotoxicity, while increasing 
the humoral immunity (lymphocyte B function). Thus, Th1 cell responses benefit 
antitumor immunity, whereas Th2 cell responses produce a down-regulation of 
antitumor cell mediated immunity and increase the humoral pro-tumorigenic 
responses [101]. However, regulatory T-cells (Treg) and immature myeloid cells 
suppress antitumor immunity. Treg cells are a distinct group of lymphocytes with 
immunosuppressive properties that usually maintain immune tolerance. Treg cell 
suppressive activity is beneficial by restricting T cell response against self-antigens 
and preventing inflammatory and autoimmune diseases. In cancer, their inhibitory 
role in limiting immune response against “pseudo-self antigens” from tumor origin 
avoids an effective anti-tumoral immune response and often culminates into negative 
outcomes for the patient. These cells may play an important deleterious role in 
cancer immunopathology due to their potent suppressive activity of both T-cell 
activation and effector functions [102]. Furthermore, immature myeloid cells induce 
cytotoxic T-cells anergy by binding to T-cell receptor (TCR) complex in absence of 
co-stimulatory signals, which suppresses the anti-tumor activity of T cells.  
Considering the anti-tumor role of the adaptive immune system, the range of 
oncolytic viruses that have been reported to facilitate the generation of adaptive 
antitumor immunity reflects the broad applicability of the principle. Sequential 
administration of adenovirus and VACV in Syrian hamster with pancreatic cancer 
xenografts induced anti-tumor CTL and further significantly improved tumor 
regression [103]. In murine models, tumor delivery of oncolytic VACV by cytokine-
induced killer (CIK) cells induced antitumor immunity [104]. Attempts have been 
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made to enhance the immunotherapeutic potential of oncolytic viruses by 
incorporating immunostimulatory transgenes. Cytotoxic T cells were induced in 
human liver cancer patients treated with VACV encoding GM-CSF (JX-594) [36]. 
Granulocyte-monocyte colony-stimulating factor (GM-CSF) promotes the 
differentiation of progenitor cells into dendritic cells, and has been successfully used 
in strategies to generate tumor-reactive cytotoxic lymphocytes. Chemokines have 
also been inserted into oncolytic viral vectors in order to promote the recruitment of 
immune effectors to the tumor microenvironment.  Oncolytic adenovirus encoding 
the chemokine RANTES recruited DCs to the tumor microenvironment, eliciting 
antigen-specific CTL and NK cell responses, and promoted tumor regression [105]. 
These observations provide important insights into future strategies for optimizing 
the immunotherapeutic potential of oncolytic viruses. However, in many of these 
experiments it is difficult to decide the relative importance of direct viral oncolysis 
and immune mediated bystander killing of uninfected tumor cells. In conclusion, 
certain components of the immune system work in concert with, rather than at odds 
with oncolytic virotherapy. Thus, designing of oncolytic virus should consider immune 
activation as a part of solution, rather than a problem. 
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  CHAPTER 2: RATINALE AND AIM  
Oncolytic virotherapy is one of the promising approaches to treat cancer. Use of 
oncolytic VACV has shown promising results in both preclinical and clinical studies 
against various human cancers. However, oncolytic virotherapy using vaccinia virus 
against canine cancers is relatively new and the role of oncolytic VACV in treating 
canine cancers is not well understood. Preclinical studies of oncolytic virus efficacy 
and its mechanism of action were traditionally conducted in rodents. However, dogs 
have a long history of use in cancer research based on their strong anatomical and 
physiological similarities to humans. Therefore, the canine model provides 
opportunity for investigating treatment strategies both experimentally and clinically. 
Human and dog tumors show extensive similarities in histological appearance, tumor 
genetics, biological behavior and response to conventional therapy. The tumor 
microenvironment of both species shows enormous similarities. Thus, studying 
oncolytic virus and tumor microenvironment interaction in dogs with cancer could 
provide valuable information related to human cancer. Moreover, clinical 
investigation in dogs is possible based on the large proportion of pet dogs that are 
diagnosed and treated for cancer. Therefore, advancing the development of 
oncolytic viruses for treatment of cancer in canines could serve both to provide 
additional safe and effective treatments for dogs, contributing to veterinary medicine, 
but also as an additional model to translate the information gained to the treatment of 
cancer in humans.   
As for other targeted therapies, a number of challenges remain for oncolytic 
virotherapy. These challenges mainly include replication of OVs in non-tumor tissue, 
poor delivery of OVs to the tumor site, relatively poor virus-spread throughout the 
solid tumor tissue, inefficient viral replication in immune-competent hosts and 
disadvantageous ratio between anti-viral and anti-tumoral immunity. Limited delivery 
of OV to the tumor site is mainly attributed to virus neutralization by blood 
components. However, components of tumor microenvironment that include 
heterogeneous tumor vasculature, premature extracellular matrix and an army of 
innate immune cells, affect the spread and replication of OVs in the tumor tissue. 
Despite this limitation, it has been shown that OVs are also able to take advantage of 
certain features of tumor microenvironment. OVs are modified or armed to inhibit the 
heterogeneous tumor vasculature density, which further improves tumor response. 
Alteration of extracellular matrix showed improved virus spread within the tumor 
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tissue. In addition, manipulation of the innate immune response helped the OV 
infection in killing the tumor tissue and thereby enhanced the anti-tumor efficacy. 
Thus, to understand the role of oncolytic VACV and its modulation by the tumor 
microenvironment, the current studies were designed with following aims. 
1) To characterize the efficacy of oncolytic VACV strains in canine cancer 
xenografts in nude mice. 
2) To analyze the role of tumor angiogenesis on modulation of oncolytic 
VACV in canine cancer xenografts in nude mice. 
3) To analyze the role of the immune response on modulation of oncolytic 
VACV therapy in canine cancer xenografts in nude mice as well as in 
canine cancer patients. 
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CHAPTER 3: MATERIAL AND METHODS	  	  
3.1 Materials  
3.1.1 Chemicals and enzymes 
Chemical  Manufacturer 
1x PBS  Sigma 
3X FLAG peptide Sigma 
Acetic acid (C2H4O2) Fisher 
Acrylamide / bisacrylamide BioRad 
Ammonium persulfate (APS) Merck 
Benzonase Merck 
Bovine serum albumine (BSA) Omega Scientific 
Bradford reagent BioRad 
Bromophenol blue Sigma 
Carboxymethylcellulose (CMC) Sigma 
Crystal Violet Sigma 
Comassie Brilliant Blue G-250 Fisher 
Collagenase I Sigma 
OneComp eBeads (Compensation beads) eBioscience 
Diaminoethanetetraacetic acid (EDTA) Fisher 
Dimethylsulfoxide (DMSO) Sigma 
Dithiothreitol (DTT) Bio-Rad 
DMEM medium Cellgro 
DNAse I Calbiochem 
ECL GE healthcare 
Ethanol (p.a.)  Sigma 
Fetal bovine serum (FBS) Cellgro 
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Ficoll - paque plus Sigma 
Hanks balanced salt solution (HBSS) Cellgro 
Hoechst 3342 Sigma 
Hydrochloric acid (HCl) 12 M VWR 
Hydrogen Peroxide (H2O2) Sigma 
Isoflurane VetEquip 
Laemmli sample buffer 4x BioRad 
Magnetic beads Sigma 
Mowiol 4-88 Sigma 
N ́, N ́, N ́, N ́-Tetramethylethylenediamine (TEMED) Fluka 
Non-essential amino acids (NEAA) Cellgro 
Paraformaldehyde  EMS 
Penicillin / Streptomycin Mediatech 
Powdered milk DB 
Potassium chloride (KCl) Fisher 
Potassium ferricyanide (K3Fe(CN)6) Sigma 
Potassium ferrocyanide (K4Fe(CN)6·3H2O) Sigma 
Prestained protein marker BioRad 
Protease inhibitors mix Invitrogen 
Roswell Park Memorial Institute medium (RPMI-1640) Cellgro 
Recovery cell culture freezing medium Cellgro 
Sodium bicarbonate (NaHCO3) Cellgro 
Sodium chloride (NaCl) VWR 
Sodium dodecyl sulfate (SDS) Fisher 
Sodium hydroxide (NaOH) 2N Fisher 
Sucrose  Sigma 
ß-Mercaptoethanol Sigma 
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3.1.2 Kits     
Kits          Manufacturer 
Cell proliferation Kit II (XTT assay)      Roche 
Canine VEGF Quantikine ELISA kit      Quantikine 
Protein purification kit        Sigma 
DC protein assay kit        BioRad 
Foxp3 / transcription factor staining buffer set     eBioscience 
 
3.1.3 Equipments        
Equipments         Manufacturer 
Accuri C6 Cytometer        BD Bioscience 
Anesthetic devices         VetEquip   
Amicon Ultra-15 Centrifugal Filter Unit 10 kDa NMWL    Millipore 
BD Conto RUO FACS machine       BD Bioscience 
Biological safety cabinet, class II       Thermo electron 
Blotting paper 3MM         Whatman 
Cell counting chamber        VWR  
Cell culture dishes (96, 24,12, 6-well)      Corning Inc 
Tissue Tek O.C.T. Sakura Finetek 
Trichloroacetic acid BDH 
Tris-HCl Fisher 
Tris-Base Fisher 
Triton X-100 Sigma 
Trypan blue Cellgro 
Trypsin-EDTA   Cellgro 
Tween 20 BioRad 
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Cell culturing flasks         Corning inc 
Centrifuge Centra CL2        Thermo Scientific 
Centrifuge Micro CL21        Thermo Scientific 
Centrifuge Sorvall RC 6 Plus       Thermo Scientific 
CO2 incubator         Sanyo 
Cryostat 2800         Leica Microsystem  
Digital caliper         VWR 
EDTA tube          DB 
Electrophoretic vertical system       Hoefer DALT 
Embedding Mold Tissue-Tek       IMEB Inc 
Film cassette          Fisher 
Film developer AGFA CP1000       Superior Radiographic 
Fluorescence microscope IX71       Olympus 
Imaging system         Carestream 
Insulin syringe-100 29G1/2       DB 
Inversed microscope CK30       Olympus 
Leica TCS SP2 AOBS confocal laser microscope    Leica microsystem 
MagNA beads         Roche 
MagNA Lyser Mastercycler       Roche 
Micro-Hematocrit Capillary Tubes       Global scientific 
Mini-electrophoresis system       BioRad 
Nitrocellulose membrane        Fisher 
Orbital shaking         VWR 
Pro Microplate Reader        Tecan Crailsheim 
PVDF membrane         Invitrogen 
Semi-Dry Blot apparatus        Peqlab 
Sonifier 450          Branson 
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Spectrophotometer         Thermo Scientific 
Stirrer           VWR 
Surgeon scissors         E.A. Beck 
Tweezers          E.A. Beck 
Vortex VX100         Labnet 
Water bath          Fisher 
 
3.1.4 Solutions and buffers 
 
1 mM Tris-HCl (pH 9.0)   0.158 g Tris-HCl 
      1 L  HyPure Cell Culture dH2O 
 
10 mM Tris-HCl (pH 9.0)   1.576 g Tris-HCl 
      1L  HyPure Cell Culture dH2O 
 
3.7% PFA     3.7 g  PFA in 37°C H2O 
      ad NaOH until solution clears 
      10 ml  10x PBS (pH7.4) 
      ad 100 ml dH2O 
 
Histology blocking buffer   0.3%  Triton X-100 
      5%  FBS 
        1X PBS (pH 7.2) 
CMC overlay medium   7.5g  CMC    
      50 ml  FBS    
      11 ml  Penicillin / Streptomycin 
      500 ml DMEM    
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Crystal violet staining solution  1.3 g  Crystal Violet   
      50 ml  ethanol 
      300 ml formaldehyde (37%) 
      ad 1L  dH2O  
    
Lysis buffer / tumor PFU determination 1 tab  Protease inhibitor comp 
      10 ml  1X PBS (pH 7.2) 
 
Lysis buffer / tumor lysate   1 tab  Protease inhibitor comp 
      50 mM Tris-HCl (pH 7.4) 
      2 mM  EDTA (pH 7.4) 
      2 mM  PMSF 
      10 ml  1X PBS (pH 7.2) 
 
PBS Tween-20    0.05 % Tween-20 
        1X PBS (pH 7.2) 
 
RIPA lysis buffer    50 mM Tris-HCl (pH 7.8) 
      150 mM NaCl 
      0.1 %  SDS 
      0.5 %  sodium deoxycholate 
      1 %  NP-40 / Triton X-100 
      1 mM  PMSF 
      1 tab  Protease inhibitor comp 
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3.1.5 Cell lines and culture media 
3.1.5.1 Cell lines  
CV-1   African green monkey kidney fibroblast cell line 
   (ATCC, catalogue number CCL-70TM) 
DT08/40  Canine prostate carcinoma cell line 
   (Kind gift from Dr. Nolte School of vet. medicine Hannover) 
STSA-1  Canine soft tissue sarcoma cell line 
   (Kind gift from Dr. Nolte School of vet. medicine Hannover) 
 
3.1.5.2 Culture media used for propagation of cell lines 
 
CV-1   500 ml  DMEM High glucose 
   50 ml   FBS 
   5.5 ml   Penicillin / Streptomycin 
 
DT08/40  500 ml  DMEM High glucose 
   100 ml  FBS 
   5.5 ml   Penicillin / Streptomycin 
 
STSA-1  500 ml  MEM with Earle’s salt 
   50 ml   FBS 
   5.5 ml   Penicillin / Streptomycin 
   2 mM   Glutamine 
   1 mM   Sodium pyruvate 
   0.1 mM  Non-essential amino acids 
 
 
	   43 
3.1.6 Antibodies 
3.1.6.1 Antibodies for staining of tumor sections 
Primary antibodies 
Primary antibody   Origin  Manufacturer 
Anti-vaccinia    Rabbit   Abcam 
Anti-CD31    Hamster  Chemicon 
Anti-mouse Ly6G   Rat   eBioscience 
Anti-mouse F4/80   Rat   eBioscience 
Anti-DDDDK     Rabbit   Abcam 
Anti-β-glucoronidase  Rabbit   Sigma 
Anti-β-actin   Mouse  Abcam 
 
Secondary antibodies 
Secondary antibody  Origin  Manufacturer 
Anti-rabbit HRP   Goat   Abcam 
Anti-mouse HRP   Rabbit   Abcam 
Anti-rat Cy3    Donkey  Jackson ImmunoResearch 
Anti-rat Cy5    Donkey  Jackson ImmunoResearch 
Anti-hamster Cy5   Donkey  Jackson ImmunoResearch 
Anti-rabbit Cy3   Donkey  Jackson ImmunoResearch 
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3.1.6.2 Antibodies for flowcytometry 
3.1.6.2.1 Antibodies for staining of mice immune cells 
	  
Antibody    Clone   Origin Manufacturer 
Anti-mouse CD16/32  93   Rat  Biolegend 
Anti-mouse MHCII-PE  M5   Rat  eBioscience 
Anti-mouse CD11b-PerCP Cy5.5 M1/70   Rat  eBioscience 
Anti-mouse F4/80-APC  BM8   Rat  eBioscience 
Anti-mouse Ly6G-APC  RB6-8C5  Rat  eBioscience 
Anti-mouse CD45-FITC  30-F11  Rat  eBioscience 
 
3.1.6.2.2 Antibodies for staining of canine immune cells 
	  
Antibody    Clone   Origin Manufacturer 
Anti-Canine CD45-FITC  YKIX716.13  Rat  eBioscience 
Anti-canine CD3-Pacific blue CD3-12  Rat  Serotec 
Anti-canine CD4-APC  YKIX302.9  Rat  eBioscience 
Anti-canine CD8a-eFlour710 YCATE55.9  Rat  eBioscience 
Anti-canine CD25-PE  P4A10  Mouse eBioscience 
Anti-mouse Foxp3-PECy7  FJK16s  Rat  eBioscience 
Anti-canine MHCII-FITC  YKIX334.2  Rat  eBioscience 
Anti-canine CD11b   CA16.3E10  Mouse Serotec 
Anti-human CD14-PerCPCy5.5 M5E2   Mouse BD Bioscience 
Anti-canine CD11c-APC  BU15   Mouse eBioscience 
Dog T lymphocyte cocktail  NA   Mix  BD Bioscience 
Dog activated T lymphocyte  NA   Mix  BD Bioscience 
Anti-mouse IgG-PE   NA   Goat  Abcam 
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3.1.7 Recombinant vaccinia virus construct 
The replication-competent recombinant vaccinia viruses used in this work have been 
constructed and engineered at the Genelux Corporation facility in San Diego, USA. 
Vaccinia virus strain LIVP6.1.1 was derived from LIVP (Lister strain, Institute of Viral 
Preparations, Moscow, Russia), a European vaccine strain (Fig. 3a). GLV-1h68 is a 
genetically stable oncolytic virus strain designed to locate in, enter, colonize and 
destroy cancer cells without harming healthy tissues or organs. The GLV-1h68 virus 
is a derivate of the vaccinia virus Lister strain (LIVP wild type). It was constructed by 
insertion of three expression cassettes [Renilla luciferase-Aequorea green 
fluorescent protein (Ruc-GFP), β-galactosidase (lacZ) and β-glucuronidase (gusA)] 
into the F14.5L, J2R, and A56R loci of the viral genome, respectively (Fig. 3b). The 
gene for the Ruc-GFP fusion protein located in the F14.5L locus is under control of a 
synthetic early/late promoter whereas the marker gene β-galactosidase in the 
TK/J2R locus is under control of the p7.5 promoter. The third genetic insertion, β-
glucuronidase was inserted into the A56R locus and is under control of the p11 
promoter [8]. 
Another virus used in this work is GLV-1h109, which is a direct derivative of the 
parental GLV-1h68. GLV-1h109 contains the gene encoding anti-VEGF single-chain 
antibody under the control of vaccinia synthetic late promoter. The lacZ marker gene 
in the J2R locus of GLV-1h68 was replaced with GLAF-1 in GLV-1h109 (Fig. 3c). 
Anti-VEGF single-chain antibody GLAF-1, comprising an Igκ light chain leader 
sequence, the VH chain sequence of the G6 Fab, a (G4S)3 linker sequence, the VL 
chain sequence of the G6 Fab, and a C-terminal DDDDK sequence (Fig. 3d). The 
GLAF-1 protein has shown to bind both murine and human VEGF with high affinity 
[72].  
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Fig 3. Schematic representation of vaccinia virus constructs and marker genes 
The LIVP6.1.1 virus strain construct with predominant genes is represented in fig. 3a. 
The LIVP wild type virus strain was used for the generation of modified GLV-1h68 
according to Zhang et al. (Fig. 3b) and the GLV-1h68 virus was used for the 
construction of GLV-1h109 (Fig. 3c). GLAF-1 is a single-chain anti-VEGF antibody 
with two variable loops joined by linker (Fig. 3d). Abberations: p11: VACV p11 late 
promoter; pSEL: VACV SEL promoter; pSE, VACV SE promoter; pSL, VACV SL 
promoter; p7.5, VACV 7.5 K early/late promoter.  
 
Fig.3d Schematic presentation of GLAF-1  
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3.1.8 Laboratory animals  
For in vivo experiments, athymic nude FoxN1 mice were used. The animals were 
purchased from Harlan. The FoxN1 mice are characterized by an autosomal 
recessive mutation in the nu locus on chromosome 11. This leads to a completely 
hairless phenotype in the mice. Additionally, these animals feature a dysfunctional 
and rudimental thymus, which manifests in a T cell deficiency. Due to the defects in 
the immune system of the mouse, athymic nude FoxN1 mice are well suited as 
adequate laboratory animals in oncology, immunology and additional fields of 
biomedical research. Another advantage of this mouse model is that these animals 
will not reject xenografts. Antibody production is possible in athymic nude FoxN1 
mice as well. Animals were kept in a circadian rhythm of twelve hours of day 
following twelve hours of night. In addition, light intensity was alleviated to account 
for the albinism of the mice. All the mice experiments were performed in accordance 
with protocols approved by the Institutional Animal Care and Use Committee 
(IACUC) of Explora Biolabs (San Diego, CA, USA; protocol number: EB11-025) 
and/or the government of Unterfranken, Germany (permit number: 55.2- 2531.01-
17/08 and 55.2-2531.01-24/12). 
 
 
 
Fig.4. Phenotype of an athymic nude FoxN1 mouse (http://www.harlan.com) 
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3.2 Methods 
3.2.1 Ethics statement 
The institutional review board / animal care and use committee approved the canine 
clinical trial protocol and all patient owners gave written informed consent to 
participation and provision of study samples.  
3.2.2 Culturing of mammalian cells 
CV-1 cells and canine cancer cells (STSA-1 and DT08/40) were cultured in well 
plates, dishes, or flasks, depending on the purpose. To get enough cells, the stock 
cells were normally scaled up in 225T flasks (40 ml medium volume). A proper ratio 
of stock cells was pipetted into a tissue culture flask containing the respective fresh 
culture medium (Material). Cells were grown in a humidified 5% CO2 incubator at 
37°C. To maintain appropriate growth of those cells, they were closely observed and 
their medium was changed regularly to ensure that the cells were in a good 
condition. At 80-90% confluence, cells were washed with PBS and treated with 5 ml 
EDTA-trypsin. After 5 to 8 minutes (cells should become detached), the flask was 
shaken to completely detach the cells. Then, 10 ml medium containing Mg2+ and 
Ca2+ (growth medium with FBS) was added to stop the EDTA-trypsin reaction. Cells 
were re-suspended by being pipetted up and down several times to disrupt the cell 
clumps. Cell counting was performed by using a hemocytometer under an inverted 
light microscope. The cells were then ready for passage with a designated ratio into 
suitable plates, dishes, or flasks.  
3.2.3 Virological methods 
3.2.3.1 Infection of cell cultures 
Cancer cells were seeded into the desired well plate format. After 24 h in culture, 
when cells reached a confluence of 95-100%, cells were infected with recombinant 
vaccinia virus with the desired multiplicities of infection (MOIs). Cells were incubated 
for 1 h at 37°C after which the infection medium (2% FBS) was removed and cells 
were cultured in fresh growth medium. 
3.2.3.2 Viral replication assay 
For the viral replication assay, different canine cancer cells were infected with VACV 
strains at an MOI of 0.1. After 1 h incubation at 37°C with gentle agitation every 20 
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min, the infection medium (2% FBS) was removed and replaced by a fresh growth 
medium. After 1, 12, 24, 48, 72 and 96 h, the cells and supernatants were harvested. 
Following three freeze-thaw cycles, serial dilutions of the supernatants and lysates 
were tittered by standard plaque assays on CV-1 cells. All samples were measured 
in triplicate. 
3.2.3.3 Standard plaque assay  
For standard plaque assay, ten-fold serial dilutions of the virus stock were prepared. 
Confluent CV-1 cells in 24-well plates were infected with 200 µL in triplicates with the 
respective virus dilution. Carboxy methylcellulose (CMC) overlay medium was added 
after 1 h of infection and the CV-1 cells were incubated for 2 days at 37°C. Well 
plates were then stained with 250 µL of crystal violet solution per well and incubated 
for several hours at room temperature. Well plates were then washed, dried, and 
virus plaques can be counted. Virus titers were calculated using the following 
formula: 
 
  Average plaque forming units (pfu) x dilution factor 
          = pfu / well 
      Infection volume 
 
3.2.4 Cell viability assay  
The amount of viable cells after VACV infection was measured using 2,3-bis [2-
methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT) 
assay. 1 × 104 cells/well were seeded in 96-well plates (Nunc). After 24 h in culture, 
cells were infected with vaccinia virus strains using multiplicities of infection (MOI) of 
0.1 and 1.0. The cells were incubated at 37°C for 1 h, then the infection medium (2% 
FBS) was removed and subsequently the cells were incubated in fresh growth 
medium. 
Viability of cells was measured using XTT assay kit (Cell Proliferation Kit II, Roche 
Diagnostics), according to the manufacturer’s protocol at 24, 48, 72 or 96 h after 
virus infection. Quantification of cell viability was performed in an ELISA plate reader 
(Tecan Sunrise, Tecan Trading AG) at 490 nm with a reference wavelength of 690 
nm. The relative number of viable cells was expressed as percent cell viability. 
Uninfected cells were used as reference and were considered as 100% viable. 
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3.2.5 Protein analytical methods 
3.2.5.1 Protein isolation 
3.2.5.1.1 From cultured cells 
RIPA lysis buffer supplemented with complete protease inhibitor cocktail was used to 
isolate total proteins. Cells cultured in 6- or 12-well plates were washed with 1x PBS 
and a proper amount of lysis buffer (300 µl of lysis buffer for 106 cells) was added. 
Adherent cells were scraped off the wells using sterile cell scrapers, and then 
transferred to 1.5 ml microcentrifuge tubes. Membranes from cells were disrupted by 
2 cycles of sonication for 1 min at 4°C. Supernatants were collected after 10 min of 
centrifugation at 10,000 rpm. Protein concentration was determined by DC protein 
assay kit (Bio-rad) or Bradford protein assay. 
3.2.5.1.2 From animal tissue 
Tissues were weighted, cut into small pieces and transferred to MagnaBead tubes 
containing cold RBM lysis buffer supplemented with complete protease inhibitor 
cocktail (0.8 g tissue in 500 µl RBM buffer, tumors in 1 ml RBM buffer). Tissues were 
homogenized using MagNA lyser (Roche Diagnostics) at 6,500 rpm for 30 sec. 
Sample went through 3 freeze-thaw cycles and 3 rounds of sonification at maximum 
level for 30 sec at 4°C. The tissue lysates were centrifuged at 10,000 rpm for 10 min 
at 4°C. Proteins in supernatants were collected, quantified and stored at -80°C. 
3.2.5.2 Protein Quantification 
A straight calibration line was established using definite amounts of protein (0, 0.2, 
0.4, 0.6, 0.8, 1.0 mg/ml bovine plasma gamma globulin) to analyze the amount of 
total protein in a sample. The BioRad DCTM Protein Assay kit was used and 
samples were incubated in the dark for 15 min at room temperature. Absorption at a 
wavelength of 750 nm was measured using a plate reader. A standard curve was 
established and exact protein amounts of the samples were calculated by plotting 
the absorbance against the equation of the trend line of the standard curve. 
3.2.5.3 SDS-PAGE 
SDS-PAGE is used to separate proteins according to their molecular weight. Sodium 
dodecyl sulfate (SDS) is an anionic detergent that is used to denature proteins by 
wrapping around the protein backbone by binding to positively charged side chains 
of amino acids. This process charges the proteins homogenously negative. Protein 
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separation is based on the molecular weight of the proteins. Generally, bigger 
proteins need wide meshed gels to quickly migrate during gel electrophoresis and 
therefore, smaller proteins migrate faster than bigger proteins. Protein samples were 
prepared with a total protein concentration of 20 µg and heat inactivation and the 
reducing agent β-mercaptoethanol was used to reduce disulfide bonds within the 
three-dimensional protein structure prior to Bis-Tris gel loading. 
3.2.5.4 Protein transfer by Western blot 
During the electrophoretic migration, the negatively charged proteins bind to the 
membrane through hydrophobic interaction. The secondary and tertiary structure of 
the polypeptides is partially restored during this process and allows antibody binding 
to specific epitopes. For protein transfer, a vertical wet blotting chamber was used. 
The applied amperage is dependent on the size of the polyacrylamide gel and was 
calculated using the following equation: 
Amperage [mA] = gel size [cm2] x 0.8 
3.2.5.5 Immunodetection 
For immunodetection, blotted proteins are incubated with primary antibodies that 
bind to epitopes of the protein of interest. Subsequently, the proteins are incubated 
with a secondary antibody that was raised against the primary antibody. Prior to 
immunodetection, blots are blocked to avoid unspecific antibody binding. Tween-20 
in intermediate wash steps is used as a detergent that separates unspecific bindings. 
Blots were incubated with the primary antibodies of according dilutions (1:1,000 – 
1:10,000) at 4°C overnight, while accordingly diluted secondary antibodies (1:5,000, 
1:10,000) were incubated at room temperature for 2 h. The secondary antibody 
binds to species-specific sites and is horseradish peroxidase- (HRP) labeled. In 
alkaline conditions HRP acts as a catalyst for the oxidation of luminol to 3-
aminopthalic acid. To exhibit its luminescence, luminol must first be activated with an 
oxidant like hydrogen peroxide (H2O2). Oxidation of luminol triggers light emission 
that can be detected using an X- ray film developer.  
3.2.5.6 ELISA 
ELISA quantitatively determined the expression of the recombinant GLAF-1 proteins 
in sera. For the standard curve, 6 two-fold serial dilutions of purified GLAF-1 protein 
ranging from 625 ng/ml to 19.5 ng/ml were prepared in PBS/2% FBS. Purified GLAF-
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1 protein required to obtain the standard curve was produced as described in the 
section 3.2.5.7. Ninety-six well plates pre-coated with recombinant human VEGF 
(Sigma) were blocked and incubated with standards or 1:25 dilutions of sera 
samples in triplicates. Following 1.5 h incubation at room temperature, the wells 
were washed with PBS/0.05% Tween and incubated with a rabbit anti-DDDDK 
antibody for 1 h at room temperature. All wells were washed and incubated with a 
secondary HRP-conjugated anti-rabbit IgG. Color was developed using 3,3,5,5′-
tetramethylbenzidine (TMB), and the reaction was stopped with 2N HCl. Absorbance 
was read in an Infinite 200 Pro Microplate Reader at 450 nm. 
3.2.5.7 Purification of GLAF-1 from VACV infected cells 
Two flasks of confluent CV-1 cells were infected at an MOI of 1 with GLV-1h109 
encoding GLAF-1 under the synthetic late promoter in 15 ml of CV-1 media 
containing 2% FBS. Two days after infection the virus and GLAF-1 containing 
medium was filtered (0.2 µm) to remove all viral particles. To concentrate the media 
from 15 ml to 1 ml, the suspension was loaded on Amicon Ultra-15 columns with a 
molecular mass cut off of 10 kDa. The samples were centrifuged using a rotating 
swing bucket 4000 rounds per minute (rpm) for 15 min. Functional GLAF-1 was 
purified from the concentrate with a FLAG Immunoprecipitation kit which allows 
immunoprecipitation and elution of an active FLAG-tagged protein. Purified GLAF-1 
was analyzed for the correct molecular weight on a Coomassie stained gel and 
protein concentration was determined using BioRad DCTM Protein Assay kit using a 
protein standard created from bovine plasma gamma globulin. 
3.2.6 Mouse experiments 
3.2.6.1 Subcutaneous xenografts 
All animal experiments were carried out in accordance with protocols approved by 
the Institutional Animal Care and Use Committee (IACUC) of Explora Biolabs (San 
Diego, CA, USA; protocol number: EB11-025) and/or the government of 
Unterfranken, Germany (permit number: 55.2-2531.01-17/08). Five to six week old 
male Hsd:athymic Nude-Foxn1nu mice (Harlan) were implanted subcutaneously 
(s.c.) with 1x106 STSA-1 or 5x106 DT08/40 (in 100 µl PBS) cells into the right hind 
leg. Treatment started when tumors reached a volume of 200-300 mm3 (DT08/40) or 
STSA-1 600-1000 mm3. Recombinant vaccinia virus was administered systemically 
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by intravenous (i/v) injection into the lateral tail vain of 5 x 106 plaque-forming units 
(pfu) in 100 µl PBS at day 0. Control animals were inoculated with 100 µl PBS only. 
Tumor growth was measured using a digital caliper and tumor volume was 
calculated as 0.5 x length x width2 (mm3). Average tumor volume was plotted against 
at each time point to monitor therapeutic efficacy. Blood (50-100 µl) was collected 
from retro-orbital vain at regular interval for further analysis. Body weight was 
measured as net body weight (body weight – tumor volume/1000 mm3) to exclude 
tumor mass. Mice were sacrificed when the body weight dropped by 20% of their 
original body weight or the tumor volume exceeded 3000 mm3. The experiments 
were terminated 42 or 49 days post injection (dpi). The significance of the results 
was calculated by Student’s t-test. Results are displayed as means +/- standard 
deviation (SD). P values of <0.05 were considered significant. Mice were also 
monitored for change in body weight and signs of toxicity. 
3.2.6.2 Anesthesia 
Laboratory mice were solely anesthetized using isoflurane, which is a highly volatile 
anesthetic with hypnotic and muscle-relaxing effects. Mice were put in a knockout 
box and a mixture of isoflurane and oxygen was administered to the mice. Isoflurane 
has a very low distribution coefficient and therefore mice react rapidly on increasing 
or decreasing concentrations. 
3.2.6.3 Determination of vaccinia viral titers in tumor tissue and body organ 
Tumors and body organs (spleen, kidney, liver, testes, lungs) of virus-treated 
animals were surgically excised at different time points post inoculation and placed in 
two volumes of homogenization buffer [50 mM Tris-HCl (pH 7.4), 2 mM EDTA (pH 
7.4)] supplemented with Complete Protease Inhibitor Cocktail. Tumors were 
homogenized using a MagNA Lyser at a speed of 6,000 rpm for 30 sec (three times). 
After three freeze-thaw cycles, supernatants were collected by centrifugation (6,000 
rpm, 5 min, 4°C). Viral titers were measured by standard plaque assay on CV-1 
cells. 
3.2.6.4 Histological and microscopic analysis of tumors 
For histological studies, tumors were surgically excised and snap-frozen in liquid 
nitrogen, followed by fixation in 4% paraformaldehyde/PBS at pH 7.4 for 16 h at 4°C. 
After dehydration in 10% and 30% sucrose (Carl Roth) specimens were embedded 
	   54 
in Tissue-Tek® O.C.T. (Sakura Finetek Europe B.V.). Tissue samples were 
sectioned (10 µm thickness) with the cryostat 2800 Frigocut (Leica Microsystems 
GmbH). Sections were incubated with 200µl permeabilization buffer (0.2% Triton-X 
100, 5% FBS in 1 x PBS), and subsequently with a primary antibody (1:100 to 
1:1000 dilution) for overnight at 4°C on shaker. After washing away the unbound 
primary antibodies, tumor sections were incubated with secondary antibodies for 1 h 
at RT. Sections were then embedded onto microscope slides with Mowiol 4-88. 
Endothelial blood vessel cells were stained with a hamster monoclonal anti-CD31 
antibody. Anti-Mouse Ly-6G, anti-Mouse F4/80 or rabbit anti-DDDDK antibody were 
used to stain granulocytes (mainly neutrophils), macrophages or GLAF-1 protein 
respectively. LIVP6.1.1 was labeled using polyclonal rabbit anti vaccinia virus (anti-
VACV) antibody. Cy3- and Cy5-conjugated secondary antibodies (donkey) were 
obtained from Jackson ImmunoResearch (Pennsylvania, USA). Hoechst 33342 was 
used to label nuclei in tissue sections. The fluorescence-labeled preparations were 
examined using the Leica TCS SP2 AOBS confocal laser microscope equipped with 
argon, helium-neon and UV laser and the LCS 2.16 soft- ware (1024 × 1024 pixel 
RGB-color images). Digital images were processed with Photoshop 7.0.  
3.2.6.5 Measurement of blood vessel density and fluorescence intensity of 
the CD31 signal in the tumor tissue 
Blood vessel density was measured in digital images (100× magnification) of CD31-
labelled 10-µm-thick tumor cross-sections using Leica TCS SP2 AOBS confocal 
laser microscope. Eighteen images per tumor were analyzed per staining (3 tumors 
per group, 3 sections of each tumor and 6 images per section). Exposure time for 
individual images was adjusted to ensure clear visibility of all detectable blood 
vessels and decorated with 8 equidistant horizontal lines using Photoshop 7.0. All 
blood vessels crossing these lines were counted to obtain the vessel density per 
section. Fluorescence intensity of the CD31-labelling in 10-µm-thick sections of 
control tumors and infected and non-infected areas of virus-colonized tumors was 
measured on digital images (100× magnification) of specimens stained for CD31 
immunoreactivity. On the fluorescence microscope, the background fluorescence 
was set to a barely detectable level by adjusting the gain of the CCD camera before 
all the images were captured with identical settings. RGB-images were converted 
into 8-bit gray scale images (intensity range 0–255) using Photoshop 7.0. The 
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fluorescence intensity of the CD31-labeling represented the average brightness of all 
vessel related pixels and was measured using Image J software 
http://rsbweb.nih.gov/ij.  
3.2.7 Detection of β-glucuronidase in mouse serum 
The lyophilized fluorogenic probe FDGlcU (Invitrogen, Karlsruhe, Germany) was 
dissolved in DMSO (36.5 mM). The collected mouse serum was diluted 1:15 with 
PBS and 80 µl of each sample were mixed with 2.5 µg FDGlcU. After incubation for 
1 h at 37°C, fluorescence was read in Lumox 384-well plates (Sarstedt, Nümbrecht, 
Germany) using an Infinite 200 Pro Microplate Reader (Tecan, Crailsheim, 
Germany).  
3.2.8 Flow cytometric (FACS) analysis  
3.2.8.1 Analysis of tumor immune cells from mouse 
Single cell suspensions of tumors were prepared at 7 days post virus injection from 
three untreated and VACV treated mice. Tumors were surgically excised, weighed, 
and minced into small (1–2 mm3) pieces with a scalpel, and immersed in 10 ml of 
digestion mixture [5% FBS in RPMI 1640, 0.5 mg/ml collagenase D (Roche), 0.2 
mg/ml hyaluronidase, type V (Sigma), and 0.02 mg/ml DNase I (Sigma)] per 0.25 g 
of tumor tissue. The suspension was incubated with agitation at 37°C for 45 min. The 
suspension was then filtered sequentially through 70- and 40-µm cell strainers (BD 
Falcon) and washed with 5% FBS in RPMI 1640 and resuspended in 2% PBS. Cells 
were counted and 100,000 cells/test were taken for further staining. To block non-
specific staining, single cells were pre-incubated with 0.5 µg of anti-mouse CD16/32 
antibody (clone 93) per one million cells for 20 min on ice. After that, the cells were 
incubated at 4°C for 15 min in PBS with 2% FBS in the presence of appropriate 
dilutions of labeled monoclonal antibodies: anti-mouse MHCII-PE (Clone M5 
114.15.2), anti-CD11b-PerCPCy5.5 (Clone M1/70), anti-F4/80-APC (Clone BM8), 
anti-Gr-1-APC (Ly-6G, Clone RB6–8C5). The Anti-Gr-1 mAb (RB6–8C5) has long 
been used to stain MDSCs and allows the distinction of at least two subsets of 
granulocytes (Gr-1highCD11b+) and monocytic cells (Gr-1intCD11b+). Stained cells 
were subsequently analyzed, using Accuri C6 Cytometer and FACS analysis 
software CFlow Version 1.0.227.4 (Accuri Cytometers, Inc.). 
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3.2.8.2 Analysis of peripheral blood mononuclear cells (PBMC) from canine 
cancer patients 
Canine PBMC were prepared by centrifugation of fresh canine peripheral blood over 
Ficoll-paque plus (Sigma-Aldrich). Initially the plasma was decanted and stored at 
−70°C for subsequent cytokine assay. PBMC were divided into 1 × 106 aliquots and 
stored in Recovery cell culture freezing medium freezing and stored in liquid nitrogen 
until analysis. On the day of staining, PBMC aliquots were thawed at 37°C and 
washed with 5% RPMI media. For each staining 100,000 cells were taken. For 
external staining, the cells were washed with FACS buffer (PBS plus 2% PBS) and 
then stained in combinations of monoclonal antibodies. The following monoclonal 
antibodies that binds canine immune cell marker were used for staining (plus the 
appropriate compensation beads): Canine CD45-FITC (clone YKIX716.13), Human 
CD3-Pacific blue (clone CD3-12), Canine CD4-APC (clone YKIX302.9), Canine 
CD8a-eFlour710 (clone YCATE55.9), Canine CD25-PE (clone P4A10), Mouse 
Foxp3-PECy7 (clone FJK16s), Canine MHCII-FITC (clone YKIX334.2), Human 
CD14-PerCP Cy5.5 (clone M5E2), Canine CD11c-APC (clone BU15), Canine 
CD11b-PE (clone CA16.3E10), Dog T lymphocyte cocktail (BD Bioscience) and Dog 
activated T lymphocyte cocktail (BD Bioscience). For internal staining (Foxp3), a 
Foxp3 / transcription factor staining buffer kit was used. Cells and antibodies were 
incubated on ice for 30  min and then washed twice in FACS buffer before being re-
suspended in 200 µl BD fixative. For controls, compensation beads (OneComp 
ebeads- eBioscience) were used. Compensation beads were stained with equal 
concentrations of antibody that was used for staining PBMCs and incubated for 30 
min and then washed twice with FACS buffer and re-suspended in 200 µl 2% PBS. 
The cells were either stored in the dark at 4°C before analysis or analyzed 
immediately on a Beckman-Coulter EPICS XL flow cytometer.  
3.2.9 Statistical analysis 
Statistical analysis of data generated from animal experiments was performed with 
SPSS, version 11 (SPSS, Inc.). To determine significance between two treatment 
groups a two-tailed unpaired t-test was used (Excel 2007 for Windows). 
          
	   57 
	  	  	  	  	  	  	  	  	  	  	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  CHAPTER 4: RESULTS	  
4.1 Aim 1: Characterization of oncolytic efficacy of LIVP6.1.1 in canine cancers 
VCAV-mediated therapy of canine cancer is of a great importance considering its 
use in veterinary medicine as well as for the development of oncolytic virotherapy for 
human cancers. In initial experiments, the efficacy of the oncolytic VACV strain 
LIVP6.1.1 in canine cancer xenografts was evaluated. Establishment of canine soft 
tissue sarcoma and canine prostate carcinoma xenografts using newly isolated 
STSA-1 and DT08/40 cell lines respectively in nude mice is described. Furthermore, 
the infiltration of innate immune cells in LIVP6.1.1-infected canine tumor xenografts 
is analyzed.   
4.1.1 Characterization of LIVP6.1.1 virus in canine cancer cells under cell 
culture conditions 
LIVP6.1.1 was isolated from a wild-type stock of the Lister strain of vaccinia virus 
(Lister strain, Institute of Viral Preparations, Moscow, Russia) and represents a 
“native” virus (without genetic manipulations). The replication efficiency and oncolytic 
potential of LIVP6.1.1 was analyzed in canine soft tissue sarcoma (STSA-1) and 
canine prostate carcinoma (DT08/40) cells. 
4.1.1.1 LIVP6.1.1 virus efficiently replicates in canine cancer cells 
The oncolytic potential of OVs is dependent on their ability to efficiently infect and 
replicate in cancer cells. In order to test the efficiency of virus replication, STSA-1 
and DT08/40 cells were infected with LIVP6.1.1 at an MOI of 0.1. Standard plaque 
assays were performed for all samples to determine the viral titers at different time 
points during the course of infection (Fig. 5). Efficient LIVP6.1.1 viral replication 
(>100-fold titer increase at 48 or 96 hpi) was observed in both cell lines. The 
maximum viral titers were observed (5.34×106 pfu/well) in STSA-1 at 48 hpi. The 
highest virus titers in virus infected DT08/40 cells were observed (8.24×106 pfu/well) 
at 96 hpi (Fig. 5). LIVP6.1.1 virus replication efficiency was dependent on the 
infection time point and tumor type. However, LIVP6.1.1 virus did replicate 
exponentially in both canine cancer cell lines. 
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Fig. 5 Replication of LIVP6.1.1 in canine cancer cell line 
STSA-1 and DT08/40 cells were grown in 24-well plates and infected with LIVP6.1.1 
at an MOI of 0.01. Supernatant and cells were collected at different time points. Viral 
titers were determined on CV-1 monolayer by standard plaque assay. Total viral titers 
(supernatant and cells) are shown here.  
 
4.1.1.2 LIVP6.1.1 virus efficiently kills canine cancer cells 
An essential feature of oncolytic viruses is their ability to efficiently infect, replicate in 
and lyse cancer cells. The ability of LIVP6.1.1 to lyse cancer cells was analyzed in 
STSA-1 and DT08/40 cells. The cancer cells were seeded three days prior to 
infection in 24-well plates and then infected with LIVP6.1.1 at MOIs of 1.0 and 0.1. 
The cell viability was analyzed at 24, 48, 72 and 96 hpi, respectively by XTT assays 
(Fig. 6). At MOI of 1.0, the LIVP6.1.1 virus was highly cytotoxic to STSA-1 (Fig. 6A) 
resulting in 83% cytotoxicity over 3 days. One day later similar cytotoxicity was 
observed in DT08/40 cells (Fig. 6B). Thus, LIVP6.1.1 virus infection efficiently killed 
both canine cancer cell types. 
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Fig. 6. Viability of soft tissue sarcoma STSA-1 (A) and prostate carcinoma DT08/40 (B) 
cells after LIVP6.1.1 infection at MOIs of 1.0 and 0.1.  
Viable cells after infection with LIVP6.1.1 virus at MOIs of 0.1 and 1.0 were detected 
using a XTT assay. Mean values and standard deviations (n=3) are shown as 
percentages of respective controls. 
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4.1.2 Oncolytic effects of LIVP6.1.1 on canine cancer xenografts in nude mice 
After characterization of LIVP6.1.1 in canine cancer cells, the effects of the 
LIVP6.1.1 virus on growth of tumor xenografts was evaluated. The therapeutic 
efficacy of LIVP6.1.1 in the soft tissue sarcoma STSA-1 and prostate carcinoma 
DT08/40 subcutaneous xenograft models was evaluated in nude mice.  
4.1.2.1 Therapeutic efficacy and toxicity of LIVP6.1.1 in STSA-1 and DT08/40 
xenografts 
Tumors were generated by implanting 1×106 STSA-1 cells subcutaneously into the 
right hind leg of 6- to 8-week-old female nude mice (NCI/Hsd/Athymic Nude-
Foxn1nu). Five weeks post implantation, all mice developed tumors with volumes of 
600 to 1000 mm3. Mice with larger tumors were selected for virus injection since the 
late stage of the tumor development is more representative of human clinical 
practice. Animals were separated into two groups (n = 6/ group) and were injected 
either with a single dose of LIVP6.1.1 (5 × 106 pfu) or PBS intravenously into the 
lateral tail vein. The single intravenous virus administration led to a significant 
decrease in STSA-1 tumor growth in all virus-treated mice compared with PBS 
control mice (Fig. 7A). Due to excessive tumor burden (>3000 mm3), all animals in 
the control PBS group were euthanized after 14 dpi. The therapeutic effect of 
LIVP6.1.1 was also evaluated on the progression of the slow growing canine 
prostate carcinoma DT08/40 tumors in nude mice by measuring the tumor volume at 
various time points. Data demonstrated again that a single injection with LIVP6.1.1 
vaccinia virus led to significant inhibition of the tumor growth (*p <0.05) of all virus-
treated mice compared with the control PBS animals on 35, 42 and 49 dpi (Fig. 7B). 
To monitor the general well being of animals, mice were weighed once a week. The 
net bodyweight was calculated in exclusion of the tumor mass. A drop in body weight 
is often indicative of a decrease in health due to viral toxicity, other infections, 
increasing tumor burden or development of metastases. As can be observed in Fig. 
7C and 7D, all LIVP6.1.1-treated mice showed relatively stable mean net body 
weight over the course of the studies. There were no other signs of virus-mediated 
toxicity. In summary, treatment with the vaccinia strain LIVP6.1.1 demonstrated anti-
tumor activity in canine soft tissue sarcoma and canine prostate xenograft models 
without signs of virus-mediated toxicity. 
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Fig. 7. Effects of intravenous LIVP6.1.1 virus injection on tumor growth (A, B) and the 
body weight (C, D) of mice with STSA-1 or DT08/40 xenografts 
STSA-1 (A, C) and DT08/40 (B, D) tumor-bearing mice (n = 6 per group) were either 
treated intravenously (i/v) with a single dose of 5x106 pfu LIVP6.1.1 or with PBS 
(control). The statistical significance was confirmed by Student’s t-test where * and ** 
indicate P <0.05 and <0.01, respectively.  
 
 
4.1.2.2 Bio-distribution and persistence of LIVP6.1.1 in STSA-1 tumor-
bearing nude mice  
The virus distribution and persistence of LIVP6.1.1 in virus-treated mice with STSA-1 
xenografts was determined using standard plaque assay. Table 3 summarizes the 
virus distribution data at 35 dpi. In all virus-treated mice the highest viral titers were 
observed in the primary tumors. In addition, low numbers of LIVP6.1.1 pfu were also 
detected in liver, lung, spleen and kidney of the treated animals (Table 3). However, 
LIVP6.1.1 was highly tumor-selective, as 104–105 fold more virus particles were 
found in the solid tumors compared to the healthy tissues of the treated animals. 
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Table 3: Bio-distribution of LIVP6.1.1 in virus-treated STSA-1 xenografts at 35 
days post injection (dpi) 
pfu/g of 
tissue 
STSA-1 xenografts treated with 5x106 pfu LIVP6.1.1 
Mouse # 
301 
Mouse # 
302 
Mouse # 
304 
Mean 
35 dpi 
STDEV 
35 dpi 
Tumor 2.75E+07 3.58E+07 3.76E+07 3.36E+07 5.38E+06 
Lung 1.14E+02 4.40E+02 1.42E+02 2.32E+02 1.80E+02 
Liver 4.00E+01 5.33E+01 1.00E+02 6.40E+01 3.10E+01 
Spleen 7.00E+01 3.33E+01 1.25E+02 7.60E+01 4.60E+01 
Kidney 2.50E+02 1.46E+02 1.06E+03 4.85E+02 4.99E+02 
The virus titres were determined by standard plaque assays on CV-1 cells using 
aliquots of the homogenized organs and are presented as mean pfu/g of organ or 
tissue. For each organ, two aliquots of 0.1 ml were measured in triplicates (estimate of 
assay sensitivity >10 pfu/organ). 
 
The virus distribution in the primary STSA-1 tumors was also evaluated by 
immunohistochemical staining at 35 dpi (Fig. 8). Since LIVP6.1.1 does not encode 
any reporter genes, we analyzed viral spread within STSA-1 xenografts by antibody 
staining to VACV protein A27L. The staining pattern of VACV protein demonstrated 
that STSA-1 tumors in all treated mice were significantly infected with vaccinia virus, 
which led to oncolysis and destruction of tumor tissues.  
 
 
Fig. 8. Immunohistochemical staining of infected and uninfected STSA-1 xenograft 
tumors at 35 dpi. 
Tumor-bearing mice were either mock-treated (PBS) or injected with LIVP6.1.1. 
Tumor sections were labeled with anti-vaccinia virus antibodies (red). Blue color 
represented nuclear staining (Scale: 200 µm) 
Nucleus 
Vaccinia 
Nucleus 
Vaccinia Nucleus Vaccinia Vaccinia Nucleus 
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4.1.2.3 LIVP6.1.1 colonization induces infiltration of innate immune cells in 
STSA-1 tumor xenografts 
To evaluate the role of the host immune system in virus clearance and the 
involvement in tumor growth inhibition, mice bearing STSA-1 tumors were either 
treated with a single intravenous injection of LIVP6.1.1 or PBS. Mice were sacrificed 
7 days post injection. Single-cell suspensions prepared from tumors were stained for 
immune cell antigen markers, which were further analyzed by flow cytometry. 
LIVP6.1.1 infection and colonization significantly increased infiltration of Gr-
1highCD11b+ (granulocytes), Gr-1intCD11b+ (monocyte), F4/80+CD45+ (macrophages) 
and MHCII+CD45+ cells in virus infected tumors compared with PBS-treated tumors 
(table 4).  
 
Table 4. Percentages of immune cells in STSA-1 xenografts 7 days after 
LIVP6.1.1 or PBS treatments 
Immune cells PBS / tumor 
Mean ± SE 
LIVP6.1.1 / tumor 
Mean ± SE 
PBS vs LIVP6.1.1 
(p value) 
CD45
+
MHCII
+ 0.66% ± 0.23% 2.67% ± 0.35% ** (p=0.002) 
CD45
+
F4/80
+ 0.77% ± 0.47% 4.61% ± 0.25% *** (p=0.001) 
CD11b
+
Gr-1
int 0.2 % ±  0.08% 3% ± 0.69% *  (p=0.018) 
CD11b
+
Gr-1
hi 0.27% ± 0.08% 2.48% ± 0.70% *  (p=0.03) 
Immune cells are defined as follows: MHCII+CD45+ (mainly B cells, macrophages and 
dendritic cells), F4/80+CD45+; (macrophages), Gr-1highCD11b+ (granulocytes) and Gr-
1intCD11b+ (monocytes). Experiments were done twice with at least 3 mice per group. 
The data are presented as % of CD45+ cells. The statistical significance was analyzed 
using two-tailed unpaired Student's test (*** P <0.001, **P <0.01 and *P <0.05). 
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4.2 Aim 2: Effect of inhibition of tumor angiogenesis on modulation of VACV 
therapy 
In initial experiments, oncolytic VACV colonization of tumors and infiltration of innate 
immune cells was shown to significantly inhibit growth of canine cancer xenografts. 
However, components of the tumor microenvironment may potentially influence the 
success of oncolytic virotherapy. Among numerous factors, tumor angiogenesis and 
tumor immunity appear to be critical in influencing the efficacy of virus-mediated 
tumor therapy [72]. In the following series of experiments, VACV strain GLV-1h109 
encoding a single-chain antibody against VEGF was utilized to augment the anti-
tumor effects of virotherapy. VEGF is a potent regulator of tumor angiogenesis and 
several anti-VEGF antibodies have been developed for the treatment of human and 
canine tumors [72, 106]. Further, as presented in the previous section, VACV 
colonization in tumor tissue induced infiltration of innate immune cells. Thus, GLV-
1h109 virus was designed to target two important components of the tumor 
microenvironment i.e. tumor angiogenesis and tumor immunity.  
GLV-1h109 was derived from the prototype oncolytic vaccinia virus GLV-1h68 by 
replacing the lacZ gene (β-galactocidase) by the GLAF-1 gene (Fig 3c). GLV-1h68 
was derived from LIVP (lister) strain by inserting three expression cassettes 
(encoding Renilla luciferase–Aequorea green fluorescent protein, β-galactosidase, 
and β-glucuronidase) into the F14.5L, J2R (encoding thymidine kinase) 
and A56R (encoding hemagglutinin) loci of the viral genome, respectively (Fig 3b). 
GLV-1h68 has been used as a simultaneous diagnostic and therapeutic agent [8]. 
Likewise, the GLV-1h109 virus retains two of the three marker proteins of GLV-1h68 
(Renilla luciferase-Aequorea green fluorescent protein, GLAF-1 and β-
glucuronidase) and the expression of these marker proteins was utilized to monitor 
virus colonization. A recombinant VACV strain GLV-1h109 was characterized in 
STSA-1 and DT08/40 canine cancer cells.  
4.2.1 GLV-1h109 efficiently replicates in STSA-1 and DT08/40 tumor cells 
One of the factors that regulate the oncolytic potential of OVs is their ability to infect 
and/or efficiently replicate in cancer cells. The replication ability of GLV-1h68 in 
canine cancer cell lines is well known [42]. However, it was important to find out 
whether replacing the lacZ gene in GLV-1h68 by the GLAF-1 might have affected the 
infectivity and replication of GLV-1h109 in canine cancer cells. STSA-1 and DT08/40 
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cells were infected with either GLV-1h109 or GLV-1h68 at an MOI of 0.1. The 
maximum viral titers were observed at 48 hpi in STSA-1 cells for both GLV-1h68 
(2.98 X106 pfu/well) and GLV-1h109 (3.01 X 106 pfu/well) (Fig. 9A). In addition, GLV-
1h68 and GLV-1h109 viruses efficiently infected and replicated in DT08/40 cells with 
a maximum titer of 1.23 x 106 pfu/well and 1.56 x 106 pfu/well at 72 hpi respectively 
(Fig. 9B). The maximum titer of GLV-1h109 in STSA-1 cells at 48 hpi was nearly 
twice the maximum titer of GLV-1h109 in DT08/40 cells at 72 hpi, indicating that 
GLV-1h109 replicates better and faster in STSA-1 cells (***P = 0.00004; Student’s t-
test). Overall, the replication efficiency of GLAF-1 encoding VACV strain, GLV-1h109 
was similar to that of the parental GLV-1h68 virus in both the canine cancer cell 
lines. 
 
	    
Fig. 9. Comparison of the replication efficiency of the vaccinia virus strains GLV-
1h109 and GLV-1h68 in canine cancer cells  
STSA-1 (A) or DT08/40 (B) cells grown in 24-well plates were infected with either 
GLV-1h109 or GLV-1h68 at a MOI of 0.1. Supernatants and cells were collected for 
the determination of virus titres at various time points. Viral titres expressed as total 
pfu per well (supernatants and cells) were determined from triplicate measurements 
by standard plaque assay in CV-1 cells. Averages plus standard deviation are 
plotted.  
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4.2.2 GLV-1h109 virus efficiently kills canine cancer cells  
It is well known that manipulation of the viral genome as occurs in recombinant 
viruses reduces their replication efficiency and oncolytic potential. Thus, the 
characterization of the newly generated oncolytic vaccinia virus strain GLV-1h109 
especially in canine cancer cells was of a prime importance. GLV-1h68 was used in 
comparison. STSA-1 cells were seeded three days prior to infection in 24-well plates 
and were then infected with either GLV-1h109 or GLV-1h68 at MOIs of 1.0 or 0.1. 
Cell viability was analyzed at 24, 48, 72 and 96 hpi respectively, by XTT-assays (Fig 
10A). Ninety-six hours after GLV-1h109-infection, only 17.8% and 17.5% STSA-1 
cells survived the treatment at MOIs of 0.1 and 1.0, respectively. At the same time 
point and MOIs, 18.6% and 18.2% of STSA-1 cells remained viable after GLV-1h68 
infection. 
The oncolytic potential of GLV-1h109 was also compared to GLV-1h68 in DT08/40 
cells (Fig. 10B). In these experiments, GLV-1h109 and GLV-1h68 virus infections 
resulted in similar oncolytic efficacy at 96 hpi and at MOIs of 0.1 and 1.0. Thus, GLV-
1h109 showed a similar oncolytic potential to that of parental virus GLV-1h68 in both 
canine cancer cell lines, however, the rate of oncolysis was greater in STSA-1 cells 
than in DT08/40 cells. 
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Fig. 10. Viability of canine soft tissue sarcoma (STSA-1) (A) and prostate carcinoma 
(DT08/40) (B) cells after GLV-1h109 or GLV-1h68 infection.  
Viable cells after infection with each virus was detected using a XTT assay. Mean 
values and standard deviations (n=3) are shown as percentages of respective 
controls. The data from one of the three independent experiments is presented 
here. There were no significant differences between groups at 72 and 96 hpi (P 
>0.05). 
 
4.2.3 GLV-1h109 expresses encoded marker proteins in canine cancer cells 
Expression of anti-VEGF single chain antibody GLAF-1 and β-glucuronidase (GusA) 
proteins in GLV-1h109-infected STSA-1 or DT08/40 cells could be used as important 
indicators in the diagnosis and treatment of canine cancers. For this purpose, 106 
STSA-1 or DT08/40 cells were infected either with GLV-1h109 or GLV-1h68 (control) 
at an MOI of 1.0 in 6-well plates. Supernatants and lysates were harvested at 24, 48 
and 72 hpi respectively, and analyzed by Western blot using anti-GLAF-1, anti-GusA 
and anti-β-actin antibodies. The β-actin was used as a loading control. 
Expression of these marker proteins in virus-infected STSA-1 cells is shown in 
Figure 8. GLAF-1 protein of expected size (30 kDa) was detected in both lysates and 
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supernatants of GLV-1h109-infected STSA-1 cells (Fig 11A). Similar expression of 
GLAF-1 protein was detected in GLV-1h109 infected DT08/40 (Figure 11B). No 
protein of similar size was detected in GLV-1h68 infected or uninfected cells of both 
cancer types. Additionally, GusA was detected in the cells infected with the GLV-
1h68 as well as GLV-1h109.  
 
 
 
 
 
Fig. 11. Expression of virus encoded proteins GLAF-1 and GusA in canine cancer 
cells 
Western blot analysis of STSA-1 (A) and DT08/40 (B) cells infected with either GLV-
1h109, GLV1h 68 virus at an MOI of 1 or PBS. Protein fractions from cell lysate and 
culture supernatant were isolated at different time points and analyzed by Western 
blot.  
 
 
 
 
4.2.4 The GLAF-1 antibody specifically recognizes canine VEGF 
GLV-1h109 significantly enhanced the therapeutic efficacy and inhibited tumor 
angiogenesis in human tumor xenografts as compared to the parental virus, GLV-
1h68 [72]. GLAF-1 was directed against human and murine VEGF and showed 
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efficient binding affinity with VEGF from both the species [72]. However, the use of 
GLV-1h109 for canine cancer therapy and effects of GLAF-1 on canine tumor 
angiogenesis was only possible, provided GLAF-1 binds to canine VEGF. Thus, the 
ability of purified GLAF-1 antibody to bind recombinant canine VEGF (R&D System, 
Minneapolis, MN, USA) was tested by standard ELISA. Binding affinity of GLAF-1 
with human VEGF was taken as positive control and relative binding with canine 
VEGF was plotted. As seen in Fig. 12, GLAF-1 was functional and recognized both 
canine and human VEGF with substantial comparability. 
 
 
Fig. 12. Interaction of purified GLAF-1 antibody with human and dog VEGF 
ELISA demonstrated affinity and cross reactivity of GLAF-1 to canine VEGF. ELISA 
was repeated three times in an independent experiment. The data presented is from 
one experiment.  
 
4.2.5 Canine cancer cells express VEGF under cell culture conditions 
VEGF is a potent mediator of both angiogenesis and vasculogenesis in dogs and 
has been proposed as a prognostic indicator in several types of canine cancers [107, 
108]. As GLV-1h109 encodes anti-VEGF single-chain antibody, the level of VEGF 
expression by canine cancer cells might affect oncolytic efficiency of GLV-1h109. 
Therefore, we analyzed the level of VEGF expression from the two tested canine 
cancer cell lines under cell culture conditions (Fig. 13). Canine VEGF concentrations 
were determined using a Quantikine ELISA kit (R&D Systems, Minneapolis, MN, 
USA) developed for detection of canine VEGF, in accordance with the 
manufacturer’s directions. STSA-1 and DT08/40 cells were plated in six-well culture 
plate and supernatants were collected at 24 and 48h respectively. Concentration of 
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VEGF in supernatant was represented as pg/106 cells. As seen in Fig 13, mean 
VEGF levels in the supernatant of STSA-1 cells were 1556.9 pg/106 cells (24h) and 
2962.2 pg/106 cells (48h), while that of DT08/40 cells were 170.8 pg/106 cells (24h) 
and 183.3 pg/106 cells (48h). STSA-1 cells produced about 9- to 16-fold more canine 
VEGF compared to the DT08/40 cells at the two different time points, respectively. 
 
 
Fig. 13. VEGF expression in STSA-1 and DT08/40 canine cancer cells in cell culture  
VEGF levels in STSA-1 and DT08/40 cell supernatants were determined by canine 
VEGF Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA). Each value 
represents the mean + standard deviation (SD) (n=3). 
 
4.2.6 Systemic administration of GLV-1h109 virus significantly regresses 
growth of STSA-1 and DT08/40 derived tumors in nude mice 
After characterization of GLV-1h109 in cell culture conditions, it was important to 
analyze the effect of virus treatment on tumor growth. Therefore, to test efficacy of 
GLV-1h109 in canine cancer xenografts, female nude mice (n=6/group) at an age of 
6–8 weeks were implanted subcutaneously with 1x106 STSA-1 cells. Four weeks 
post-implantation, all mice developed tumors with volumes of 600 to 1000 mm3. 
Animals were separated into two groups (n=6) and were injected with a single dose 
of GLV-1h109 (5x106 pfu) or PBS (100µl) into the tail vein. The virus treatment 
resulted in a significant tumor regression in all GLV-1h109 treated mice (Fig. 14A). In 
contrast, due to excessive tumor burden (>3000 mm3), all animals of the PBS control 
group were euthanized after 14 dpi. The therapeutic effect of GLV-1h109 was also 
evaluated in canine prostate carcinoma DT08/40 tumor xenografts in nude mice. 
Tumors were generated by implanting 5 x 106 canine prostate carcinoma cells 
subcutaneously into the right hind leg of 6- to 8-week-old nude mice. When tumors 
reached to an average volume of 200-300mm3, groups of mice (n = 6/group) were 
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injected (i/v) either with 5x106 pfu of GLV-1h109 virus or PBS (control). Tumor 
volume was measured subsequently after every 7 days. Data demonstrated that a 
single injection with GLV-1h109 vaccinia virus led to significant inhibition of the tumor 
growth (*p <0.05) of all virus-treated mice compared to PBS treated mice (Fig. 14B). 
Statistical significance between untreated mice and GLV-1h109-treated mice was 
first observed after 35 days. Finally, the toxicity of the GLV-1h109 virus was 
determined by monitoring the relative net body weight change of mice over time (Fig. 
14C, D). All GLV-1h109-treated mice showed stable mean body weight over the 
course of the study. There were no signs of virus-mediated toxicity. 
 
Fig. 14. Effects of systemic GLV-1h109 virus injection on tumor growth (A, B) and the 
body weights (C, D) of mice with STSA-1 or DT08/40 xenografts   
STSA-1 tumor-bearing mice (n = 6) (A, C) and DT08/40 tumor bearing mice (n = 6) 
(B, D) were either treated with a single dose of 5x106 pfu GLV-1h109 intravenously 
(i/v) or with PBS (negative control). Tumor growth and relative net body weight was 
monitored subsequently. The statistical significance was determined by Student’s t-
test where * and ** indicate P <0.05 and <0.01, respectively. 
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4.2.7 Bio-distribution of the virus and presence of GLAF-1 in tumor-bearing 
nude mice 
The GLV-1h109 distribution in STSA-1 and DT08/40 xenografts was analyzed at the 
last time points after virus treatment. Table 5 summarizes the virus distribution data 
in both xenograft models. The highest viral titers were identified in the primary 
tumors of virus-treated mice (table 5).  
 
Table 5: Bio-distribution of GLV-1h109 in DT08/40 and STSA-1 xenografts at 49 
or 35 days post virus injection (dpi), respectively. 
pfu / g DT08/40 xenografts STSA-1 xenografts 
Mouse 
# / dpi 
424 /    
49 dpi 
429 /   
49 dpi 
433/   
49 dpi 
329/         
35 dpi 
343/    
35 dpi 
335/     
35 dpi 
Tumor 2.7E+02 4.5E+03 1.3E+04 1.9E+07 4.9E+07 2.7E+07 
Liver n.d n.d n.d 5.4E+01 1.2E+02 4.9E+01 
Lung n.d n.d n.d 2.7E+02 9.6E+01 1.1E+02 
Heart n.d n.d n.d n.d n.d n.d 
Kidney n.d n.d n.d 5.6E+01 n.d n.d 
Spleen n.d n.d n.d 4.7E+01 7.2E+01 3.5E+01 
The virus titres were determined by standard plaque assays on CV-1 cells using 
aliquots of the homogenized organs and were displayed as mean pfu/g of organ or 
tissue. For each organ, two aliquots of 0.1 ml were measured in triplicates. n. d.: not 
detected (estimate of assay sensitivity >10 pfu/organ). 
 
Interestingly, the mean GLV-1h109 titers in primary solid tumors of STSA-1 
xenografts at 35 dpi were about 104 fold higher than that of DT08/40 xenografts at 49 
dpi. In addition, we observed the presence of plaque forming units in some organs of 
virus-injected STSA-1 mice, but not in the virus–treated DT08/40 xenografts. 
However, the numbers of GLV-1h109 virus particles in the healthy tissues were 
substantially reduced; e.g. in whole organs: livers (mean weight 1.2 g) about 89 pfu; 
lungs (mean weight 0.142 g) about 19 pfu and spleens (mean weight 0.2 g) about 10 
pfu at 35 dpi (Table 5, here the pfu were given per gram of organ). In contrast, we 
found about 104–105 fold more GLV-1h109 pfu in solid tumors at this time point, 
which clearly shows that GLV-1h109 virus displays an enhanced tumor specific 
replication. 
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4.2.8 Use of GLV-1h109 as a diagnostic tool for canine cancers 
GLV-1h109 expressed Renilla-luciferase GFP and β-glucuronidase when replicated 
in human tumor tissue [72]. GFP protein expressed by recombinant VACV strains 
enabled non-invasive optical imaging as well as allowed to monitor virus colonization 
in tumor tissue [8, 79]. In addition, we have recently shown that the detection of virus 
encoded β-glucuronidase (GusA) in the serum could be used to evaluate tumor 
colonization and/or transgene expression of oncolytic vaccinia virus in tumor-bearing 
mice [109]. Furthermore, GLV-1h109 was encoded with single-chain antibody GLAF-
1 that was regulated by secretory promoter. Therefore, in this study we tested the 
presence and persistence of the GusA marker protein in combination with the GLAF-
1 antibody. As seen in Fig. 15, the level of GusA marker protein was increased 
initially on day 7 (STSA-1) and day 21 (DT08/40) after virus injection. However, the 
level decreased over time. The maximum level of GLAF-1 in the serum of GLV-
1h109-injected mice with STSA-1 xenografts was about nine-fold higher than in 
corresponding DT08/40 xenografts at 7 dpi. Interestingly, the maximal GLAF-1 
protein in serum occurred a week earlier than the maximal GusA-signal in both the 
xenograft models (Fig. 15A, B).  
 
 
Fig. 15. Presence and persistence of GLAF-1 and GusA in serum of GLV-1h109-
injected mice with tumor xenografts 
A, B: Blood samples were collected at day 7, 14, 21 and 28 respectively from (A) 
STSA-1 and (B) DT08/40 tumor bearing mice (n = 6). Expression of GLAF-1 in 
sera was quantitatively determined using ELISA. GLAF-1 values shown (bars) are 
mean + SD. GusA activity (represented by lines) was measured by detecting the 
activation of the fluorogenic compound FDGlcU.  
 
The different kinetics could be due to the fact that virus-infected cancer cells secrete 
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demonstrated that analysis of GLAF-1 in the serum could also be used as a 
pharmacokinetic marker for virus colonization and persistence of GLV-1h109-tumor 
injection and virus activity. 
4.2.9 GLV-1h109 replication resulted in GLAF-1 protein expression in tumor 
In previous section (4.2.8), it was demonstrated that anti-VEGF single-chain antibody 
GLAF-1 was secreted into the circulatory system of tumor bearing mice injected with 
GLV-1h109. However, the expression of GLAF-1 protein in the tumor tissue may be 
crucial to inhibit tumor angiogenesis. Therefore, the expression of GLAF-1 in GLV-
1h109, GLV-1h68 and PBS treated STSA-1 tumor sections was analyzed. The 
tumors were harvested at an early time point, 7 days after virus treatment. As the 
GLAF-1 protein had the DDDDK tag, tumor sections were stained with anti-DDDDK 
antibody. As seen in Fig. 16A, GLV-1h109-treated tumor sections showed 
expression of the GLAF-1 protein. GLV-1h68 and PBS-treated tumor sections did not 
stain for the GLAF-1 protein. Additionally, the presence of GLAF-1 protein was also 
analyzed in tumor tissue of STSA-1 and DT08/40 xenografts on day 35 and 49, 
respectively. GLAF-1 protein of approximately 30 kDa was detected by Western blot 
(Fig. 16B). 
 
                                  
Fig 16. Expression of GLAF-1 in GLV-1h109-infected tumor tissue 
A: Localization of GLAF-1 protein in virus-infected STSA-1 tumors. Overlays 
represent the virus infection GFP fluorescence (green) and the presence of GLAF-1 
(red). Scale bars, 500 µm. (200× magnification).  
B: STSA-1 and DT08/40 tumor-bearing mice injected with GLV-1h109 and PBS were 
sacrificed on day 35 and day 49, respectively (end point of study). Tumors were 
collected, and proteins from tumor lysate were separated by SDS/PAGE. Western 
blot analysis was performed using anti-DDDK antibody. 
 
 
Thus expression of GLAF-1 protein in tumor tissue was detected both at the initial 
stage as well as at the late stage of the tumor treatment. 
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4.2.10 GLV-1h109 colonization in tumor xenografts significantly inhibited 
development of tumor vasculature 
Previously we have seen that STSA-1 cells express 9-16 times more VEGF than 
DT08/40 cells as well as expression of GLAF-1 was higher in STSA-1 xenografts 
than DT08/40 xenografts. In addition, an anti-VEGF strategy was successfully 
evaluated in dogs with canine soft tissue sarcomas [110]. Considering all these 
factors, the effects of GLV-1h109 on tumor vasculature and tumor microenvironment 
were tested in the STSA-1 xenograft model. The possible anti-VEGF effect of the 
GLAF-1 antibody on tumor angiogenesis and vasculogenesis was analyzed using 
the CD31 staining to visualize the vascular network in tissue sections of GLV-1h109, 
GLV-1h68 (VACV not encoding anti-VEGF antibody) and PBS-treated STSA-1 
tumors by fluorescence microscopy. CD31-labeled cross-sections of tumors from 
PBS-, GLV-1h68- and GLV-1h109-treated mice were used for determination of the 
vascular density at the day 7 after treatment (Fig. 17). The vascular density of GLV-
1h109-infected tumors was significantly decreased compared to GLV-1h68- and 
PBS- injected control tumors (GLV-1h109 vs GLV-1h68 ***P <0.0001; GLV-1h109 
vs. PBS ***P <0.0003) (Fig. 17A, B). Interestingly, a significant reduction of the 
vascular density was observed in areas positive for virus infection detected by 
colonization of GFP fluorescence (Fig. 17A, B; inf+). However, the reduction in 
vascular density was not seen in the corresponding GFP negative areas of tumor 
sections (Fig. 17C; inf-), indicating that the reduction in vascular density is mediated 
not only by the expression of GLAF-1, but also by virus colonization in tumors. The 
vascular density between infected (inf+) areas of the GLV-1h109 tumor was also 
significantly lower than in non-infected (inf.-) areas. [inf+ GLV-1h109 (Fig. 17B) vs. 
inf- GLV-1h109 (Fig. 14C); ***P < 0.0006].  
In addition, the fluorescence intensity of the CD31 signal was measured in 
immunohistochemically stained (inf+) sections of STSA-1 tumors (Fig. 17D). The 
fluorescence intensity (blood vessel-related pixels) of GLV-1h109 virus-infected 
tumors was significantly decreased compared to GLV-1h68 or PBS-injected control 
tumors (GLV-1h109 vs. PBS **P=0.0051; GLV-1h109 vs. GLV-1h68 ***P=0.00001). 
This means that only the GLV-1h68 virus colonization up-regulated expression of the 
CD31 protein. The significant decrease of fluorescence intensity in GLV-1h109-
infected tumors might be due to the reduction in the vascular density. Therefore, this 
study clearly demonstrated that the virus colonization and expression of GLAF-1 led 
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to a local inhibition of tumor angiogenesis in the GLV-1h109 virus-infected tumor 
tissue. 
 
 
 
 
Fig. 17.  Vascular densities in virus-treated (GLV-1h68 or GLV-1h109) and non-treated 
(PBS) tumors at 7 dpi  
A-C:  Blood vessel density in virus-infected (A, B; inf+) and virus non-infected (C; 
inf-) STSA-1 tumor areas  
The vascular density was measured in CD31-labeled tumor cross-sections (n=3 
mice per group, 18 images per mice) and presented as mean values +/- SD. (*** P 
<0.001, **P <0.01, Student’s t-test) 
D:  Fluorescence intensity of the CD31 signal in virus-infected (inf+) STSA-1 
tumor areas  
The fluorescence intensity of the CD31-labeling represented the average 
brightness of all vessel-related pixels (VRP). The fluorescence signal representing 
the amount of CD31 expression in the blood vessels was measured in 18 images 
of each tumor (n = 3 mice per group). Mean values are shown as mean+/-SD. (*** 
P <0.001, **P <0.01, Student’s t-test). 
 
 
PBS GLV-1h68 GLV-1h109 A 
CD31 
GFP 
CD31 GFP CD31 
GFP 
GFP CD31 CD31 
GFP 
GFP CD31 
In
f$
+
$
Inf+$
* * * 
* * * 
* *  
PBS GLV-1h68 GLV-1h109
0
2
4
6
F
lu
o
ro
s
c
e
n
t 
In
te
n
s
it
y
 /
 a
re
a
DInf&$C 
PBS GLV-1h68 GLV-1h109
0
20
40
60
80
N
o
 o
f 
b
lo
o
d
 v
e
s
s
le
 /
 a
re
a
B Inf+$
* * * 
* * * 
PBS GLV-1h68 GLV-1h109
0
20
40
60
80
N
o
 o
f 
b
lo
o
d
 v
e
s
s
le
 /
 a
re
a
PBS GLV-1h68 GLV-1h109 A 
CD31 
GFP 
CD31 GFP CD31 
GFP 
GFP CD31 CD31 
GFP 
GFP CD31 
In
f$
+
$
Inf+$
* * * 
*  * 
* *  
PBS GLV-1h68 GLV-1h109
0
2
4
6
F
lu
o
ro
s
c
e
n
t 
In
te
n
s
it
y
 / 
a
re
a
DInf&$C 
PBS GLV-1h68 GLV-1h109
0
20
40
60
80
N
o
 o
f 
b
lo
o
d
 v
e
s
s
le
 / 
a
re
a
B Inf+$
* * * 
* * * 
PBS GLV-1h68 GLV-1h109
0
20
40
60
80
N
o
 o
f 
b
lo
o
d
 v
e
s
s
le
 /
 a
re
a
	   77 
4.2.11 Anti-angiogenesis therapy improved virus replication and distribution 
in STSA-1 tumor xenografts 
In initial cell culture experiments, GLV-1h109 and its prototype virus GLV-1h68 had 
similar replication efficiency in STSA-1 cells. Additionally, anti-VEGF encoding virus 
significantly inhibited tumor angiogenesis. Recently, R. Jain et al. demonstrated that 
inhibition of tumor angiogenesis improved drug delivery to the tumor tissue [111]. 
Thus, whether inhibition of angiogenesis increased the replication and spread of this 
oncolytic VACV in STSA-1 xenografts was examined. As stated earlier, GLV-1h68 
and GLV-1h109 encode a Renilla luciferase-GFP fusion protein enabling the 
visualization of viral colonization in tumors. Viral GFP expression in GLV-1h109-
treated tumors was monitored by FACS analysis. In this experiment, three tumors 
from each treatment group were excised, single cell suspensions were prepared and 
cells were analyzed for GFP-positive signals by flow cytometry. As expected, STSA-
1 xenografts from PBS control mice did not show GFP-positive signals (Fig. 18). 
However, GLV-1h109-infected tumors showed significantly increased number of 
GFP positive cells (14.27 ± 1.8%) compared to GLV-1h68 infected tumors (8.67% ± 
2.4%) (GLV-1h109 vs GLV-1h68 *P=0.036).  
The number of infectious viral particles in STSA-1 tumor xenografts was then 
determined. Tumor-bearing mice were sacrificed at day 7 after GLV-1h68 or GLV-
1h109 injection. Tumors were harvested, homogenized and analyzed for virus 
content with standard plaque assay. STSA-1 tumor xenografts injected with GLV-
1h68 had a mean of 1.55x107 pfu/g tumor and GLV-1h109 infected STSA-1 
xenografts had a mean of 3.17x107 pfu/g tumor. GLV-1h109 infection yielded a 
statistically significant (2 fold) increase in infectious viral particle compared to GLV-
1h68 (p=0.024) (Fig. 18) 
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Fig. 18 Replication and distribution of virus in STSA-1 tumor xenografts 
A: GFP-positive cells from STSA-1 tumor xenografts infected with VACV strains. GFP-
positive cells were examined by FACS analysis and displayed as mean + SD (n=3).  
B: Virus titres from STSA-1 tumor xenografts infected with VACV strains. The virus 
titres were determined by standard plaque assays on CV-1 cells using aliquots of 
the homogenized tumor tissue and were displayed as mean pfu/g of tissue (n=3).  
	  
4.2.12 Combination of VACV with anti-angiogenic therapy improves infiltration 
of innate immune cells in STSA-1 xenografts 
Since oncolytic VACV GLV-1h109 displayed higher replication in tumors compared 
to GLV-1h68, the effect of anti-angiogenic therapy on the modulation of the host 
immune response was of interest. Therefore, the effect of GLV-1h109 and GLV-1h68 
virus infection on host immune cells in tumors of STSA1-tumor-bearing mice was 
analyzed. Single cell suspensions prepared from STSA-1 tumors, resected 7 days 
after treatment with virus were analyzed by flow cytometry for the presence of host 
immune cells (Fig. 19). The presence of various innate immune cells was assessed 
using cellular antigen-specific markers. CD45 (leukocyte common antigen), Gr-1 
antigen (Ly6C/Ly6G) of MDSCs, CD11b (Mac-1, mainly myeloid cells), F4/80 
(macrophages) and MHCII (B cells, monocytes, macrophages and dendritic cells) 
were used to visualize the respective cell types in STSA-1 tumors. The tumor-
derived Gr-1+CD11b+ cells consisted of 2 major subfractions based on differential 
Gr-1 expression, high (Gr-1high) and intermediate (Gr-1int). Gr-1high represents 
immature and mature granulocytes, and a Gr-1int, represents monocytes and other 
immature myeloid cells [42]. A significant increase of Gr-1highCD11b+ (granulocytes), 
Gr-1intCD11b+ (monocytes) and F4/80+CD45+ (macrophages) cells was observed in 
both GLV-1h109- and GLV-1h68-treated tumors compared to PBS-treated tumors 
(Fig. 19A, B, C). However, within the two virus-treated groups, GLV-1h109-treated 
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tumors showed significantly higher increase in infiltration of these immune cells 
compared to GLV-1h68-treated tumors. However, no significant differences were 
seen in the percentage of MHCII+CD45+ cells within GLV-1h109 and GLV-1h68 
treated tumors (Fig. 19D). Thus, anti-angiogenic therapy increased the infiltration of 
the innate immune cells in tumor tissue treated with virus.   
 
 
Fig. 19 Presence of immune cells in tumor bearing mice with STSA-1 xenografts at 7 
days after GLV-1h68, GLV-1h109 or PBS treatment  
Percentage of (A) Gr-1highCD11b+ (granulocytes), (B) Gr-1intCD11b+ (monocytes), 
(C) F4/80+CD45+ (macrophages) or (D) MHCII+CD45+ (mainly B cells, 
macrophages and dendritic cells) cells in STSA-1 xenografts. Experiments were 
done twice with at least 3 animals per group. The data presented as mean values 
+/- SD. The statistical significance was analyzed using one-way ANOVA followed 
Bonferroni`s multiple comparison test (*** P <0.001, ** P <0.01, *P <0.05).  
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and 0.15% of Gr-1intCD11b+ (monocytes) and 0.24% and 0.81% of 
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were infected with vaccinia virus or that they had phagocytized virus-infected tumor 
cells. 
 
Table 6. Percentage of GFP-positive immune cells in virus-treated STSA-1 tumor 
Cell Markers GLV-1h68 GLV-1h109 P value Cell type 
GFP+/ 
Gr-1highCD11b+ 
0.11% ± 
0.073% 
0.37%  ± 
0.051% 
**(P = 0.006) 
GFP+ tumor associated 
granulocytes 
GFP+/ 
Gr-1intCD11b+ 
0.06% ± 
0.043% 
0.15%  ± 
0.073% 
*(P = 0.042) 
GFP+ tumor associated 
monocytes 
GFP+/ F4/80+ 
0.24%  ± 
0.072% 
0.81% ± 
0.28% 
* (P = 0.028) 
GFP+ tumor associated 
macrophges 
Percentage GFP-positive cells in tumors from mice with STSA-1 xenografts at 7 days after 
GLV-1h109- or GLV-1h68-treatments. The data are presented as mean values +/- standard 
deviations. The statistical significance was analyzed using two-tailed unpaired Student's test 
(**P <0.01, *P <0.05). 
 
 
The distribution of granulocytes and macrophages in tumors was also examined by 
staining of histological sections from STSA-1 tumor xenografts. As expected, the 
increased accumulation of granulocytes and macrophages was observed in GLV-
1h109-infected tumors compared to PBS treated or GLV-1h68-infected tumors (Fig. 
20A, B). Interestingly, the Gr-1+ cells (granulocytes) were mostly co-localized with 
virus in infected tumor regions (Fig. 20A), whereas the macrophages were diffusely 
distributed throughout the tumor (Fig. 20B). 
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Fig. 20. Immunohistochemical staining of infected and uninfected STSA-1 tumors at 7 
dpi for granulocytes (A) or macrophages (B)  
Tumor bearing mice were either infected with GLV-1h109 or GLV-1h68 or mock 
treated (PBS). Cryosections (10 µm-thick) from STSA-1 tumors were labeled with 
either anti-Gr-1 (Ly-6G) antibody (A) for granulocytes or anti-F4/80+ antibody (B) 
for macrophages; both red. Virus infection and/or phagocytosis were indicated by 
GFP fluorescence (green). Overlays represented Gr-1+ and GFP (A) or F4/80+ and 
GFP (B). Scale bars: 500 µm (200X magnification). 
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4.3 Aim 3: Modulation of immune response by VACV therapy in canine 
cancer patients 
Three way interactions between the administered oncolytic virus, the tumor and the 
host immune system are paramount in determining the therapeutic outcome of 
oncolytic virotherapy. In previous sections we have seen that oncolytic VACV strain 
LIVP6.1.1 induced infiltration of innate immune cells in tumor tissue. In addition, 
VACV treatment combined with inhibition of tumor angiogenesis significantly 
increased infiltration of innate immune cells in tumor compared to only VACV 
therapy. However, both these studies were carried out in nude mice that were 
deficient in immune system functional. Dogs with cancer were more ideal 
experimental models in that they could mimic human cancer patients [43]. Genelux 
Corporation San Diego, USA had started a phase I safety and dose escalation study 
with oncolytic VACV LIVP6.1.1 (V-VET1) in dogs with measurable malignancies. To 
elucidate the effect of VACV on modulation of the immune response, innate and 
adaptive immune response to V-VET1 therapy in canine cancer patients enrolled in 
this phase I clinical trial were analyzed. 
4.3.1 Details of canine cancer patients and dose escalation scheme 
The clinical trial was designed as an open-label, dose-escalating, non-randomized, 
single-center phase I study of V-VET1 administered intravenously in four 7-day 
cycles in dogs with measurable malignancies. In each cohort three dogs were 
enrolled and they were individually assessed for safety and dose-limiting toxicity 
(DLT).  The dose escalation scheme was as shown in Table 7 
Table 7: V-VET1 dosing schedule  
Cohort Dose per 
treatmenta 
Number of  
treatment / cycle 
Number 
of Cycles 
Total Volume of Each 
Injection 
1 1 × 108 1 4 Final volume of preparation 
will be 1:1 (ml:kg) ratio with 
patient’s weight to be infused 
within 15 minutes 
2 3 × 108 1 4 
3 1 × 109 1 4 
4 3 × 109 1 4 
a. Listed dose was per 25 kg dog. Actual dose was adjusted based on body weight of individual dog. 
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To date, a total of eleven canine cancer patients were enrolled into a phase I dose 
escalation study. Three patients were recruited in each cohort. However, cohort 2 
had four patients as one of the patients had only one cycle of treatment. As the study 
is not yet completed, only one patient from the last cohort has been analyzed for 
immune response. Each patient was treated with four cycles of V-VET1 at 7 days 
interval. The dose of V-VET1 was per 25 kg body weight of dog (table 7), however 
the final dosing was adjusted according to the body weight of each dog. The majority 
of patients had advanced stage cancers. Details of the tumor diagnoses, and the 
number of cycles of V-VET1 received by individual patients are presented in table 8. 
 
Table 8: Patient details enrolled in phase I clinical trial 
Cohort Dose Patient ID Tumor type Cycles of 
V-VET1 
Cohort 1 1 x 108/25kg 
V-VET-1-101 Adenocarcinoma 4 
V-VET-1-102 Soft tissue sarcoma 4 
V-VET-1-103 Osteosarcoma 4 
Cohort 2 3 x 108/25kg 
V-VET-1-104 T cell Lymphoma 2 
V-VET-1-106 Multiple mast cell tumors 7 
V-VET-1-107 Multiple mast cell tumors 4 
V-VET-1-108 Osteosarcoma 4 
Cohort 3 1 x 109/25kg 
V-VET-1-109 Soft tissue sarcoma 4 
V-VET-1-110 Sarcoma 4 
V-VET-1-111 Adenosarcoma 4 
Cohort 4 3 x 109/25kg V-VET-1-113 Soft tissue sarcoma 4 
 
Blood samples were collected from each patient at pretreatment and at multiple time 
points during the first week and then weekly thereafter. Precise timings of samples 
for PBMC subset and cytokine analysis were as follows  
PBMC analysis: Baseline (Week 0), Week 2, Week 4 and Week 8 
Cytokine analysis:  Baseline (Week 0), Week 1 Day 3, Week 2, Week 4 and Week 8 
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4.3.2 Optimization of canine PBMC staining for flowcytometry analysis 
Peripheral blood from four healthy dogs was obtained in heparinized tubes from CVS 
Angel Care Cancer Center, Carlsbad, CA, USA. Control dogs were determined to be 
healthy by a veterinarian based on owner observations, physical examinations and 
complete blood count examination. PBMCs, isolated and aliquots prepared in 
freezing medium were stored in LN2 according to mimic the clinical trial protocol. The 
presence of various immune cells was assessed using cellular antigen-specific 
markers. CD3, CD4, CD8, CD25 and Foxp3 were used for staining of subsets of T 
lymphocytes and CD11b, MHCII, CD14 and CD11c for staining of innate immune 
cells. In addition, cocktails of antibodies were used to stain activated T cells and B 
cells. Various cell types of canine PBMCs were defined as shown in table 9. 
  Table 9: Staining of canine immune cell types  
Cell Markers Cell type Reference 
CD3+CD4+ T helper Cell  [112] 
CD3+CD8+ Cytotoxic T Cell [112] 
CD25+ Activated T cells [113] 
CD21+ B Cell [114] 
CD4+CD25+Foxp3+ Regulatory T cell (Treg) [113] 
CD11b+MHCII-CD14- Myeloid derived suppressor cells 
(MDSCs) 
[115] 
CD14+ Macrophages [116] 
CD11c+ Dendritic cells [117] 
  
Flow cytometric analysis of all the immune cell subsets was in line with other 
published series. Among living cells immune cells were gated based on their forward 
and side scattering properties. After exclusion of cellular doublets in a FSC-A vs. 
FSC-H plot, gating of each immune cell type was performed as shown in Fig. 21. All 
the canine immune cell populations were within normal range for the respective dog 
breed (table 10). Thus, we confirmed that our methodology yielded results that were 
in line with other published series by measuring all subsets in PBMCs from four 
healthy dogs that had no active medical problems.  
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Fig. 21. Gating strategies to determine subpopulations of canine immune cells 
All PBMCs were evaluated using the P1 gate (live cells) and subsequently gated based on 
relative expression levels of A: CD4+ (T helper) & CD8+ (Cytotoxic T lymphocyte) cells B: 
CD11b+MHCII-CD14- cells (MDSCs) C: CD4+CD25+Foxp3+ (Treg) cells and D: Activated 
T cells. 
 
Live Cells  CD3+ cells CD4+ and CD8+ cells 
A 
Live cells CD11b+ cells MHCII-CD14- cells 
B 
C 
Live cells  CD4+ Cells CD25+Foxp3+ Cells 
D 
Live Cells  Activated T Cells 
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4.3.3 V-VET1 treatment induced circulating cytotoxic T cell response in 
canine cancer patients 
After standardization of canine immune cell staining, the components of the adaptive 
immune system in peripheral blood of canine cancer patients treated with V-VET1 in 
phase I clinical trial was analyzed by flow cytometry. Components of the adaptive 
immune system that mainly included for analysis were CD3+CD4+ (T-helper cells), 
CD3+CD8+ (Cytotoxic T cells) and activated T cells. PBMC subsets were analyzed 
pre and post viral therapy in 11 canine cancer patients from cohorts 1-4. Cell types 
were expressed as a proportion of total PBMC. Normal values of the immune cell 
populations in dogs vary extensively with age, breed, gender and disease status. 
Therefore, it was not appropriate to compare the immune cells in different dogs, 
therefore, the percentages of immune cells before V-VET1 treatment as baseline 
value and relative fold changes after virus treatment were reported. 
Following injection of V-VET1, PBMC subset analysis from individual canine cancer 
patient showed a marked heterogeneity, but certain trends were observed and in 
some patients a correlation between specific subsets and therapeutic cycles was 
apparent. There was a non-significant increase in the concentration of CD3+CD4+ T 
cells one week after the first cycle of V-VET1 treatment compared to baseline (Fig. 
22A). However, subsequently in a majority of patients, CD3+CD4+ T cell level 
decreased. As a result of VACV treatment, CD3+CD4+ T-cell numbers increased in 
eight (72.7%) patients one week after the first treatment, while three (27.3%) patients 
showed decreases in CD3+CD4+ T cells (table 10). The level of CD3+CD4+ was 
reduced to its initial levels subsequently (Fig. 22A). In contrast, VACV treatment 
increased CD3+CD8+ T cells in circulation in the majority of canine cancer patients. 
V-VET1 treatment showed incremental increase in CD3+CD8+ T cell levels in ten 
(90.9%) patients while in one (9.1%) patient the level decreased (table 10). A 
significant increase in CD3+CD8+ T cells was observed 21 days after initiation of V-
VET1 treatment (Fig. 22B). However, eight weeks after initiation of V-VET1 
treatment (four weeks after last cycle of virus treatment), the level of CD3+CD8+ T 
cells reached again the baseline level indicating that level of CD3+CD8+ T cells were 
influenced by VACV. 
Similarly, VACV treatment increased the levels of activated T cells after completion 
of four cycles. Activated T cell levels were increased with virus treatment in nine 
(81.8%) canine cancer patients, while, two (18.2%) patients showed decreased 
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levels (table 10). Although increased levels of activated T cells were associated with 
V-VET1 treatment, the cell concentrations were not significantly higher compared to 
the baseline level before virus treatments (Fig. 22C). 
 
 
 
Fig. 22. V-VET1 treatment significantly increased in circulating CD8+ T cells in canine 
cancer patients.  
Patients treated with V-VET1 (week 1, week 2, week 3 and week 4) were 
monitored for subsets of circulating T lymphocytes. Peripheral blood mononuclear 
cells from patients were isolated before and after the treatment and stained for 
CD4, CD8, Treg and activated T cells. Percentage of CD8+ T cells (A), CD4+ T cells 
(B), activated T cells (C) and Treg cells (D) in the total PBMC was represented here. 
V-VET1 treatment led to significant increase in CD8+ T cells 21 days after initiation 
of virus treatment. Red arrows indicate time of V-VET1 treatment.  
 
The level of regulatory T (Treg) cells in circulation of canine cancer patients enrolled 
in phase I clinical trial was analyzed. The frequency of Treg (defined by 
CD4+CD25+FoxP3+ expression) cells was determined using antibodies against cell 
surface molecules CD4 and CD25, and intracellular staining of FoxP3 expression. 
A B 
D C 
	   
* P = 0.018 
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Treg are immunosuppressive cells that inhibit functions of CD8+ cytotoxic T cells. 
Although Treg cells were seen to increase in response to treatment in two patients 
(18.2%), in all other patients (81.8%), the levels of Treg cells were either decreased or 
unaffected by the V-VET1 treatment (table 10). However, overall analysis of Treg 
percentage did not show any significant change after V-VET1 treatment (Fig. 22D).  
4.3.4 V-VET1 treatment reduces circulatory MDSCs in canine cancer patients 
MDSCs are a recently described population of innate immune cells that accumulate 
in established tumors, exhibit immune suppressive functions, and block activation of 
T cells. Therefore, the effect of V-VET1 treatment on these inhibitory cells was of 
great interest. We defined the MDSC population in dogs as cells with CD11b+MHCII-
CD14- expression [115]. The percentages of MDSCs in dogs with cancer were 
evaluated by flow cytometry. Circulatory MDSCs in all canine cancer patients (100%) 
before treatment were found at high levels but decreased after treatment with V-
VET1 (table 11). A gradual decrease in circulatory MDSCs started after first 
treatment, however, a significant decrease was observed 21 days (week 4) after 
initiation of virus treatment (Fig. 23). When treatment was stopped the frequency of 
MDSCs was reduced again to pretreatment levels indicating that circulatory MDSC 
frequency was affected by V-VET1 treatment in canine cancer patients.  
   
 Fig. 23. Circulating MDSCs (CD11b+CD14−MHCII−) in canine cancer patients 
Circulatory MDSC (CD11+CD14−MHCII−) population frequency was monitored over 
the time in canine cancer patients treated with V-VET1. (** Indicates P<0.01). Red 
arrows indicate time of V-VET1 treatment.   
	  
** P = 0.004 
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Additionally, the frequency of other subtypes of innate immune cells like dendritic 
cells and monocytes was also analyzed by flow cytometry. V-VET1 treatment did not 
change the level of either monocytes or dendritic cells in canine cancer patients. The 
percentage of subsets of adaptive and innate immune cells in each patient is 
presented in table 10 and 11. 
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CD4 
Week 0 15.20 18.69 26.53 32.10 15.76 24.06 20.31 49.59 16.07 41.84 14.55 
Week 2 18.13 32.86 33.14 47.56 20.26 27.82 17.51 50.16 28.76 34.61 12.28 
Week 4 14.78 23.07 30.08 NA 11.29 27.27 24.53 41.04 22.07 34.83 11.74 
Week 8 19.22 NA NA NA 11.28 21.32 NA 42.71 23.00 36.09 18.38 
CD8 
Week 0 18.87 15.72 11.60 12.80 8.69 20.82 25.64 21.36 25.21 24.61 24.41 
Week 2 20.37 25.55 7.69 16.35 11.71 24.62 17.67 18.35 26.09 32.82 39.21 
Week 4 30.93 42.75 NA 19.56 9.37 36.56 20.70 31.97 36.62 31.21 48.13 
Week 8 10.65 NA NA NA 6.74 16.64 NA 27.09 30.21 28.60 33.32 
Treg 
Week 0 22.63 10.23 6.78 1.52 5.83 7.84 2.93 4.39 12.43 3.80 4.83 
Week 2 25.22 9.36 5.57 0.55 8.15 8.12 3.53 4.38 8.05 7.22 7.31 
Week 4 20.08 9.63 6.42 NA 8.66 12.86 2.97 4.45 5.01 6.17 7.66 
Week 8 24.18 NA NA NA 7.29 6.78 NA 3.15 5.49 6.11 6.29 
Activated T 
cell 
Week 0 3.12 2.84 6.84 3.05 1.28 3.15 6.37 7.60 3.96 1.10 1.28 
Week 2 2.99 3.23 9.65 10.71 1.76 5.02 7.13 6.78 5.71 3.96 1.77 
Week 4 1.56 2.19 3.28 NA 2.44 4.35 8.60 6.86 6.61 1.49 3.38 
Week 8 8.63 NA NA NA 2.13 3.19 NA 6.57 6.96 1.97 6.80 
Table 10: Percentages of T lymphocyte subsets in canine cancer patients treated with V-VET1 
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MDSC 
Week 0 1.24 2.31 2.64 90.83 33.83 25.59 47.41 20.14 1.89 50.90 34.15 
Week 2 1.00 0.53 1.65 56.86 24.89 27.55 47.93 15.01 21.42 48.91 27.03 
Week 4 0.88 0.58 1.88 NA 34.11 9.19 21.33 18.66 39.94 23.67 20.19 
Week 8 0.84 NA NA NA 52.85 47.62 NA 25.28 49.47 11.47 37.93 
CD14 
Week 0 26.93 45.30 6.49 32.22 56.51 28.85 42.25 30.90 56.59 24.84 29.87 
Week 2 32.36 51.53 13.15 10.87 54.51 26.19 39.47 27.36 39.39 14.16 27.01 
Week 4 17.03 20.04 NA 31.98 48.74 8.76 62.06 21.58 23.70 NA 31.54 
Week 8 28.72 NA NA NA 40.99 20.17 NA 13.39 24.57 34.81 29.43 
DC 
Week 0 27.87 49.28 30.71 56.05 82.86 52.96 82.54 47.65 56.06 54.96 43.76 
Week 2 33.36 53.19 38.10 16.66 80.32 94.71 76.84 45.67 50.18 31.11 38.74 
Week 4 18.12 22.10 30.44 NA 77.99 78.52 81.55 28.09 57.42 47.56 42.46 
Week 8 30.02 NA NA NA 90.31 74.63 NA 66.37 65.33 49.17 48.39 
Table 11: Percentages of subsets of innate immune cells in canine cancer patients treated with V-VET1 
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4.3.5 Tumor type and viral dose did not affect modulation of immune 
response 
Our study demonstrated that V-VET1 therapy modulated immune response 
especially frequency of circulatory CD8+ T cells and MDSCs in canine cancer 
patients. However, one of the main purposes of the phase I trial was to find 
maximum tolerable dose (MTD). Therefore, V-VET1 dose given to each patient 
varied based on the cohort in which the dog was enrolled. Other objective of the 
study was to analyze the effects of V-VET1 in canine patients with solid tumors. 
Tumors from the patients were categorized based on the clinical diagnosis as soft 
tissue sarcoma (3 patients), mast cell tumors (2 patients), osteosarcoma (2 patients) 
and adenocarcinoma (2 patients). Thus we hypothesized that viral dose and tumor 
type were one of the confounding factors that affect modulation of immune response 
after V-VET1 therapy. Therefore, we analyzed the frequency of circulatory 
CD3+CD8+ T cells and MDSCs (percentages of both immune cell types were 
changed after VACV therapy) as markers to compare effects of viral dose and tumor 
type on modulation of immune response.  
Although frequency of CD3+CD8+ T cells increased as the dose of virus increased, 
however the increased frequency was not statistically significant (Fig. 24A). 
Likewise, frequency of CD3+CD8+ T cells did not differ significantly based on types 
of tumors (Fig. 24B). In addition, we compared the population of MDSC based on 
virus dose and tumor type. MDSC cells significantly decreased after V-VET1 
treatment however there was no significant difference in frequency of these cells 
when compared based on different virus doses and tumor types (Fig. 24 C, D). 
Canine cancer patients were grouped according to the dose of virus injection in four 
cohorts. PBMCs from patients from first three cohorts given respective virus dose i.e. 
cohort 1 (1×108), cohort 2 (3×108) and cohort 3 (1×109) were analyzed for frequency 
of CD3+CD8+ T cells and MDSCs. Cohort 4 was not included for comparative 
analysis as only one patient was enrolled in this group till the end of study.           
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Fig. 24 Virus dose and tumor type did not influence the modulation of immune 
response after V-VET1 injection in canine cancer patients 
Canine patients treated with V-VET1 were monitored for frequency of CD3+CD8+ T 
cells (A, B) and MDSC (C, D). Peripheral blood mononuclear cells from patients 
were collected before and after the treatment and stained for CD8+ T cell and 
MDSC cells. Change in frequency of CD3+CD8+ T cell (A) and MDSC (C) 
depending on virus dose was observed. Similarly changes in population of 
CD3+CD8+ T cells (B) and MDSC (D) based on tumor type was analyzed. Both 
virus dose and tumor type did not influence the frequency of circulatory CD3+CD8+ 
T cells and MDSC after virus treatment.  
 
Our studies analyzing effect of LIVP6.1.1 (V-VET1) in canine cancer patients have 
shown that VACV indeed modulated immune response. We could show that canine 
cancer patients treated with V-VET1 significantly increased CD8+ cytotoxic T cells 
after 21 days of initiation of virus treatment. In addition, V-VET1 treatment inhibited 
circulatory MDSCs, which are immunosuppressive in nature.  Moreover, the changes 
in frequency of these immune cells did not depend on the dose of virus as well as 
C D 
A B 
	   94 
tumor type. We conclude that VACV positively influence the immune response in 
canine cancer patients, which will ultimately help to improve efficacy of oncolytic 
VACV therapy.  
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  CHAPTER 5: DISCUSSION 
Cancer is the leading cause of disease-related death in both human and dogs 
worldwide. Cancer in mankind accounts for about 7.6 million deaths annually [1]. By 
2030, it is projected that there will be ∼26 million new cancer cases and 17 million 
cancer deaths per year [2]. Likewise, cancer is the most common cause of natural 
death in dogs. The incidence of cancer is 1 to 2% in the canine population and 
accounts for about half of the deaths in dogs older than 10 years [3]. The major 
treatment options available for human cancers include surgery, radiation therapy, 
chemotherapy, immunotherapy or combinations of either of them. Veterinarians use 
more or less similar therapeutic protocol for the treatment of canine cancers as those 
used for treatment of human cancers. However, the overall prognosis for both 
human and canine patients diagnosed with cancer has not significantly improved. Till 
today, canine cancers are considered incurable with ineffective treatment options. 
Therefore, there is an urgent need for development of new treatment options against 
canine cancers. Furthermore, dogs with natural cancer are considered as one of the 
best animal models to develop new drugs for cancer therapy. Traditionally, rodent 
cancer models have been used for analyzing the biology of cancer initiation, 
promotion, and progression as well as development of cancer therapeutics. 
However, they do not adequately represent several important features that define 
cancer in humans, including biology of initiation of tumor, the complexity of cancer 
recurrence and metastasis and outcomes to novel therapies. To the contrary, dogs 
develop cancers naturally and share many characteristics with human malignancies. 
Tumor microenvironment, histopathology, molecular and genomics data from dog 
tumors has significant similarities with the corresponding human tumors [118]. These 
advantages of dog cancers provide a unique opportunity to integrate canine cancer 
patients in the studies designed for the development of new cancer drugs targeted 
against both human and canine cancers.  
The need for effective therapies for human and canine cancers has led to extensive 
research in the cancer field, which has resulted in the testing of oncolytic viruses as 
a novel therapy to control tumor growth. Oncolytic viral therapies have made their 
mark on the cancer research world as another potential therapeutic option, with the 
possible advantages of lessening side effects as well as strengthening treatment 
efficacy due to higher tumor selectivity. Results have been so promising that 
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oncolytic viral treatments have now been approved for clinical trials in human cancer 
patients, and the first oncolytic viral therapy has now been marketed as a treatment 
for head and neck cancers in China [6]. Currently, a variety of oncolytic viruses are 
being evaluated for their ability to be used in anti-cancer therapy for human and 
canine cancers. One of the viruses being studied as an oncolytic virus is vaccinia 
virus.  
Vaccinia virus belongs to the family of orthopox viruses and gained worldwide fame 
for its role as a vaccine for smallpox. One of the vaccinia virus strain used to study 
its oncolytic potential was GLV-1h68. The recombinant VACV strain GLV-1h68 was 
engineered with three gene insertions, Ruc-GFP fusion, β-galactosidase and β-
glucuronidase, and has been successfully used for therapy of human and canine 
tumor xenografts with minimal toxicity to normal tissue [8, 42, 119]. Recently, a 
phase I trial was completed at the Royal Marsden Hospital in London, England, 
which demonstrated that administration of GL-ONC1, clinical grade GLV-1h68, is 
well tolerated with minimal toxicity with preliminary evidence of anticancer activity. In 
patients treated with GL-ONC1, no dose limiting toxicities were observed [79].  
Like for other targeted therapies, a number of challenges remain for oncolytic 
virotherapy. These challenges mainly include replication of oncolytic viruses in non-
tumor tissue, poor delivery of oncolytic viruses to the tumor site, relatively poor virus 
spread throughout solid tumor tissue, inefficient viral replication in immune-
competent hosts and disadvantageous ratio between anti-viral and anti-tumoral 
immunity [120]. The limited delivery of oncolytic virus to tumor site is mainly 
attributed to virus neutralization by blood components [121, 122]. However, the 
components of the tumor microenvironment that include heterogeneous tumor 
vasculature and an army of innate immune cells, affect the spread and replication of 
oncolytic viruses in tumor tissue [120]. Despite this limitation, it has been shown that 
oncolytic viruses are also able to take advantage of certain features of the tumor 
microenvironment. Oncolytic viruses are modified or armed to inhibit the 
heterogeneous tumor vasculature density, which further improves tumor response 
[72]. Manipulation of the innate response helps the oncolytic virus infect and kill the 
tumor tissue and thereby enhanced the anti-tumor efficacy [120]. Thus, to analyze 
the oncolytic potential of VACV in canine cancer xenografts and to understand the 
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effects of modulation the tumor microenvironment using VACV the studies in this 
thesis were designed in following parts.  
5.1 Therapeutic efficacy of the oncolytic VACV LIVP6.1.1 in canine cancer 
xenografts 
The first part of the study was focused on the potential of oncolytic VACV in the 
treatment of canine cancer xenografts in nude mice. The efficacy of the wild-type 
VACV strain LIVP6.1.1 was tested in two canine cancer xenografts models i.e. 
canine soft tissue sarcoma and canine prostate carcinoma. As the oncolytic potential 
of viruses depends on the ability of the virus to efficiently infect and replicate in 
cancer cells, in initial experiments, the new virus strain LIVP6.1.1 was characterized 
for its replication efficiency and oncolytic potential in STSA-1 and DT08/40 canine 
cancer cells in culture. Infection of canine cancer cells with LIVP6.1.1 demonstrated 
that the virus replicated efficiently in both STSA-1 and DT08/40 cells. The maximum 
virus titer was observed after 48 and 96 hours post infection in STSA-1 and DT08/40 
cells respectively, indicating that the virus replicates more efficiently in STSA-1 cells 
compared to DT08/40 cells. The replication of the oncolytic vaccinia virus in cancer 
cells is influenced by many host factors including the type of cancer cell [123]. The 
canine cancer cells used in the current study were obtained from two different canine 
patients. STSA-1 cells were derived from a biopsy obtained from a dog with grade II 
soft tissue sarcoma [42], DT08/40 cells were derived from biopsy material obtained 
from a dog with prostate carcinoma [124]. Thus, the variation in the speed of 
LIVP6.1.1 replication in STSA-1 and DT08/40 cells may be attributed to different 
origin and tumor types of these cancer cells. Furthermore, the oncolytic potential of 
virus is linked to its replication efficiency. STSA-1 and DT08/40 cells when infected 
with LIVP6.1.1 demonstrated efficient cytotoxicity. However, the rate of killing was 
much faster in STSA-1 cells compared to DT08/40 cells, which was not surprising 
considering the fact that LIVP6.1.1 replicated faster in STSA-1 cells. Taken together, 
LIVP6.1.1 efficiently infected, replicated in and killed STSA-1 and DT08/40 cancer 
cells although at different rates. 
Further, we analyzed the therapeutic efficacy and safety of LIVP6.1.1 in mouse 
xenografts produced by implanting STSA-1 and DT08/40 cells. STSA-1 and DT08/40 
tumor-bearing athymic nude mice were injected with a single dose of LIVP6.1.1 or 
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PBS as a control. Treatment of STSA-1 tumors with LIVP6.1.1 led to tumor inhibition 
14 days after treatment with subsequent tumor regression. The tumor growth 
occurred in three phases: growth (Phase I), inhibition (Phase II) and regression 
(Phase III) as established by Zhang et al. for mammary carcinoma xenografts [8]. 
Further, virus treatment resulted in more efficient tumor regression and in some 
cases almost complete tumor regression. In contrast, LIVP6.1.1-treated DT08/40 
tumors did not show the typical three-phase growth pattern. Virus-treated tumors did 
not grow as large as in the untreated controls in the early course of treatment as 
would have been expected. However, significant tumor regression was observed in 
virus treated groups compared to animals injected with PBS. The onset of tumor 
regression was observed after 35 days of treatment. STSA-1 tumors showed tumor 
regression 21 days earlier compared to tumor regression in DT08/40 xenografts. 
Therefore, virus treatment demonstrated that the rate of tumor regression was faster 
in STSA-1 tumors compared to DT08/40 tumors. It was previously demonstrated that 
the rate of virus replication in tumor xenografts influences the therapeutic efficacy of 
various oncolytic viruses like oncolytic VACV, herpes virus and adenovirus [125-
127]. Therefore, faster therapeutic efficacy in STSA-1 tumor xenografts compared to 
DT08/40 tumor xenografts is likely attributed to faster replication of LIVP6.1.1 in 
STSA-1 cells. Additionally, the treatment with LIVP6.1.1 was well tolerated by the 
animals as evidenced by no major change in relative body weight of mice and by the 
fact that the virus was mainly detected in the tumor tissues. The concentration of 
virus in the STSA-1 tumors was 10,000- to 100,000- fold higher compared to tested 
normal body organs indicating the tumor-specificity of virus infection. However, 
minimal numbers of virus particles were also detected in normal body organs (table 
3), which might be explained by the leakiness of blood vessels in solid tumors which 
uptake the virus that is released from the tumor cells and transport it to normal 
organs via blood circulation. Additionally, circulating virus-infected tumor cells or cell 
particles escaping from leaky tumor blood vessels may end up in healthy tissues 
such as the lung, liver, spleen and kidney. In summary, the data demonstrated that 
the replication of virus was (mostly) tumor-specific. Additionally, tumor-colonization 
of LIVP6.1.1 and viral oncolysis was as analyzed by immunohistochemistry and it 
was demonstrated that the virus efficiently colonized tumor tissues. Staining of tumor 
sections with fluorescent-labeled anti-VACV antibody identified virus-colonized 
patches in tumors. Increased viral patches were correlated with decreased nuclear 
	   99 
staining in STSA-1 tumors, indicating an increase in virus-mediated cell death in 
vivo. 
Analysis of tumor associated innate immune cells in tumor-bearing mice was 
performed 7 days after initial treatment. Upon virus treatment, an enhanced 
concentration of (infiltrating) granulocytes and macrophages in tumors was 
observed. Moreover, it was reported that virotherapy induces massive tumoral 
infiltration of MDSCs resembling neutrophils and macrophages, which may be part of 
a virotherapy-mediated antitumor mechanism [42]. The initiation of the innate 
responses and recruitment of immune cells might lead to tumor regression in co-
operation with oncolysis [42, 128]. Thus, anti-tumor mechanism in STSA-1 
xenografts could be a combination of the direct viral oncolysis of tumor cells and the 
virus-dependent infiltration of tumor-associated host immune cells.  
5.2 The recombinant VACV strain GLV-1h109 encoding the anti-VEGF 
single-chain antibody was equally efficient in canine cancer xenografts 
In the first part of the study, the effective oncolytic potential of the wild-type VACV 
strain LIVP6.1.1 in canine cancer xenografts was demonstrated. However, like other 
therapeutic modalities, oncolytic virotherapy encountered with several challenges. 
One of the major challenges faced by oncolytic virotherapy is the role of the tumor 
microenvironment in compromising the efficacy of the treatment. The components of 
the tumor microenvironment, especially heterogeneous tumor angiogenesis, have 
been shown to limit the spread and replication of oncolytic virus and thereby the 
efficacy of the therapy [120]. Therefore, the second part of the study was designed 
to understand the effects of modulation of tumor angiogenesis on the spread and 
replication of oncolytic VACV. The major strategy to inhibit tumor angiogenesis is 
blocking the growth factors required for the formation of new blood vessels. VEGF 
has shown to be one of the growth factors that play a key role in the signaling 
pathways that mediate tumor angiogenesis, tumor growth, and metastasis [87], and 
blocking of VEGF inhibited angiogenesis and restricted tumor growth [129, 130]. 
Therefore, VACV strain GLV-1h109 encoding the anti-VEGF single-chain antibody 
GLAF-1 was used to understand the effects of modulation of tumor angiogenesis on 
oncolytic virotherapy in canine cancer xenografts. The GLV-1h109 strain was 
derived from the prototype virus strain where the lacZ gene in GLV-168 was 
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replaced by a gene encoding the anti-VEGF single-chain antibody GLAF-1. In all the 
cell culture experiments GLV-1h68 was used as a control. 
In initial experiments, the characterization of the new VACV strain GLV-1h109 was 
carried out in canine cancer cells. The replacement of the lacZ expression cassette 
with GLAF-1 at the J2R locus was confirmed by Western blot. The GLAF-1 insertion 
did not affect the expression and fluorescent protein function of the marker genes 
(Ruc-GFP and gusA) when compared to the parental virus GLV-1h68. GLAF-1 being 
a single-chain antibody with a secretory signal was expected to secrete into the cell 
supernatant. Western blot analysis of Infected STSA-1 and DT08/40 cells with GLV-
1h109 indeed demonstrated the secretion of GLAF-1 in the cell supernatant (Fig. 8). 
The secretion of GLAF-1 by the infected cell might enable its quick delivery to the 
surrounding tumor tissue and more widespread binding to VEGF (Fig. 9). In addition, 
tumor infection by the virus was associated with GLAF-1 in peripheral blood (Fig. 
12). The data clearly demonstrated that GLAF-1 could also be useful as a 
pharmacokinetic marker to monitor virus colonization and persistence in GLV-1h109-
injected xenograft mice (Fig. 12). These findings have very well demonstrated the 
application of this virus-based system for efficient expression and distribution of 
recombinant sinlge chain antibodies in the tumorigenic host. Furthermore, the new 
virus strain was characterized for replication efficiency and cytolytic potential in 
canine cancer cells in culture. GLV-1h109 was effective at infecting, replicating in, 
and killing STSA-1 and DT08/40 cells in cell culture as efficiently as the parental 
virus GLV-1h68. This indicated that insertion of the GLAF-1 gene did not negatively 
affect virus replication or the cytolytic activity in cell culture. The results were 
concomitant with the previous results where insertion of GLAF-1 did not influence the 
replication of GLV-1h109 in human cancer cell lines [72]. However, GLV-1h109 
replicated better and faster in STSA-1 cells compared to replication in DT08/40 cells 
(***P= 0.0004). As described earlier for LIVP6.1.1, this variation in the efficiency of 
GLV-1h109 replication can be attributed to different origin and types of cancer cells. 
Additionally, the replication efficiency of GLV-1h109 encoding the anti-VEGF single-
chain antibody was shown to be better in the cells expressing higher level of VEGF 
[131]. Therefore, the higher level of VEGF expression in STSA-1 compared to 
DT08/40 cells (Fig. 10) could explain the better and faster replication of GLV-1h109 
in STSA-1 cells. 
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The oncolytic effects of GLV-1h109 were tested in mice with STSA-1 and DT08/40 
tumor xenografts. The results demonstrated that GLV-1h109 achieved a significant 
inhibition of tumor growth in both STSA-1 and DT08/40 canine xenograft models. 
However, the tumor regression was faster in STSA-1 tumor xenografts compared to 
that in DT08/40 xenografts. Virus-treated STSA-1 tumor xenografts demonstrated 
typical three-phase growth curve and tumor regression was observed as early as 14 
days while DT08/40 tumor xenografts showed tumor regression only after 35 days. 
The faster therapeutic efficacy in STSA-1 tumor xenografts compared to DT08/40 
tumor xenografts could be explained by faster replication of GLV-1h109 in STSA-1 
cells. These findings were identical to the results obtained in previous studies where 
more efficient replication of LIVP6.1.1 in STSA-1 tumor xenografts led to better 
tumor regression compared to DT08/40 xenografts. 
Furthermore, effects of the anti-VEGF single-chain antibody GLAF-1 on tumor 
vasculature were tested in STSA-1 xenografts. There were two reasons to prefer 
STSA-1 tumor xenografts to DT08/40 tumor xenografts. The canine soft tissue 
sarcoma STSA-1 cells expressed higher levels of VEGF compared to DT08/40 cells 
(Fig. 10). Additionally, the serum of GLV-1h109-injected mice with STSA-1 
xenografts contained a nine-fold greater level of GLAF-1 expression than in mice 
with DT08/40 xenografts on 7 dpi (Fig. 12). GLV-1h109-treated STSA-1 tumor 
xenografts demonstrated the intratumoral expression of GLAF-1 at 7 and 49 dpi (Fig. 
13). In addition to intratumoral expression, it was important to examine the binding 
efficiency of GLAF-1 to canine VEGF. The GLAF-1 protein encoded by GLV-1h109 
had binding affinity to human and mouse VEGF [72]. Cross-reactivity of GLAF-1 with 
VEGFs from other species other than human and mouse was not tested. It was 
demonstrated that GLAF-1 could specifically bind to canine VEGF (Fig 9). The 
GLAF-1 binding to VEGF from both canine and mouse origins is advantageous in 
canine xenograft models, as blocking of the both VEGF forms could be important for 
therapeutic efficacy [132].  
STSA-1 tumors sections were tested for blood vessel staining at 7 days after virus 
treatment. Staining of STSA-1 tumor sections for CD31 (angiogenesis marker) 
showed a significant decrease in the number of blood vessels in GLV-1h109-infected 
tumors compared to GLV-1h68- and PBS-injected control tumors at 7 dpi (Fig. 14B). 
The drastic reduction of the vascular density of tumors might be due to the presence 
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of the GLAF-1 in GLV-1h109-treated STSA-1 tumors (Fig. 13). Interestingly, the 
significant reduction in vascular density was observed in virus-infected areas only 
(Fig. 14B, C). Localized effects of GLAF-1 on tumor vasculature might be due to the 
low concentration of GLAF-1 at the specific site in the tumor bed. It has been 
demonstrated that the inhibition of tumor vasculature requires complete blockade of 
VEGF [132] and blocking of VEGF is largely dependent on the concentration of anti-
VEGF antibody [133, 134]. Highest concentrations of GLAF-1 in the virus-infected 
areas of STSA-1 xenografts compared to non-infected areas. Therefore, 
concentrations of GLAF-1 might not have been sufficient to completely block VEGF 
that might led to localized inhibition of vasculature in STSA-1 xenografts. Moreover, 
the effect of GLAF-1 showing decreased vascular density in STSA-1 tumor 
xenografts is well supported by the previous findings which demonstrated that the 
treatment with GLV-1h68 and another GLAF-1-negative oncolytic vaccinia virus 
strain, LIVP1.1.1, did not affect the blood vessel density of STSA-1 tumors [42]. In 
conclusion, systemic administration of oncolytic vaccinia virus GLV-1h109 encoding 
an anti-VEGF single-chain antibody led to significant decrease of tumor vasculature, 
which further inhibited tumor growth.   
5.3 Anti-angiogenic therapy improved the spread and replication of VACV 
as well as infiltration of the innate immune response in canine cancer 
xenografts 
Initial animal experiments have demonstrated that GLV-1h109 injection in mice with 
canine cancer xenografts was safe and significantly inhibited the tumor growth as 
well as decreased tumor blood vessel density. Further, virus-encoded single-chain 
anti-VEGF antibody GLAF-1 led to an enhanced therapeutic effects in different 
human tumor xenograft models compared to oncolytic viral therapy with the 
prototype strain GLV-1h68 alone [72]. The continuous production of the GLAF-1 in 
virus-colonized tumors led to an inhibition of tumor angiogenesis. This possible 
VEGF blockade and the proximate anti-angiogenesis effects would normalize the 
tumor vasculature that would enhance virus spread and ultimately virus replication in 
tumor tissue. In order to test this assumption, the replication and spread of GLV-
1h109 was analyzed by counting the viral titers and viral-encoded GFP expression, 
respectively in STSA-1 xenografts at seven days after systemic viral injection. Flow 
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cytometry analysis demonstrated that the numbers of GFP-positive tumor cells were 
significantly higher in tumors treated with GLV-1h109 compared to GLV-1h68-treated 
tumors. Higher number of GFP-positive cells indicated a better spread and 
distribution of virus. The extent of virus replication was analyzed by viral titer 
determination in GLV-1h109- and GLV-1h68-treated tumor xenografts at 7 days post 
injection. A statistically significant (nearly 2-fold) increase in infectious viral particles 
was observed in GLV-1h109-treated STSA-1 xenografts compared to GLV-1h68-
treated tumor xenografts. Inhibition of tumor angiogenesis has demonstrated an 
enhanced spread and replication of several oncolytic viruses (HSV, VACV and 
adenovirus) in tumor xenografts and thereby improved tumor regression [131, 135, 
136]. A possible reason for these findings may be explained by the phenomenon 
called “vascular normalization” [137]. Vascular normalization is the process where 
blockade of VEGF can reverse many of the structural and functional abnormalities 
seen in tumor vessels [138]. An anti-VEGF therapy can improve tumor vessel 
perfusion, reduce tumor hypoxia, and in turn can enhance delivery of systemically 
administered therapeutic agent [139] in this case VACV. The “changed” vasculature 
seemed to allow an increased virus spread and thereby replication of GLV-1h109 in 
STSA-1 tumor xenografts. Therefore we conclude that modulation of tumor 
angiogenesis by the anti-VEGF single-chain antibody indeed influenced the spread 
and replication of VACV.  
Furthermore, modulation of tumor angiogenesis and increased replication of 
oncolytic virus has shown to influence the infiltration of immune cells in tumor 
xenografts [120]. To investigate the GLV-1h109 virus interactions with the host 
immune cells, we analyzed the innate immune response in the early phase of virus 
infection by flow cytometry. Significantly increased accumulation of host immune 
cells especially granulocytes and macrophages was observed in GLV-1h109-
infected tumors as compared to PBS or GLV-1h68-infected tumors (Fig. 15). Several 
recent studies have described that intratumoral replication of VACV induces massive 
tumoral infiltration of granulocytes, mainly neutrophils, that may be exerting 
antitumor effects in vivo through a number of different mechanisms [30, 42, 99, 140]. 
As the replication of VACV was higher in GLV-1h109 treated tumor xenografts, a 
significant increase in accumulation of these innate immune cells was not surprising. 
Furthermore, Breitbach and colleagues have postulated that neutrophils (Gr-1+ cells) 
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could mediate antitumor effects by the induction of vascular collapse in tumors [30]. 
In addition, a recent study has identified a cytotoxic population (N1) of tumor-
associated neutrophils expressing CD11b+Ly6G+, capable of killing tumor cells [141]. 
In the current work, we found evidence of direct interactions of vaccinia virus or 
virus-infected cells with granulocytes and macrophages in the STSA-1 tumor tissue 
(Table 6; GFP-positive cells). Others and we in previous study have reported that 
these interactions may increase the activation and strength of host antitumor 
immune responses [42, 99, 141, 142]. This indicates that inhibition of tumor 
angiogenesis increases virus spread and replication, which further induces infiltration 
of innate immune cells in tumor bed. Consequently, the interactions of granulocytes 
and macrophages with vaccinia virus in the tumor bed may be crucial for the success 
of the virotherapy. 
5.4 VACV injection induced circulatory immune response in canine patients 
recruited in phase I clinical trial 
Anti-tumoural immune responses dictate the long-term therapeutic success of cancer 
treatment. Previous sections of this study have demonstrated that VACV replication 
in canine tumor xenografts induced infiltration of innate immune cells in the tumor 
xenografts and modulation of tumor angiogenesis significantly improved the 
frequency of the innate immune cells in the tumor bed. Similarly, recent reports in 
animal models [143-145] as well as in human clinical trials [146] support the 
hypothesis that virus-induced anti-tumoral immune responses significantly contribute 
to the outcome of the therapy. However, antitumor immune response has seldom 
been translated into clinical benefits. Given the lack of success of existing cancer 
immunotherapeutics, it is necessary to examine the immune response to VACV in 
canine cancer patients. Therefore, we have analyzed the immunomodulatory effects 
of V-VET1 (clinical grade LIVP6.1.1) treatment in canine cancer patients recruited in 
phase I clinical trial. This is the first reported clinical trial with an oncolytic VACV 
designed to study its safety and dose escalation in dogs with malignancies. Ideally, 
immune responses should be monitored within the tumor, but the tumor biopsy is not 
always accessible for analysis. In our study the amount of tumor biopsies obtained 
from individual canine patients were not sufficient to analyze the immune response. 
However an alternative method to monitor adaptive and innate immune response is 
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the characterization of circulating immune cells in the peripheral blood [147, 148]. 
This method has several advantages e.g. enough material is available and 
pretreatment immune monitoring can be performed without additional invasive 
interventions. Furthermore, in advanced cancer patients, tumors are located at 
different anatomical locations, it is of great importance that immune cells have the 
capacity to migrate to and eradicate tumor cells at different tissue sites. In preclinical 
and clinical studies, it has been shown that anti-cancer treatment results in increased 
population of anti-tumor immune cells in peripheral blood, highlighting the capacity of 
these cells to migrate to different body sites [149, 150]. Therefore, peripheral 
responses are of great relevance and can be considered as indirect analysis of the 
effects taking place in the tumor microenvironment.  
In the present study, we performed evaluation pre- and post-V-VET1 treatment 
levels of circulatory T lymphocyte subsets in canine cancer patients. The frequency 
of circulatory CD3+CD4+ T lymphocytes and activated T lymphocytes was non-
significantly increased in 72.7% and 81.8% patients, respectively, post-virus 
treatment compared to pre-treatment levels. CD3+CD8+ T lymphocyte was the only 
subtype that showed significantly increased levels at 21 days after initiation of 
treatment compared to pretreatment levels. The increased frequency of circulatory 
CD3+CD8+ T cells was observed in almost all patients  (90.9%), irrespective of virus 
dose and tumor type. Since CD3+CD8+ lymphocytes are generally regarded as the 
major cytolytic cells, their increased frequency in circulation would suggest an 
increased population in the tumor microenvironment that would potentially allow the 
killing of infected cells [151]. The presence of cytotoxic T cells has been shown to be 
a favorable prognostic indicator in a number of human cancers, and gene expression 
profiling demonstrated that patients with high baseline tumor expression of genes 
related to both innate and adaptive immune response were more likely to favorably 
respond to immunotherapy [152]. Furthermore, tumor-associated CD8+ T cells in 
several canine cancers have shown to improve the prognosis of the disease [153, 
154]. Therefore, increased circulatory CD3+CD8+ T cells from baseline in canine 
cancer patients treated with V-VET1, suggest that the cytotoxic T lymphocytes may 
have anti-tumor activity, and that changes in the immune microenvironment of the 
tumor may slow disease progression.  
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Further, the outcomes of the peripheral monitoring of Treg (CD4+CD25+Foxp3+) and 
MDSCs (CD11b+MHCII-CD14-) in V-VET1-treated canine cancer patients were also 
encouraging. The significant decrease in circulating MDSCs after 21 days paralleled 
an increase in the overall CD3+CD8+ T cell population (Fig. 19). MDSCs generated 
in large numbers in cancer patients are able to directly inhibit Ag-specific T cell 
responses [155]. Increased MDSC level in both canine and human cancer patients 
represents a mechanism of immune suppression in cancer and therapeutic options 
that reduced the level of MDSCs have improved the prognosis of disease [156, 157]. 
Here, a similar regulatory impact of V-VET1 treatment upon MDSCs in canine cancer 
patients was documented. While there is substantial variation in identification of 
human MDSC and canine MDSC, the CD11b+MHCII-CD14- subset was defied as a 
key MDSCs subset in the recent study [115]. Similarly, another subtype of immune 
cells that play an important role in negatively regulating the development of anti-
tumor immune response are regulatory T cells (Treg) [158]. Treg have been shown to 
directly suppress immune responses to tumors in mouse tumor models [159]. Treg-
induced immune suppression also appears to occur in humans as evidenced by 
clinical studies that correlate high Treg numbers with impaired immune function [160]. 
In this study, the levels of Treg cells were either decreased or unaffected by the V-
VET1 therapy in almost all canine cancer patients (81.8 %) (Fig. 18D). However, the 
overall analysis of Treg population did not show any significant change in the 
percentages of the circulatory Treg after V-VET1 treatment. Interestingly, ratio of 
CD8/Treg is a useful prognostic marker for canine cancers [158]. Decreased CD8/Treg 
ratio in peripheral blood of canine osteosarcoma patients was associated with 
decreased survival [158].  In the current study, the percentages of CD8+ T cells 
increased over the time after V-VET1 treatment and consecutively increasing the 
ratio of CD8/Treg post V-VET1 treatment. Therefore, it was encouraging that immune 
inhibitory cell population (concentration of MDSCs and relative concentrations of Treg 
as described by CD8/Treg ratio) in circulation has been significantly decreased after 
V-VET1 treatment.  
Furthermore, type of tumor or dose of virus in canine patients did not affect the 
changes in frequencies of immune cells. Canine patients diagnosed for cancers were 
categorized in four different tumor types mainly, soft tissue sarcoma, mast cell tumor, 
adenocarcinoma and osteosarcoma. However, the frequencies of both CD3+CD8+ T 
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cells and MDSCs did not significantly change according to the type of tumor. 
Similarly, canine patients were given different virus doses to test maximum tolerable 
dose. Although, increase in virus dose showed increased CD3+CD8+ T cells post 
treatment; the change was not statistically significant. Therefore, it was concluded 
that the dose of virus and tumor type did not affect the changes in the frequencies of 
immune cells.  
Lastly, the changes in percentages of the immune cells were observed only during 
the course of V-VET1 treatment. Total four cycles of V-VET1 were given (1 cycle 
every week) in individual patients and PBMCs were analyzed from pre-treatment till 
eight weeks after initiation of treatment at regular interval. Surprisingly, the positive 
change in the percentages of immune cells (increased CD3+CD8+ T cells and 
decreased MDSCs) was observed only during the course of V-VET1 treatment. 
However, when V-VET1 treatment was terminated the CD3+CD8+ T cell and 
MDSCs percentages were returned to the baseline level (Fig. 19 and Fig. 20). This 
phenomenon suggests that the modulation of immune cells were driven by the V-
VET1 and VACV induced the changes in the frequencies of circulatory immune cells 
in canine cancer patients. The association between clinical activity of V-VET1 and 
change from baseline in CD3+CD8+ T cells and MDSCs that was studied in the 
current trial needs to be explored further.  
In conclusion, systemic administration of oncolytic VACV strains led to significant 
inhibition of tumor growths in the treated canine tumors. Consequently, VACV 
showed capability to modulate the tumor microenvironment. Therefore, modulation of 
immune responses during treatment is of great importance to investigate the 
immunogenicity of the oncolytic viruses and the potential correlation between the 
immune response and the clinical outcome of the patients and also for future 
treatment design. 
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APPENDIX  
% Percent 
°C Degree Celsius 
α Anti 
µ Micro 
µg Microgram 
µL Microliter 
µm Micrometer 
BSA bovine serum albumine 
CCD Charge-coupled device 
CEV Cell-associated enveloped virus 
cm2 Centimeter square 
CMC Carboxymethylcellulose 
CO2 Carbon dioxide 
CPE cytopathic effect 
dH2O Double-distilled H2O 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxid 
DNA Deoxyribonucleic acid 
dpi days post injection 
ds Double-stranded 
EDTA diaminoethanetetraacetic acid 
EEV Extracellular enveloped virus 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmatic reticulum 
FACS Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
Fig. Figure 
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g grams 
GFP green fluorescent protein 
h hours 
H2O2 Hydrogen peroxide 
HCl Hydrochloric acid 
hpi Hours post infection 
HRP Horseradish peroxidase 
IEV Intracellular enveloped virion 
IMV Intracellular mature virus 
IV Immature virion 
i./v. Intravenous 
kDa kilo Dalton 
mA milli Ampere 
mg Milligram 
min Minute 
ml Milliliter 
mm Millimeter 
mM Millimolar 
mm3 Cubic millimeter 
mRNA messenger RNA 
MOI Multiplicity of infection 
MVA Modified vaccinia virus Ankara 
N Normal 
N2 Nitrogen 
NaOH Sodium hydroxide 
n.d. Not detectable 
NEAA Non-essential amino acids 
neg Negative 
NK Natural killer 
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PBS Phosphate buffered saline 
PFA Paraformaldehyde 
pfu Plaque forming units 
pg Picogram 
pH Potential hydrogenii 
PI Propidium iodide 
PMSF Phenylmethylsulfonyl fluoride 
pos Positive 
PVDF Polyvinylidene difluoride 
RNA Ribonucleic acid 
RPMI Roswell Park Memorial Institute medium 
RT Room temperature 
Ruc Renilla luciferase 
SDS-PAGE 
 
Sodiumdodecylsulfate polyacrylamide gel electrophoresis 
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